{
  "directed": true,
  "multigraph": true,
  "graph": {
    "pybel_version": "0.13.2-dev",
    "document_metadata": {
      "name": "Cholinergic system during the progression of Alzheimer’s disease: therapeutic implications",
      "version": "1.0.0",
      "description": "This file encodes the article Cholinergic system during the progression of Alzheimer’s disease: therapeutic implications by Mufson, 2008",
      "copyright": "Copyright © 2018 Fraunhofer Institute SCAI, All rights reserved",
      "authors": "Rana Aldisi",
      "licenses": "Private Ownership to Fraunhofer Institute SCAI",
      "contact": "rana.al.disi@scai.fraunhofer.de"
    },
    "namespace_url": {
      "MESH": "https://raw.githubusercontent.com/pharmacome/terminology/01c9daa61012b37dd0a1bc962521ba51a15b38f1/external/mesh.belns",
      "CHEBI": "https://raw.githubusercontent.com/pharmacome/terminology/1b20f0637c395f8aa89c2e2e342d7b704062c242/external/chebi-names.belns",
      "HGNC": "https://raw.githubusercontent.com/pharmacome/terminology/1b20f0637c395f8aa89c2e2e342d7b704062c242/external/hgnc-symbols.belns",
      "GO": "https://raw.githubusercontent.com/pharmacome/terminology/1b20f0637c395f8aa89c2e2e342d7b704062c242/external/go.belns",
      "HBP": "https://raw.githubusercontent.com/pharmacome/terminology/3074b85b858455d8eeb76cfcdef685ced19bbe11/export/hbp-names.belns",
      "FPLX": "https://raw.githubusercontent.com/sorgerlab/famplex/1b7e14ec0fd02ee7ed71514c6e267f57d5641a4b/export/famplex.belns",
      "GFAM": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/hgnc-gene-families/hgnc-gene-families-20170710.belns",
      "MESHC": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/mesh-chemicals/mesh-chemicals-20170725.belns",
      "MGI": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/mgi-mouse-genes/mgi-mouse-genes-20170725.belns",
      "RGD": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/rgd-rat-genes/rgd-rat-genes-20170725.belns"
    },
    "namespace_pattern": {},
    "namespaces_uncached": [],
    "annotation_url": {
      "CellLine": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell-line/cell-line-20170511.belanno",
      "Disease": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/disease/disease-20170511.belanno",
      "MeSHAnatomy": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/mesh-anatomy/mesh-anatomy-20170511.belanno",
      "MeSHDisease": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/mesh-diseases/mesh-diseases-20170511.belanno"
    },
    "annotation_pattern": {
      "Species": "\\d+"
    },
    "annotation_list": {},
    "path": "mufson2008.bel"
  },
  "nodes": [
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "amyloid-beta polypeptide 42",
      "id": "c2da54109c90719396dfdfb558be74582b8522863849a50f3f5029b7d60f4d53df3cfa1a97b787e760a2f74ea1f74012eb49273beeded42a2873d788953b4a13"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "amyloid-beta",
      "id": "a9487b29439483c6840095610dd3e496e3ca9cccc3a8d71e0385a39b570f3c0a26965ac06d83265e1c08deaae7998272d4f4c21ec0534f8be3fd8e4e57dbb3a2"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "acetylcholine",
      "id": "bae5841bb74f1e9eb73cd433cda657927031217c24e17f21bb2975128d1d9be4dc899448ede71d9aa18224145a1681b90b33287454eabf938f405bc1b8894b62"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "donepezil",
      "id": "e1d832febdffe3cc8c4fa21718e0b21719272a1a10c2945cdd3b36cc6ff66c3ec70289ed1ddc3a7a6b79ca44a4bc0fac6ecb12683fc043cdac26b952f7cf5223"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "physostigmine",
      "id": "4863cd75469275d1fdae01cd33cc5695cff4b2e8f14b82887b79659862c96e5d2ebd72c6b76f6c8772ca126c36e3f8bb680e9c4a80c7d9a5edc319fb822a45c8"
    },
    {
      "function": "Abundance",
      "namespace": "HBP",
      "name": "3R tau",
      "id": "76b706b2562039eea237549b88d1543e6df0989d65b85572213389c2681b03cef38dbf0e1d0e75624aa0c73f06bf21f8f5345d69a692544bfa404bcd90d3b6c1"
    },
    {
      "function": "Abundance",
      "namespace": "HBP",
      "name": "Tau C3",
      "id": "dc1ae25162671f1c7af10d6b10b9cd158360e5db8463aca69b3470ad0cae83231e623766af70671f318cc3807025aa2f33fa75a85177f698132478683f4aeff2"
    },
    {
      "function": "Abundance",
      "namespace": "HBP",
      "name": "Tau MN423",
      "id": "40bd3a6699f5e07b21b55a59026ba4843b0db5a85b7a83cb0a54fb43abc059ae296fe02979e08f5bdca16a398467e7d7fecd2e615ad21741490ff988ddb53d42"
    },
    {
      "function": "Abundance",
      "namespace": "MESH",
      "name": "D002800",
      "id": "094d80a48e7aa7ca487de38c5a885c720dae5f211d4964b9765cfcb1ebe1b1dbc197bd9e013055ee61708c81e934675c46fb9e666ad4f870de958eb5c5d0ac3b"
    },
    {
      "function": "Abundance",
      "namespace": "MESH",
      "name": "D005625",
      "id": "5fbe1c22f689a9c5a15f1daa90782170ccb23312491389520d09288000b18e1958c48e5f5b5814be24bb714a645ae4c762abb3d62ed9c70a4d09b74be071dc83"
    },
    {
      "function": "Abundance",
      "namespace": "MESH",
      "name": "D009414",
      "id": "b06f8aff773e56acbc39b21430843ccfc3152c949f5f880d5622c386f07d78d63063ae5d5da5f1b82d5f277f94d90c3d67b154d0c2c9b0ecbd71fb19afa8f5b7"
    },
    {
      "function": "Abundance",
      "namespace": "MESH",
      "name": "D009479",
      "id": "448d911057ab49a43eae767e0ffc586d5957898a7283a4d4cb467fe9055c1b5cfcbb7b11edbbb9174e346e281d3170caeb3d4752acd3382ba022e7e350d77a2f"
    },
    {
      "function": "Abundance",
      "namespace": "MESH",
      "name": "D013569",
      "id": "623aebf6f49c1943b4da07b7edc709eb9d6f7bd63108d47dc739cc444996931dcc300fb0564e0338eedd94bcc04567d3263868ceb1c1ed7c205884a9113fdf4c"
    },
    {
      "function": "Abundance",
      "namespace": "MESH",
      "name": "D016874",
      "id": "f4908d8200c745b0c00c888044883016e8c6dac426e92d6efe4dbed65b0b055428488e0a2ffcbf87530104bc1034bc4f4b50bca089ec9addd66c833c8b6b47f2"
    },
    {
      "function": "Abundance",
      "namespace": "MESH",
      "name": "D059329",
      "id": "b29f01e9ea52931772b85ee2a1ffc1f7a369025961c7b07f8071fe6f3788f4dbb3995542b095992be333fde8688269aa977dcede61861e7e6313a88b0da82664"
    },
    {
      "function": "Abundance",
      "namespace": "MESH",
      "name": "D059330",
      "id": "257cf9bc434d8604ebb3d440fe5fe05c5be70c5d5bf59f5ab9c8ce7c3d176584d05b87c24101628fb2e977be1b3bd2df8f717ab43fc39bcd4298249c4f5e85f5"
    },
    {
      "function": "Abundance",
      "namespace": "MESHC",
      "name": "(S)-2-ethyl-8-methyl-1-thia-4,8-diazaspiro(4.5)decan-3-one",
      "id": "b0d1cd69643720607e8a3025ea1814e4508ecacd5afaa4cac6aeb91f045586f8a45d891a4ca0f7306018e9bc24827ed824262ac13a2e94d25c44872d97053ba6"
    },
    {
      "function": "Abundance",
      "namespace": "MESHC",
      "name": "gambogic amide",
      "id": "429b3b11f769f29d4c2060831ca6d6fb0b3ffd6b905b4dae1fdd9bb3e600f55008f22bfe27ef584eb90442021faef99398c134065b80f969347910910ebb3291"
    },
    {
      "function": "Abundance",
      "namespace": "MESHC",
      "name": "pro-nerve growth factor, human",
      "id": "646cae87a17f321169391c78d3e2fad5faeb9ab8b4ed4e583f0c5474188142ebcb82bae7e150ce8786cdd68c3bf5637847be0acb8e237b84e5a8c2439feba42f"
    },
    {
      "function": "Abundance",
      "namespace": "MESHC",
      "name": "latrepirdine",
      "id": "4cfe485325c8410a062022820717157a54e5f3a9c503410c43cfccc03852333899c8b641ea164c4f0f78b693b59b0a9051dfa098f571cdc644a46aa92987a140"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "GO",
      "name": "GO:0000165",
      "id": "b15cfd21d37252c86ed68832c0f7d99934ad1995fcf0b8612300bbf9117ec375b5d4a3ef84b2a66501a0933642a949fe67def6213dfd0cd0d957c00f3a6056ce"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "GO",
      "name": "GO:0006665",
      "id": "18f8be6bd442fdb771bd090dc6398658ceeeda1c286cff5740b21c0b124a3a910e40c61af5fed9034a8fcd1772556addd3ffe9425159d679112b37b394ecc716"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "GO",
      "name": "GO:0006915",
      "id": "9923d5d571c6bdea2a87c29db72af8bef2abe83d05ec53b12d9a76d309f700ea32aa8d1ec12e8afddcd6e348919e1c7629efe25cda27a670387f0e1bfb098c83"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "GO",
      "name": "GO:0007254",
      "id": "e1c12845ab5ebda0c1984f86d4bcb423b53caf39d3652e589d331c0297d9cf50b6c246068e7c005e3516c62c01ced664f6d63b96bafc366ec7dfb9a2b158a6a8"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "GO",
      "name": "GO:0007269",
      "id": "4a9670b676009e99c40155c335a7f0b4d3e0ec078de8a9648f6f9134fe6b42e47b5181ba9c82c247d3b485d423e507b32b76485e2be047e8df7364033d7f34e3"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "GO",
      "name": "GO:0007271",
      "id": "19ad0be19cf8814cf03473c099dd36ec10002c5405d27730a6c2a68da5bb05017708a28031e4d434847b884ea7460b76f1348c5f5329e6003d912b5c72503827"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "GO",
      "name": "GO:0014065",
      "id": "4deda16d8c83b013b053df1f9f39575f677003a3127a71deb7979a8a46fbab50e265dbd787fc4220c3a5e3f65a9a296704c9e7fc269b71f5b46f3304670624f1"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "GO",
      "name": "GO:0030182",
      "id": "24d400cb08c85e14d0128962940c8cf2ccd8f80aabfbfba829dc4301983227da32da48b2b1650b0ff40e75b87474496162b942874a377dd416ee0c0622d99a1f"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "GO",
      "name": "GO:0031175",
      "id": "ecd8a8e46b4f0dd141e429f5111d941dbf6021b5835f6cbc96802929638940bfadf25624680559106008855d33383c7c3601aa2126d9619c96117ee38613f138"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "GO",
      "name": "GO:0031629",
      "id": "94e3a67c817f4f426b24307dc0cb60b5b1f409b2dce4114743753f148279316479c041e27b33cd6e05797501a393d52d5f43d8f74a3222d4b65d4c73c7c9f33c"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "GO",
      "name": "GO:0032455",
      "id": "c71e8b13948e3ca994b2451b9b79189de4f9f1bb2b15e7ad1265833e19bb38019dabd6529d58371d167c7d60d0f481763f8b6d466134bb56dfae778950c3df6d"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "GO",
      "name": "GO:0038061",
      "id": "d2f05f5f3c91bc5f53fcec9962a72f1247472cb22d798237d32b9bbc4bc1b41d3c1f825a3fabb966adf3fe5a89a67e08805216af53ceed2133c0636216a8746d"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "GO",
      "name": "GO:0038180",
      "id": "a69b3dd1c97503623775195b2427001823d4d823352eaaf206c02323942be937dcece3bfb56c1e45bd621286704257aff21e8f1b5b003898419933a1bfd7dde2"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "GO",
      "name": "GO:0043491",
      "id": "c30204c8833f9966e9b3f60df91aab5a79d0f511eb3d032a1240af6ed20ae6e71369b754c3fe8cf5989c2750dc9c50023475ab0c46c0a2a7232bc9dbaa7be770"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "GO",
      "name": "GO:0046902",
      "id": "f272a4a17e8c19ff035c903befd754542d6a169832af17bf669ee88ea2ab7bd2849a2f0a23a6edce724d23da353a2ea75aa1faa29a90b37f413e60c889d0398a"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "GO",
      "name": "GO:0048485",
      "id": "e2969102093827f62a7eaf1732e7463c50dd232986adc17b4df864814e303ae5fc72566b7f2785ee00b01aa697d38e4c1e75fc9361fdf26f45b5862cd073b50d"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "GO",
      "name": "GO:0050435",
      "id": "33291de7351f075135ab572aa35f9bb2ba071a51bd7a990376a2753eb664cb01aa757a432112eeaea08f40fc03cbbe2fc82c0f6732c38f0217ce733bc307e1a7"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "GO",
      "name": "GO:0060384",
      "id": "62d1dcf20d20616b0bf86b9552a6fa9246f8806a7b3a45b36dae8265968952aec8804eeac1e72faa6e7a0270b1032d645c174ba25dd3e8404997c8d016f349b2"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "GO",
      "name": "GO:0098989",
      "id": "56133250beb463ca02d3e03fb069ae1c0cbfc240a5fb7247d2ba04ee2c11f61d6dbcae426ba6fa320b97669b1dc72618d2d98fff2e860031502d934bea59a96a"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "GO",
      "name": "GO:1901214",
      "id": "d829b0cf2b5d9e044cb000c4df76a37e3b5204651e77c4ffc5165e070b395510478878e5062d42918b0bcf958413df9c9675d3d2c1ca94f4a8cffb060fe9f2e4"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "GO",
      "name": "GO:1990000",
      "id": "2fa5c785fb9133476aa618ca2e28ebfd207f0499b19757194cd55408e6cc3befc5aaf8aba7a2dfa8d0fcf34978d426b4350e340b9aa8286b87402959b069de7c"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "GO",
      "name": "GO:1990089",
      "id": "7ff87fd82b8fb0368f7d1025017df5398b3af24ddf0b9437e16a28797a74501a69dbe1cec38d6e1b12cf59de97b31c1bd2c1396d0dea435258e931a01349ef15"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "HBP",
      "name": "Excitotoxicity",
      "id": "babcd501fc9db645c0a7d37c53f8efe40dc06e2cdc453512d4183f5390ad7c497eb90ea9ab2ef33a8734ccf4bf4a4041ff4b0979eb40763196ea2321f7c6f3a0"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "HBP",
      "name": "Neurodegeneration",
      "id": "8f63d9ba3869712b675d29e11f0c0fb09685ddaec0a3a1584becd70b306380d15de58814844a018655820ca2a6e6eca66b0ec6a21ec2e428e8a52dc13eeff56e"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "HBP",
      "name": "hyperphosphorylation",
      "id": "92ea415ca9272a038a69779ea53382e1b4aa426ee017d1ee785be687fc72f5765bb867648cd28587e5dcef4bf9b3f07e3566d0c482abdb7022fac6b4e308035c"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "MESH",
      "name": "D000066829",
      "id": "6ef71a95d47c5d6ce72365c206a8074d5788ffbc8eb64411f72bcedd23da07434900c470e1a48e4942c7703008d213c0ba431a923a8f6f125441640db90a98b3"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "MESH",
      "name": "D000375",
      "id": "c44681c0795aff6bcb71227d69bc5be4e0513bf79431fb057dabe19b1a54bfd4371eb7f368cf62235dae8b860027a113bbc63476b90159724392f3c6bec76c09"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "MESH",
      "name": "D002470",
      "id": "8f36d271cea6628685cb36c6cbf56e7a78524c90f56a417fbf2133c4a93ee4a0523f1f0a2ecc1b7f598ef2febedaba006d44dd7df89f1af322ca63a6bfd1e775"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "MESH",
      "name": "D009473",
      "id": "fadc6eef2a30a103aa806be3604d44daddd5856a3f3767fef30c9283b851e71cd0800ed54409297465ee254d6253c81c551c435a6be794daf8f136948a84e1f1"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "MESH",
      "name": "D018384",
      "id": "084ac607b5ef088a1d326ba72eee230d44f2efc2e6d7e30c1e8f771c307fb74a31b7899912fbc7c6c971afdd5928ad0a0810a60648ec2f7080268a702ff0b39e"
    },
    {
      "function": "Complex",
      "members": [
        {
          "function": "Abundance",
          "namespace": "CHEBI",
          "name": "amyloid-beta",
          "id": "a9487b29439483c6840095610dd3e496e3ca9cccc3a8d71e0385a39b570f3c0a26965ac06d83265e1c08deaae7998272d4f4c21ec0534f8be3fd8e4e57dbb3a2"
        },
        {
          "function": "Protein",
          "namespace": "HGNC",
          "name": "CHRNA7",
          "id": "6f517aad2a254d42d4e0bd5118246057049b85324ab857629d0caa2da5e997bfcc08f9a0a2cd83bbb2b536c048ce402c0d521604c43b1b9c720f4e20b4dacd99"
        }
      ],
      "id": "8357c1828c09a0ec54af61d181d1ebf59a7aab25510ecc68252f54f264154b88a01a5b82b91fa4f0cbc03f1564c4f66fec744dec219b833b8aba47a5dd9fcbf4"
    },
    {
      "function": "Complex",
      "members": [
        {
          "function": "Abundance",
          "namespace": "MESHC",
          "name": "gambogic amide",
          "id": "429b3b11f769f29d4c2060831ca6d6fb0b3ffd6b905b4dae1fdd9bb3e600f55008f22bfe27ef584eb90442021faef99398c134065b80f969347910910ebb3291"
        },
        {
          "function": "Protein",
          "namespace": "HGNC",
          "name": "NTRK1",
          "id": "56a34234bbcb67bd79c9a5894e4f2c17e8f84594a6b24bcd330a2805ad0891070443a7da277b0047b37c52af334bb3889dc8cca264557242381b7b65f19ccd24"
        }
      ],
      "id": "2ef464c23ef82253853229af1d4e0b5d582448499df7d6998d96db88c2a7d2b1e82f3948a81d061fa514f4eff0ca3ef5feab03f580f79e483726c24f2c6888b2"
    },
    {
      "function": "Complex",
      "members": [
        {
          "function": "Abundance",
          "namespace": "MESHC",
          "name": "pro-nerve growth factor, human",
          "id": "646cae87a17f321169391c78d3e2fad5faeb9ab8b4ed4e583f0c5474188142ebcb82bae7e150ce8786cdd68c3bf5637847be0acb8e237b84e5a8c2439feba42f"
        },
        {
          "function": "Protein",
          "namespace": "HGNC",
          "name": "NGFR",
          "id": "cd78700c9feba4b7aed402f9d26d83106682ce3f4d3e862f85d599795b156db4845164e76939ebc527639b83487714396dec6e2a2acf6b0fb6283ef3be7fc6fa"
        }
      ],
      "id": "ff7b65877ca5e287ba6d918b22d690b8dfaedbd58899d68f909bae21bf8cad620dba99d02a89b58fe570d40ffdb6d5e163fad65e29cd8460d082655397ba0b0f"
    },
    {
      "function": "Complex",
      "members": [
        {
          "function": "Abundance",
          "namespace": "MESHC",
          "name": "pro-nerve growth factor, human",
          "id": "646cae87a17f321169391c78d3e2fad5faeb9ab8b4ed4e583f0c5474188142ebcb82bae7e150ce8786cdd68c3bf5637847be0acb8e237b84e5a8c2439feba42f"
        },
        {
          "function": "Protein",
          "namespace": "HGNC",
          "name": "NTRK1",
          "id": "56a34234bbcb67bd79c9a5894e4f2c17e8f84594a6b24bcd330a2805ad0891070443a7da277b0047b37c52af334bb3889dc8cca264557242381b7b65f19ccd24"
        }
      ],
      "id": "a5952e78b081f335e08056663bed157a4083f0ec2860d19e53721c3eef2c68f82258f12cc9e0deb2143f72f14ae4ab46313ffe8f040ab986a1fb46d2482ddad5"
    },
    {
      "function": "Complex",
      "members": [
        {
          "function": "Protein",
          "namespace": "HGNC",
          "name": "APP",
          "id": "ed1d45f3255226e4210017e6c179950e0e04a300727326d7fea6a9659868e8818ff64fd5e8a2a92a703fb1566b3f48323750ac6c28e7adb40843053d276710bc"
        },
        {
          "function": "Protein",
          "namespace": "HGNC",
          "name": "CHRNA7",
          "id": "6f517aad2a254d42d4e0bd5118246057049b85324ab857629d0caa2da5e997bfcc08f9a0a2cd83bbb2b536c048ce402c0d521604c43b1b9c720f4e20b4dacd99"
        }
      ],
      "id": "1c9253ea773ac5c69a2df20bb88e60a8acc705bf7194defd26e02274093dc90d4f9749657bad0f2ce8c27488571eb87814d266de95711faffbdec1e039ab81df"
    },
    {
      "function": "Complex",
      "members": [
        {
          "function": "Protein",
          "namespace": "HGNC",
          "name": "NGF",
          "id": "6280e1263996aa31e327521e5975bd06ec1fcc254924ed2e22ada8044eaafa6aeb9242e083f65427b4461e8f6a7d39b80be9b9a35d3509d266e3ced9c2b7afe4"
        },
        {
          "function": "Protein",
          "namespace": "HGNC",
          "name": "NGFR",
          "id": "cd78700c9feba4b7aed402f9d26d83106682ce3f4d3e862f85d599795b156db4845164e76939ebc527639b83487714396dec6e2a2acf6b0fb6283ef3be7fc6fa"
        }
      ],
      "id": "829f1ff01b7ed2096d774973d263778f8bdea55b2ea3ce454649e6fa3bf50d3e54bd39f534d8beb7133e3df31cea526a2581f7ea6c7b0d57757d9d409ea4ef58"
    },
    {
      "function": "Complex",
      "members": [
        {
          "function": "Protein",
          "namespace": "HGNC",
          "name": "NGF",
          "id": "6280e1263996aa31e327521e5975bd06ec1fcc254924ed2e22ada8044eaafa6aeb9242e083f65427b4461e8f6a7d39b80be9b9a35d3509d266e3ced9c2b7afe4"
        },
        {
          "function": "Protein",
          "namespace": "HGNC",
          "name": "NTRK1",
          "id": "56a34234bbcb67bd79c9a5894e4f2c17e8f84594a6b24bcd330a2805ad0891070443a7da277b0047b37c52af334bb3889dc8cca264557242381b7b65f19ccd24"
        }
      ],
      "id": "36fd1eda52ed68eb784e608edcb45f03c963da23d0d851ba9818d2a5c8e6cbba4e14c4a10b4906a6698f058c110a3025bee1265bb2c80dbea31c8982171e3efa"
    },
    {
      "function": "Complex",
      "members": [
        {
          "function": "Protein",
          "namespace": "HGNC",
          "name": "NGFR",
          "id": "cd78700c9feba4b7aed402f9d26d83106682ce3f4d3e862f85d599795b156db4845164e76939ebc527639b83487714396dec6e2a2acf6b0fb6283ef3be7fc6fa"
        },
        {
          "function": "Protein",
          "namespace": "HGNC",
          "name": "SORT1",
          "id": "60662f42b6fa5e2f4e921e66dbfaaa21f663b1f4c428a37bcf94a378c694385bfc1a02fa173693ff7fbfff6b39fd1fcd7f331639f557d14e641bf24bf6692c61"
        }
      ],
      "id": "4d198caf910079d602588364b8f57fd4309f7bac9f3d410d3673ff09905e002dcc073e8227a758e6ebe5e4553445ca0c878418227f7cb92842751233e670f4c0"
    },
    {
      "function": "Composite",
      "members": [
        {
          "function": "Abundance",
          "namespace": "MESHC",
          "name": "pro-nerve growth factor, human",
          "id": "646cae87a17f321169391c78d3e2fad5faeb9ab8b4ed4e583f0c5474188142ebcb82bae7e150ce8786cdd68c3bf5637847be0acb8e237b84e5a8c2439feba42f"
        },
        {
          "function": "Complex",
          "members": [
            {
              "function": "Protein",
              "namespace": "HGNC",
              "name": "NGFR",
              "id": "cd78700c9feba4b7aed402f9d26d83106682ce3f4d3e862f85d599795b156db4845164e76939ebc527639b83487714396dec6e2a2acf6b0fb6283ef3be7fc6fa"
            },
            {
              "function": "Protein",
              "namespace": "HGNC",
              "name": "SORT1",
              "id": "60662f42b6fa5e2f4e921e66dbfaaa21f663b1f4c428a37bcf94a378c694385bfc1a02fa173693ff7fbfff6b39fd1fcd7f331639f557d14e641bf24bf6692c61"
            }
          ],
          "id": "4d198caf910079d602588364b8f57fd4309f7bac9f3d410d3673ff09905e002dcc073e8227a758e6ebe5e4553445ca0c878418227f7cb92842751233e670f4c0"
        }
      ],
      "id": "c0bff86672571285c17d1161ec62d4580cf98ce615f0c482cbe08fb2f9e77590a0217b40d490f3ad31f4e4e03966f0d24b06e30cb617f7717bbb699d800d07ce"
    },
    {
      "function": "Gene",
      "namespace": "HGNC",
      "name": "NGF",
      "id": "5b48eb3e31d2a4083e1a0edf5a278abe1170e54ad3052d571edd87f1f1da195bda0170cc64199bd33d2d1a95bf644ece4f930ecccd403f90ce4afd5c683a6f79"
    },
    {
      "function": "Gene",
      "namespace": "HGNC",
      "name": "NGFR",
      "id": "eb5aa2f48010d4384c062c19c52a822c87e34658762caa4889ceef5b432051410484332cfd6453e586bb28ef592ed6230cbb8dc617960f14812b1df9fba3a729"
    },
    {
      "function": "Gene",
      "namespace": "HGNC",
      "name": "NTRK1",
      "id": "3d00b1dd22be65fbf0285d8ad74ffb2214809a76743a884d6c1041b63663af7cfe3e7dfd2ade7e55c5f9168f911eae90f9b4a1dc7c8a1ee7e37d34afc7f7de6d"
    },
    {
      "function": "Gene",
      "namespace": "HGNC",
      "name": "NTRK2",
      "id": "a5653264a6a3564067142404e13effef367892ab3dcddd9d01a9150266e068c57cfe63e79eb8f340aee42396db80830206f91330470742be4374b949a1e1e355"
    },
    {
      "function": "Gene",
      "namespace": "HGNC",
      "name": "NTRK3",
      "id": "b83892a4993429b02d78b582822ab08c27fcc70109be4b1b67bc6e09d450ae8bd0c5f0cd0b2af6307d30df9470702a0bc8af689f5850fa6c4e458f6aff573f0e"
    },
    {
      "function": "Protein",
      "namespace": "FPLX",
      "name": "MEK",
      "id": "4ac766b2223a0ece52652b729c4bc387bbbd5b53e9b41a3a706a75373c2bbb95b9f3816f8dfec1d0a1bdd0abda20b2caf3e6c1c87ba06dd488a83ebe2177c706"
    },
    {
      "function": "Protein",
      "namespace": "FPLX",
      "name": "P90RSK",
      "id": "a34906eaf8bdc48bffb7792071c46279abdbbea6527b1e43e9cfb816c3cd92438c9b07f52ba6270642e40461aea2ed4924e7b0fb78cd6c8fc996976470fd6c38"
    },
    {
      "function": "Protein",
      "namespace": "FPLX",
      "name": "RAF",
      "id": "f2fdfc44698ce7aca1382af631182a5260bfb2b49f9cdebd6f67a57cb729805925a3e3e18175e7289f36af7e23114924dda6a67094f4f7727705df04d2880b79"
    },
    {
      "function": "Protein",
      "namespace": "FPLX",
      "name": "RAS",
      "id": "827fa01503f207ffb1fc7d67c67ad93d6fc3a1e59a61d1b1c030d813f85cd74c6e1c9e3c94a645a1e4c8aedf5b6054a296f63ca9edd222014f077d8bba56100c"
    },
    {
      "function": "Protein",
      "namespace": "GFAM",
      "name": "Cholinergic receptors muscarinic",
      "id": "821c6c20562dbf60d42d0f3102db00efb270f6616a3f75fc508ce25ed30b528a1ea8a07a66324a2bcd1a8277d68ebee225e27fe50a5ed0ad1c5b725213d6c658"
    },
    {
      "function": "Protein",
      "namespace": "GFAM",
      "name": "Cholinergic receptors nicotinic subunits",
      "id": "77620072165b499fa28a36d7c16986201080a35736962ffbfd1c37246bc34cfe47ca1f6028b7daec981f1039afdb29cd23e7db2d93935a40391cbc532ac2467b"
    },
    {
      "function": "Protein",
      "namespace": "GFAM",
      "name": "Mitogen-activated protein kinases",
      "id": "850113236ee57f9b36df5d7c7cfc2f3b996914045d29813385faf887861ca1d0be7137f9e4f9b86a18b21be145316feb6fbfb7834660c28ba2918a25307cf17f"
    },
    {
      "function": "Protein",
      "namespace": "GFAM",
      "name": "Mitogen-activated protein kinases",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          }
        }
      ],
      "id": "e0d9cc15b4c0230e764bf4e677effa661a453742e0917ab17418fcc8c31c69d15060bb8971b6299ff956f0b3bfbc1b122dcf70b006939a9abe0ededc7b005f79"
    },
    {
      "function": "Protein",
      "namespace": "GFAM",
      "name": "Protein phosphatase catalytic subunits",
      "id": "e5a6ee449dfd337e6fcbfd2fe92cb4ea136e301ca69e893e64ba6ff86548792e7367b252a67dedffcc148d24acf1e67938fef764aeba9db80e54442fbe5977b7"
    },
    {
      "function": "Protein",
      "namespace": "GFAM",
      "name": "Synaptotagmins",
      "id": "2b597e712ce37887edbc63d5781998ea9409a59f257e836a059cbf57c6e95d6818f89e4324b395d20d5f4e1414c7161faba828cd4c7067624dc546f06f91aaea"
    },
    {
      "function": "Protein",
      "namespace": "HBP",
      "name": "Tau isoform A (316 aa)",
      "id": "5f46ab5acb31431da9b1ef9cbb79736e8685b1a84baace10d6d2e9e5a0bb9ed5185eacb8e943ca55038f64f19b453b707818fddf6d2693dec726a243ff3c4d1a"
    },
    {
      "function": "Protein",
      "namespace": "HBP",
      "name": "Tau isoform B (381 aa)",
      "id": "7a1392dc957a5ef0724b75f6c268592fbf3c1d9072e58e0e2950411958100bf88575d173fca8618253b8af6548a9d0e4fe74934f70b9f583c6549dddcac2d818"
    },
    {
      "function": "Protein",
      "namespace": "HBP",
      "name": "Tau isoform C (410 aa)",
      "id": "90c0b29e2bc1a6ac4a39734ba64f73a12ef82c738fb9b7ea023b54c9e7f77bf494107c7c0c617adf6de46a6935b6ffe77a42ec0f154f3aa1d517e22a219c5f50"
    },
    {
      "function": "Protein",
      "namespace": "HBP",
      "name": "Tau isoform D (383 aa)",
      "id": "a885b09efbbb1b5a4fd8c70427bd70ae64c59f603b45be3e6a0dc2fe01af0db09c357967c5b82a267f8d05dbd2ce073ede42d7b2f9780e48d796d145c2e745e3"
    },
    {
      "function": "Protein",
      "namespace": "HBP",
      "name": "Tau isoform E (412 aa)",
      "id": "428154eded959050664a0ee9bb617262e506c867fe2b8059cfedd3e192df9140c83569a63dd1f1bfb98b780a11887bfc19696f28bb2a64c4d6a4007214160211"
    },
    {
      "function": "Protein",
      "namespace": "HBP",
      "name": "Tau isoform F (441 aa)",
      "id": "6f77e66c8e6368b067f47a9e99af43c53de45b1decba4c781f56e3d00bc2250510977965c81031b9b64a3e71da16a521a52f27bb16fd9846d5816bd36abd9ee7"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "ACHE",
      "id": "9d3104b5d47c472fac8109aed790de48a5955d80c72a1ca46580350b0d6c41e96ee75cb1cb868657d107abf241c10c81b1c892d4eee5a68f558f78cd14ca802f"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "APP",
      "id": "ed1d45f3255226e4210017e6c179950e0e04a300727326d7fea6a9659868e8818ff64fd5e8a2a92a703fb1566b3f48323750ac6c28e7adb40843053d276710bc"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "BACE1",
      "id": "88f17e7dffb6947c01414f79e5a3bb9cdd3e932c355af7f0c8907d2b5d07742883eaf63866fe7fc938401ce0c366856fd5e306f324e6c1f474c1a984c8e46a51"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "BCHE",
      "id": "82b8adb88edcf051792b8febba4d4eefb691627fdd5794e92fff61d19796df78598312e9daad8390028c4c45e1b1868d1839098cc3edc45e25a2c1b92260d458"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "BCHE",
      "variants": [
        {
          "kind": "hgvs",
          "identifier": "p.Ala539Thr"
        }
      ],
      "id": "fa232001ca276f5e3acfc4f2cbc556df8eb815824ee279b427f4e93d13f728d060e208a0fb6146a18dca8d042c4a5058f6c4d44651788a58b357ca6865bba9ad"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "CHAT",
      "id": "83616fc651645c99c1241b56d867a50ae4c018175bde3ba565013689e69f634139b6a62407ad56c90279b66bb2ed0f021686ef2123872c34ad71eb747efce213"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "CHRM1",
      "id": "962b8a84d274a6e78416261efc2137bcf03c8035a7be3138736624f9c08fe9ae92738ac20d9edd54a6ace6ff161f28793df367f2e084e2837fd799e530fddbbd"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "CHRM2",
      "id": "3f3bd4efac7c25609453f906264cb2c3b1de4eb8eee23d557332d4dec2c604a062717a3aaa3a273ae625f7290f3815251c76cd5b9300f8f684085d5526c1cbb5"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "CHRM3",
      "id": "321acd12eb1b51bc2a14b21c01d30c83c6a4ce5c3255ef3cf2690b65596f9594c541dc6fe9a23210d952a2fdac2f2d05aa91e4299d1942926ea0932119e338ff"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "CHRM4",
      "id": "92e568f0e1bc4f13da9c8c905c0894d766ba624982320637733a3097dc72ffc572e6c948301c16f49c9bcbd674b9c3586f48c8643e70247024048401ae1dd969"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "CHRM5",
      "id": "7127c478eb6b98b42d944576f420df9017725b724e77febd046f52a2dcc8662133f1e33f6981df086ad9fb9aafb0854d39dffa37131f122cd1e0fd6d4cbc981b"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "CHRNA1",
      "id": "2c954be76ae672869d04b052482aff81e8668f2b0c084e05a07b56bc45478c32c71764e3875f446be6d7e0117f400a88ca72e5d5fc0029229d0c16c4ae3e8e6f"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "CHRNA10",
      "id": "0bbc48a8cfa60e08e8a1ba5af2709f120f3f13d715aee919c66261813355c8676197175be8c1904aef415d92c7c0d776e87a2149fc30b3d7f1665158f1c0c645"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "CHRNA2",
      "id": "019d1c092def2bddf48f48ad995d60d9628fb0125b814a5e643e6910d6eeac771b60993b4c3408eb54aa70f35c7ae8fe499737202541875d1f38277a8bb9b237"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "CHRNA3",
      "id": "6f78ff6a0f6731184d18899c2d440e5a27e7d27df60a82118f44199252b2aaac56d93dc20fb99caf759ea575a26ffe4179b16e056eea94d72bb48e24ab188c2c"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "CHRNA4",
      "id": "c49a9652cba613af55ca7c03c108df12ef9ea4e37760fcb7b2302e019899a0eaa11f06c1dcd9b9eb143b9baba0daa89737d73dafbfde9d8ddd8dd53b2a8269e0"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "CHRNA5",
      "id": "615cec2665d995fe2c996d1183a4728e324f4b0f6225b7b3c5f0a0543ff18b97454ba99ae0984cf85ff27bb465eaa83c00cd65aefa96193d58a3332751cca192"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "CHRNA6",
      "id": "538307ae2a1fc2af82c7e0a0286320b0366e3e9a4e5b9597803273c5c0f3049fadef72ad508f6edec030727aaf62edd6170575aaa6046e40567d53e7322aaabe"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "CHRNA7",
      "id": "6f517aad2a254d42d4e0bd5118246057049b85324ab857629d0caa2da5e997bfcc08f9a0a2cd83bbb2b536c048ce402c0d521604c43b1b9c720f4e20b4dacd99"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "CHRNA9",
      "id": "8d5d3a89881c31692ed5f732b23bf994b16f9ac57317f45527031b0c2258040a2761bf4bb5132efa27de3f9d8dfa9d0950b3d1a094913610ff2bc9b8d01e8c04"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "CHRNB1",
      "id": "1c047d2b05c2943c0d93829faf7eca2f2847720340809607e7aa7e77cf2565d0ce5534dc0153fcd6d94cf666bef778540900bf0f642be98eb5ca383f7f9e8770"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "CHRNB2",
      "id": "fe8a0d337c8dfad7d9bbfcd38db3a76bbbfa276ae7af2e39600a1b845049505e52dd605173e1b8a8b67178c31bb8cde3f2669676e398c994800c15170b63033e"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "CHRNB3",
      "id": "cab3d2b7a9a4321d552b5fbe2ff10363ec8ef4b6600f91369ec41f7131fc6d427e0b159e6626d5c42f2eea7b9c11390fc4a6b2964471ee70776ea8960135e7ca"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "CHRNB4",
      "id": "54a4217f39d22f6dab3931757d3288776dce65f089209e15d5c6b0a31c7346fc28b6bd9fd28653945fa42712c1e563e6e62e9b484a4896e5f385b0248ac2f9ea"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "CHRND",
      "id": "0fc12a3743f6213b0a8c9854f102f96f98b6d4ca5f6b93243215c6be9ef59d1071e4a981dfef35497424c052ed7d381aad79e113dad69e8c322a85d581ef69e9"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "CHRNG",
      "id": "fdc2324c7ab13b542120da2e930dae1aa2c84562e3bc9a659ddf97ae7412bf4cd7e8ad8fa72eca411b79eb3b1dc8c21dbdeb575bf3d6015c33aae8e21ca0cdf8"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "CREB1",
      "id": "b4e6626fd4f7ff2ad89229ed553876d0719aa42b70768f79a8e96d81ad027944187f1b2d5e8f56f424e36180c05426785b7501c5965fa85d1a9b2011dc2b124e"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "CREB1",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          }
        }
      ],
      "id": "bb49dd8415a2743f090c639377beb6641cce04d505353c40bf92778ac0fefc685c38c44cc65cdf86f3e42c2453b9250532abb6dd3a87a92ab3a59889ef6c6ddf"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "ELK1",
      "id": "ace0af9309f5a0815c90fd053df0fd9b068742fbc7d89f0d09693336636aa4cee18b0553da9138e852708fac25805bfd9fbd4b5abdbb6840668a08673b400e01"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "ELK1",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          }
        }
      ],
      "id": "fa98ecfa5d6ae27bd50148476fec33ba061252042441f235220847ee69f9edb8d0193d8b9fa84dc1f5ef10b3839c3885e8c91a5a39850f4ec9b37ddae1d3ec3f"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "GAB1",
      "id": "024268de0aa2868f2cda12a71293624a719752d30d035dff70f6c48a5b48ba1dc99adcbb9b729db4fde31cd27d3ac07c3762bd72b8d098f68ec6a95b39aeb6ce"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "GAL",
      "id": "57d9ab49d0be5819ca4d59a2db1d414b33c10534dacd371b85cde9d985aff13542e37c51455c5ef5a6ba52a51bb5cfb66982284bef1e98eb0f42d75cb624e36e"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "IRS1",
      "id": "695da0e7d607d0d8061d5373f9a98d49bc0f3b60bca1ab602f2ddb4a4b1a7c127fd71bea902b99954f596c02aff9fdf1e4cb788a6db5f90172dc8c808a3c0bf7"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPKAPK2",
      "id": "719001825d3c2c4bf249d396e76334c6ddfe903b76bd41ba5ecee55dcecae12f8068b32376758f1602adf57901beef561c673d51bf54dca0beabfa87301446a9"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "id": "ad82d360f02888e890bb2d1f91d1dc020c21cebed2b4eed0193a58e6b396b5f0797d607568dea382c05ffe2a003537d10190b020739af8d51c8d7dbc19bf5ab1"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          }
        }
      ],
      "id": "526bae251987f8c4f55f6e2451662fa55e087c57585beae7c389b020d73487c739834e9b8ec841783de6a5b5fb9df8b138e9eff4406a9ec5e606766575dcac0e"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MMP9",
      "id": "8fe636fadbffa82d6204b08f82973c63c9f603b4de9d10db707b7a6978c7c86c8a9c4a31d16caa3480ffd334bf56d8f856a8639c32e2fce7764ef4decafd6bef"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "NGF",
      "id": "6280e1263996aa31e327521e5975bd06ec1fcc254924ed2e22ada8044eaafa6aeb9242e083f65427b4461e8f6a7d39b80be9b9a35d3509d266e3ced9c2b7afe4"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "NGFR",
      "id": "cd78700c9feba4b7aed402f9d26d83106682ce3f4d3e862f85d599795b156db4845164e76939ebc527639b83487714396dec6e2a2acf6b0fb6283ef3be7fc6fa"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "NTRK1",
      "id": "56a34234bbcb67bd79c9a5894e4f2c17e8f84594a6b24bcd330a2805ad0891070443a7da277b0047b37c52af334bb3889dc8cca264557242381b7b65f19ccd24"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "NTRK1",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          }
        }
      ],
      "id": "51fe1a013e316b06bacc12f10312091bf121b96a3949381890d7b23fca12c41709330e7d46daa9c8a82893cb5da66247acaa895f8e3da9eaf25b896ea96123f8"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "PLCG1",
      "id": "1512790a6177cbcb3e1fa3670ab32a1e96cb66ceb251a6717153f95adb12b12bc42d7a8b96a468e6b27fb7365da5f4c302ebb64b5bb611fec1d9c50a25d334f1"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "SLC18A3",
      "id": "54407dc029292e71e6aa6d83b76ba173d7a64aded707423b0c2afbe6e4fcdba7a178ba1ded256b115be7cba323d1f3f68060181bc944a73f6d8e08ff3245397d"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "SORT1",
      "id": "60662f42b6fa5e2f4e921e66dbfaaa21f663b1f4c428a37bcf94a378c694385bfc1a02fa173693ff7fbfff6b39fd1fcd7f331639f557d14e641bf24bf6692c61"
    },
    {
      "function": "Protein",
      "namespace": "MGI",
      "name": "Adam17",
      "id": "97d3c00c0ab9d1d2af027bb915f07e57dc287ad2a1bcab8537828a3b19d0da1c45c8e028f006ef0763525d4eede5d3b224c544d8c212c7b97c6840fa4d6c7e40"
    },
    {
      "function": "Protein",
      "namespace": "MGI",
      "name": "Bace1",
      "id": "0ed08903c69f611a662ac9b5d440fe052d2fa731e4ca12d3b56f81efcf760a1333e4ad10a5c3ede57dedebb2462cdb32f458ea86d531a9a2113aa8b026505c94"
    },
    {
      "function": "Protein",
      "namespace": "MGI",
      "name": "Chrm1",
      "id": "45b464adf68bffe5d23f53634e7064e00306d71fed21b4cb0954c6336acf4bc5dae8b45abaf6ee19656e8ca4815e390c82062a5f79cd7dae6da61103e87f5e29"
    },
    {
      "function": "Protein",
      "namespace": "MGI",
      "name": "Gsk3b",
      "id": "b736f9678213df5d00e417b39eb991aea58a169a9b2d00bc986629a81d8bc014dac30bb5e246f35a286104e3959c859ab388a6b724bbb1e7c8e6a98ca23de14f"
    },
    {
      "function": "Protein",
      "namespace": "RGD",
      "name": "Gal",
      "id": "2c2cb768858e7c7bf0379504d8fa74effd744c5f4013374770cc7476723d841a7718be8039e121ed60a8c86f5d325994dfc38f49e53772b0e9452611d85760da"
    },
    {
      "function": "Protein",
      "namespace": "RGD",
      "name": "Ngf",
      "id": "c0caf851a7c2d64fef3b8459e9765f5af8845f3b997fd4ad6c979363c1c4b74556398a91c19cc8706abfa70919c2199edea31e4c22fcadad16b28b1da35b30ff"
    },
    {
      "function": "Pathology",
      "namespace": "HBP",
      "name": "aMCI",
      "id": "7c4c62f53881417cd48cdc7c703d2b7ee9b0d8b9fa346dbbd33849ad4be0f8610e5135c0ceaba01d1a07dcc2ec32c88714c3b9bb3eb861dafbb0c9b9c1623c28"
    },
    {
      "function": "Pathology",
      "namespace": "HBP",
      "name": "mdMCI",
      "id": "a0129a1e599116792db5535ca52326e1fb1949a80971bf7b7ef1b53ab7acd50697b8de47cf3718a3c05fb02a53b3447986de665b80087b872c5e5fec97ccf09b"
    },
    {
      "function": "Pathology",
      "namespace": "MESH",
      "name": "D000375",
      "id": "f7db37d1bfb5e1c2c81f44933bed00b04ee14f2b47f73788db7823e7c0fee345c2b0bf96848143e9685e322a964a715d0b384b0e5be80ea57681a4f77dba54c0"
    },
    {
      "function": "Pathology",
      "namespace": "MESH",
      "name": "D000544",
      "id": "7b9cf1c7ea7ae87bbeaadab15ab82e2b54cc85a10079afdb10d56f83a9d7fd536cecf3a4774fa80695526878d7e53737f273bf9418db7c86929ff600291fd8cf"
    },
    {
      "function": "Pathology",
      "namespace": "MESH",
      "name": "D000686",
      "id": "e4f36f2a433ba8b7af3a769d9840e458ad94bc0baeb4942bec483ec76bd0618d7b818daad67249c63e13216b5b1d893f3897cd3c5aa235186e318e6f21de5379"
    },
    {
      "function": "Pathology",
      "namespace": "MESH",
      "name": "D000855",
      "id": "64f2213c0ad3c5c9c3bc2187c895aead62348207b7a69645da9a68d2bf3d2ebf5b337b988337e0c9d0bcc4e5e799869b977de13db191bdc678924f59c0d92631"
    },
    {
      "function": "Pathology",
      "namespace": "MESH",
      "name": "D001284",
      "id": "12e5d57bb562702b71437c67433edd6ff5f6d2ab2ef9d2de26d3acb2f297ec22358201bd1341f47bd26eddd1aaf175eb9f8b569de5e16e6523bdd39602f6f12c"
    },
    {
      "function": "Pathology",
      "namespace": "MESH",
      "name": "D001288",
      "id": "dcee3eff6ddada9ecfed2a4230bbcdb5a71e0b791f141c3271d490a50dcc21421947ed075d7efd6b11527ab218abfd64a079555ac218d7f5a48976089d24e71e"
    },
    {
      "function": "Pathology",
      "namespace": "MESH",
      "name": "D001526",
      "id": "f22794e34d55ccd5f913bb6bd55762d6ad837936d0ad30a27be3b3465a38d87d1c97771c481d995bb321ddc45d0c3b8c60e99965ba3ffea9c3aed375ed702785"
    },
    {
      "function": "Pathology",
      "namespace": "MESH",
      "name": "D002100",
      "id": "a7b299d660eaf6b6df11466159f660e86dff74e8389a534af35f94c06f45a49ab97b7d0cd827d66c5fe186ccba525fdbf4c0ae2d03f199ceec65daba52c0dbe7"
    },
    {
      "function": "Pathology",
      "namespace": "MESH",
      "name": "D003071",
      "id": "e0805a91d1f32864206cf22865b0ef84d41f10d8c2aa54424e24b32c0b7e746897cb483e8057972a9569cdad8a61699fe9cf487ccd93d30f340a553efdd77013"
    },
    {
      "function": "Pathology",
      "namespace": "MESH",
      "name": "D003072",
      "id": "e7d53d5d69ed81ee21431a8e7802998c643fc2f68da4fa6a8e0777c57dce9995701266af7defe14ad5d72a6731ab35970886f9b2eda61d0e465aba0b80fc475e"
    },
    {
      "function": "Pathology",
      "namespace": "MESH",
      "name": "D003704",
      "id": "4a36ba330ff42ab7ce3f2b414a707f71bfde84395078b0fd68d8fca7ffbc0bc9f0e74e320e9a3a26788f17b154cc50a08e6b506c8e910532f89a1c837f251bbd"
    },
    {
      "function": "Pathology",
      "namespace": "MESH",
      "name": "D003929",
      "id": "0c858c8761fa88c2895629bed826ab6cac0d6a1358b8a9721794790ba4093df6f7be218b87e20e9a353b11f742ed4f6906b26a6fc56765947637600dc5d88cb6"
    },
    {
      "function": "Pathology",
      "namespace": "MESH",
      "name": "D003967",
      "id": "9b96288053743742e868ae834f9dd121fb6aca8a57f2a03b770112801526cda727ecd6dbb7e8efcf88c119eb340b45a0c6a5e848a7edbc7a96a11db36ccd5b8a"
    },
    {
      "function": "Pathology",
      "namespace": "MESH",
      "name": "D005221",
      "id": "df14a36407b972ae4de7d7e769e6e27979da4e677c712d08c3c0b77ab82d4441ec6efa06c3030b6958ed38ce093183cd1169a77445176d59cfe370b48c51209c"
    },
    {
      "function": "Pathology",
      "namespace": "MESH",
      "name": "D006930",
      "id": "4041ed3f866f72c3837ff23f0ad0ffbf87c47d8320ec2c35ea1cd680bd8ac09dd0ccff63dd0174e5a26870fc34b810ae0101509aa2e0eb99c8499d360a2b165e"
    },
    {
      "function": "Pathology",
      "namespace": "MESH",
      "name": "D007319",
      "id": "b18fb0bf60f429738bb3c262bec26a45172f72adf7e056dae133f41b2623967178466ada55c31550495a5eb82bd29518aad57e0ea90abb3c1c89c2faa95ad422"
    },
    {
      "function": "Pathology",
      "namespace": "MESH",
      "name": "D008568",
      "id": "e477d196c4693402ebf4c644e177bdadc83b6d1bb03e35486d798e9c208d61b72e9c78b7119e786713f2e9c4245299a385d456b46375ade63992cb3ae26ca4d5"
    },
    {
      "function": "Pathology",
      "namespace": "MESH",
      "name": "D008569",
      "id": "242613fc5039b4ca4cf88d65cad4deb4cb3b93098d906816e4fa9ca55f4119d3dd7811b1b94bbe81b26b4800c30ed4a9aa8f7da8569a696665d5aac9e9d10b0b"
    },
    {
      "function": "Pathology",
      "namespace": "MESH",
      "name": "D008570",
      "id": "e8c51a317540dc1f7ba9a73b6b28bd2319b2a4fd8e81ce1cfe970e0b18526783d83990b61ccceea9662fce8a141165c29aa9c1f1abe778f275d8b5acd486fd31"
    },
    {
      "function": "Pathology",
      "namespace": "MESH",
      "name": "D009325",
      "id": "6e3cdb9a25ca4509b926dcf1f75440ae8f29e8e68add352e99e1ba27910fb2d554f4fbebe9d5c14f3b975fed649d7474e150d09a1be556dc5993754f7742bcfc"
    },
    {
      "function": "Pathology",
      "namespace": "MESH",
      "name": "D009410",
      "id": "9b6b20be7fe528fc80a66c0f670079dec2fc8e7b27ffc527c8b191ac5dd3e3d51a5cd3d3f533688be48db98326899450345be6cbfaa08697c1d5678a1b264b62"
    },
    {
      "function": "Pathology",
      "namespace": "MESH",
      "name": "D011597",
      "id": "89b76efacacc430fca418438d555c4bde35efe9453c3dae7c750a3f3d13df95d671163dee7e6f0b11b04ac5bb2826d5aac11c0274c6d7f06ed816d6ee9afae35"
    },
    {
      "function": "Pathology",
      "namespace": "MESH",
      "name": "D016263",
      "id": "25ef51fb31b2c9fdb3c330167c9762e92b869a6586f9c7acb9abbee0ad1e76ec579823472724d93b26046e3cba222ecfae86fcacd44f336ff3debdf3a9b2ca28"
    },
    {
      "function": "Pathology",
      "namespace": "MESH",
      "name": "D016874",
      "id": "374191e01f2a7a45f281068924e97a3c6e619b33035d252a6e3db69b5372b9c6a6debdc9d01d07662c0e2ff2d979e29524ec29d20ccddbfd0595544258271ecf"
    },
    {
      "function": "Pathology",
      "namespace": "MESH",
      "name": "D019636",
      "id": "3c4f3499b72b13a532eb32f4578d6474a141f3a7419728a0618e660a48e25287d2d4e3491abf6261b777792f66eea54eec6b376755409c64ab39db3a7609d1f3"
    },
    {
      "function": "Pathology",
      "namespace": "MESH",
      "name": "D024801",
      "id": "d6513db090091aff9cc0486c85e29fa4b2e0d3d6cc7495e24b8b4afa87402235aa01404efb78fb9677dcf4a2ef82982bfb8c343c9bc14921af537ec15368321b"
    },
    {
      "function": "Pathology",
      "namespace": "MESH",
      "name": "D058225",
      "id": "57fd983c3b4355ab5d48d9f22714190313dd4d486c12fa9e15fb06686ae551ec367274c7ba60e22deb098f72c31d2fa25f721f99996aca1fe6c446d919fb69b5"
    },
    {
      "function": "Pathology",
      "namespace": "MESH",
      "name": "D059329",
      "id": "e6943e881cd789ac6ec73a6b938263dc406003a2a05f5105dc5bada8bffd55f03ca4363f99768ad0226e07cb1cb93d4a381c61e01d5be80466e5d0825929054f"
    },
    {
      "function": "Pathology",
      "namespace": "MESH",
      "name": "D060825",
      "id": "6ae0361454dff4bd410f7d7a8ee4f57d3608b84b33d15f57c4588e2d4a51c98cf41719d961891332ec7a455821c38c65a129dbf352264727d0334b5cea1d5ea4"
    },
    {
      "function": "Pathology",
      "namespace": "MESH",
      "name": "D062706",
      "id": "7a67b4d1fef6e5599fe1dba305e8eb1ef5d66e7bac3f69078075cac5d2d1d9b15a125170c829042cde6afbbc504b438ad9f580f4be0fddb906adb2036e480c96"
    },
    {
      "function": "RNA",
      "namespace": "GFAM",
      "name": "Synaptotagmins",
      "id": "9a658c5f29a8107592253c4d70b2e91c887780ae5a87df522aa4994fefa6bfe48eb65000d6ccf1ceb28439cae715fb70bcd0ecf684b5541b6939ae6d861f9649"
    },
    {
      "function": "RNA",
      "namespace": "HGNC",
      "name": "APP",
      "id": "c6b028851602848c14739966342f7889f96911d3d64424c5d5489428c11fd520f3b4b468faa76f02e64c225eb9603347dc86317f6fa4f4ddc3718d40b35449d9"
    },
    {
      "function": "RNA",
      "namespace": "HGNC",
      "name": "CHAT",
      "id": "db3f45ee6c46466c45ceeef6d4e14ac12979e1787a8be54fee5e34eadf546401b8474f34d6c38930d09dcef7658a989f3e41291cb0ba0c227d035a687fa9a596"
    },
    {
      "function": "RNA",
      "namespace": "HGNC",
      "name": "CHRM1",
      "id": "f0382795c514ceb035810b3c47b8ddc07fba16d7ad177c72c5b9d6fdbbd72d05d60d3fb58c0d6e6ffe126657ea7e7a09fe4fa1d1784c314fbe53f8973ae812f5"
    },
    {
      "function": "RNA",
      "namespace": "HGNC",
      "name": "CHRNA7",
      "id": "a05aa727d187aba9ed37f09183caad69734432d7986be00a7e4d4c0b221431d56c8ed588073cd0a9e76046cca38bd11b903a3ed354351e9b01094db398835d19"
    },
    {
      "function": "RNA",
      "namespace": "HGNC",
      "name": "CTSD",
      "id": "fbdc656726f2f60d7f66d7ab36bf34e7e606f25f15d914223ba56b18951339e4f0a721929cbbc560201d6f704c4e0f189e719c5c0fc495269ca6e78030bd507d"
    },
    {
      "function": "RNA",
      "namespace": "HGNC",
      "name": "MAPT",
      "id": "54fd242f396c4644b46548885bfbc0e1c22320972c8b0b6c3008a5a1d9152f5a5287d81a693f85e739f039db27862a857420216fe3eb25d300f63e68d47cdad3"
    },
    {
      "function": "RNA",
      "namespace": "HGNC",
      "name": "NOTCH1",
      "id": "7e40369640236850d1a19817696aeb12cecb4f4d0c0154b4b754c7c3b45b17d92f56c8b9abe024b6de80901cea8a5b8e72f6933737db8d1801dc943f00bf9a69"
    },
    {
      "function": "RNA",
      "namespace": "HGNC",
      "name": "PPP1CA",
      "id": "94e61c49f026280f6314f4308a824b4a51ea6da0817bf6e366dfff01a86d5a86b11fc160658be93de739d735ff172e1ab6518ace05b2d08956a1401b293b8038"
    },
    {
      "function": "RNA",
      "namespace": "HGNC",
      "name": "PPP1CC",
      "id": "2bb0f87fec2fb33ca2d45fff78738ffd463bd46863c96d42e5ddf2db193323d7358df43efcb1da48e22a89e599edae20337ed2b54314394ed2e5ba912764dc32"
    },
    {
      "function": "RNA",
      "namespace": "HGNC",
      "name": "SNAP29",
      "id": "2f048073b6fd9ae21d6265aca03f138c2d1b2101d1f27a49aa32beb1caa962965fe09d1fd8bcced565414bc75c7766e42755f87864bf8f658d2b1721d30823a3"
    },
    {
      "function": "RNA",
      "namespace": "HGNC",
      "name": "SYP",
      "id": "5564a6ac0af9c7166799d349d201de4bfb9946af2894d60d7ef36ff7bf028fd33182e3be40b0e03456efa1a4975d9682fcc3ff48c3b4da79e2107da3ecc73e43"
    },
    {
      "function": "RNA",
      "namespace": "HGNC",
      "name": "VAMP1",
      "id": "2c5ce575e8e52e2c36c599a52843da5c8d9be399f477b21f792440839279da48bb2ba5d5b7ad3f96cc56e0f48874631d22fcdb81c5daac83b077b9dbf79d8366"
    },
    {
      "function": "RNA",
      "namespace": "RGD",
      "name": "Gal",
      "id": "2afe2be3de5659ede86c3709de43ed69c2afb02aeb6609670bef0b7277fc974bd2eb1ea96956476c20915386c3ff9d8eef9498d69a80452fe27ce6ee58da46de"
    }
  ],
  "links": [
    {
      "line": 63,
      "relation": "association",
      "evidence": "Alzheimer’s disease (AD) is a progressive and fatal neurodegenerative disorder manifested by cognitive and memory decline and progressive impairment of activities of daily living, as well as a variety of neuropsychiatric symptoms and behavioral dysfunctions.",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "source": 133,
      "target": 156,
      "key": "f6cb8fb6cc1ebacc9886381a25265bb173eaa824e2c24b323447153a2a0b97c9692611ab2d0e10084b4da9ee7dc9df20adb41dd3abf9e8d4f49143ba53019442"
    },
    {
      "line": 65,
      "relation": "association",
      "evidence": "Alzheimer’s disease (AD) is a progressive and fatal neurodegenerative disorder manifested by cognitive and memory decline and progressive impairment of activities of daily living, as well as a variety of neuropsychiatric symptoms and behavioral dysfunctions.",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "source": 133,
      "target": 148,
      "key": "031a4ad34ac068c0db77807384c08146e04fa9e4deac48c93c0c5703c49b9a72ebdb7c444a66441cc07d4c380c3ce7605d7cdea12c727bcfdea3fb6dfe8b6120"
    },
    {
      "line": 67,
      "relation": "association",
      "evidence": "Alzheimer’s disease (AD) is a progressive and fatal neurodegenerative disorder manifested by cognitive and memory decline and progressive impairment of activities of daily living, as well as a variety of neuropsychiatric symptoms and behavioral dysfunctions.",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "source": 133,
      "target": 140,
      "key": "8b4e3f70781bd46017a7d94222b92c01a32b5b7f05cac4dfcc5dc8ecf022521a3eed91460c8b1e0287f25d8fe47b9eae22a6654135f3d1987bcc57fd1c5aecfe"
    },
    {
      "line": 69,
      "relation": "association",
      "evidence": "Alzheimer’s disease (AD) is a progressive and fatal neurodegenerative disorder manifested by cognitive and memory decline and progressive impairment of activities of daily living, as well as a variety of neuropsychiatric symptoms and behavioral dysfunctions.",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "source": 133,
      "target": 138,
      "key": "96bd2678d366b2775a85c526d1474a625a8cf2be41af30b19050abd44209739a873f7cdd363a474dfd457695d6c4d88573b569082649887acc429cb392b2fec8"
    },
    {
      "line": 91,
      "relation": "association",
      "evidence": "People with a clinical diagnosis of MCI comprise a heterogeneous cohort of which those with memory deficits only are classified as amnestic MCI (aMCI) and those with impairment in other cognitive domains lacking a clinical diagnosis of dementia are designated multidomain MCI (mdMCI) [3,4]. Many individuals characterized with aMCI progress steadily to greater stages of dementia severity, and in many instances exhibit the neuropathologic, molecular and biochemical hallmarks of AD [5–9]. These clinical pathobiologic studies suggest that MCI, in general, represents a prodromal or preclinical stage of AD.",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "source": 133,
      "target": 130,
      "key": "6f310c86b66d386feaf98670750a3241ef4360a55b23ab55f368ef5065ff6006e690d23ef783180c35cceda5422f4166814e4b28d52f470bbe464bdf0b03e0bb"
    },
    {
      "line": 107,
      "relation": "decreases",
      "evidence": "Although there is a widespread decline in various neurotransmitter containing cell bodies in end-stage AD, the most consistent losses throughout the progression of AD are seen in long projection neurons, including cholinergic neurons of the basal forebrain [11–13]",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "Disease": {
          "Alzheimer's disease": true
        },
        "MeSHAnatomy": {
          "Basal Forebrain": true
        }
      },
      "source": 133,
      "target": 14,
      "key": "15f4bd26817b14ecb8fca035ca42eefd52eeaf45240fca2701aa52e2c66ac7497434b14ee9a0d0a68b3c9734009f33d69de536e2a05e61fa309fa77e95da99f3"
    },
    {
      "line": 141,
      "relation": "association",
      "evidence": "Cholinergic basal forebrain (CBF) cortical projection neurons contain the pathological AD hallmark, neurofibrillary tangles (NFTs), and undergo chemical phenotypic alterations during the progression of AD, making them an excellent natural model for studying mechanisms of cell death, survival and treatment approaches both in vitro and in vivo, including relevant animal models of neurodegeneration as well as human postmortem clinical pathological tissue studies [14].",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHAnatomy": {
          "Basal Forebrain": true
        },
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "source": 133,
      "target": 14,
      "key": "1139b3268bcf8a949845cab669fa7a8fa3f1e30d90884c2a39dbcd8f498c364309de2a0135602cc113b6a0ae1da016c082c5b19b816ea341aedd2ef0c4dd08f4"
    },
    {
      "line": 177,
      "relation": "decreases",
      "evidence": "Specifically, progressive phenotypic downregulation of markers within CBF neurons as well as frank CBF cell loss has been observed consistently, along with an associated reduction of choline acetyltransferase (ChAT) and acetylcholinesterase (AChE) activity within the cortex in AD [16]. Most researchers presumed that progressive disruption of cholinergic function underlies much of the short-term memory loss seen in AD",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "source": 133,
      "target": 14,
      "key": "e60f6167316d2aac9a8cff6ba3ef65815027603c999c4dccac2b573131e708cb3f371151ba0a8a635dee1f0b75ef629cc950e0b87b791635b3dfeae397f4a97f"
    },
    {
      "line": 140,
      "relation": "association",
      "evidence": "Cholinergic basal forebrain (CBF) cortical projection neurons contain the pathological AD hallmark, neurofibrillary tangles (NFTs), and undergo chemical phenotypic alterations during the progression of AD, making them an excellent natural model for studying mechanisms of cell death, survival and treatment approaches both in vitro and in vivo, including relevant animal models of neurodegeneration as well as human postmortem clinical pathological tissue studies [14].",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHAnatomy": {
          "Basal Forebrain": true
        },
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "source": 133,
      "target": 13,
      "key": "c75d1949c62961e7d26fe8ce7c66c946190c7447212fcb75869512f1b1820331b2c65fe14ca07c812f8b1f7db437eafac31ae5ff640b7d63d3962a8fc9dd6dcb"
    },
    {
      "line": 178,
      "relation": "decreases",
      "evidence": "Specifically, progressive phenotypic downregulation of markers within CBF neurons as well as frank CBF cell loss has been observed consistently, along with an associated reduction of choline acetyltransferase (ChAT) and acetylcholinesterase (AChE) activity within the cortex in AD [16]. Most researchers presumed that progressive disruption of cholinergic function underlies much of the short-term memory loss seen in AD",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "source": 133,
      "target": 85,
      "key": "dcaef754bb0eb75967f9a7e5815a1396cac4439c164465d300bf638e7a54ce7021211ff7a348ef3459d408e849fbcfbaeae178fcf726a98e05cf49d09d0294d6"
    },
    {
      "line": 179,
      "relation": "decreases",
      "evidence": "Specifically, progressive phenotypic downregulation of markers within CBF neurons as well as frank CBF cell loss has been observed consistently, along with an associated reduction of choline acetyltransferase (ChAT) and acetylcholinesterase (AChE) activity within the cortex in AD [16]. Most researchers presumed that progressive disruption of cholinergic function underlies much of the short-term memory loss seen in AD",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "source": 133,
      "target": 80,
      "key": "dec5a25938623e7c547f3897d62b109f3d30095ade37ebfa037c2f29006a143f105a906ed0e9afd24723095b3640c44841aa1b57b5d7e206aa5946730098fcc5"
    },
    {
      "line": 302,
      "relation": "causesNoChange",
      "evidence": "Butyrylcholinesterase (BChE) is a serine hydrolase similar to AChE that is widely distributed throughout the CNS and also catalyzes the hydrolysis of ACh. BChE is localized to neurons and glia, and is associated with NFTs and senile plaques (SPs) in AD brain [32]. Interestingly, population-based genetic studies of AD have identified a point mutation that changes Ala539 to threonine in the K variant of BChE, which effectively reduces serum BChE concentrations, and may be associated with cognitive decline [33]. BChE activity also increases in AD brain whereas AChE activity remains unchanged or declines [34,35].",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        },
        "MeSHAnatomy": {
          "Neuroglia": true,
          "Neurons": true
        },
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 133,
      "target": 80,
      "key": "f5e605d6efe86bb4c6c185faeaa01bcd3dfb71fb7e489959f89ce55858eca206c07012db9b9e5c0283e57e33fc2c61301f4a9d6aa9449ae7c85cf78016fedf66"
    },
    {
      "line": 303,
      "relation": "decreases",
      "evidence": "Butyrylcholinesterase (BChE) is a serine hydrolase similar to AChE that is widely distributed throughout the CNS and also catalyzes the hydrolysis of ACh. BChE is localized to neurons and glia, and is associated with NFTs and senile plaques (SPs) in AD brain [32]. Interestingly, population-based genetic studies of AD have identified a point mutation that changes Ala539 to threonine in the K variant of BChE, which effectively reduces serum BChE concentrations, and may be associated with cognitive decline [33]. BChE activity also increases in AD brain whereas AChE activity remains unchanged or declines [34,35].",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        },
        "MeSHAnatomy": {
          "Neuroglia": true,
          "Neurons": true
        },
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 133,
      "target": 80,
      "key": "d201922d1919ac21da325adc353119158a9ea1106c731f03840e294c64bc909aed38961c94159d557d2a77b7e284c19293ad94a1ec7eb7f5e1fd3349e4c9bf01"
    },
    {
      "line": 320,
      "relation": "decreases",
      "evidence": "For example, the vesicular ACh transporter (VAChT), which is co-expressed with ChAT in human CBF neurons and participates in loading ACh into synaptic vesicles in cholinergic terminals, is not severely altered in AD [40]. In this regard, pharmacological studies of VAChT in postmortem AD tissue or in vivo imaging studies using vesamicol and its analogs, suggest that VAChT levels remain steady or are minimally decreased coincident with a severe decline in ChAT activity in cortical areas [41].",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 133,
      "target": 80,
      "key": "17b4b8d818aa476185235c7532c7f483d26e8ac51e1cb09de08693d796788d75a5944a783ec08afdf4548ce99696d4f7ce5a00f2d8260aa9085a0cb8f68f6b5e"
    },
    {
      "line": 301,
      "relation": "increases",
      "evidence": "Butyrylcholinesterase (BChE) is a serine hydrolase similar to AChE that is widely distributed throughout the CNS and also catalyzes the hydrolysis of ACh. BChE is localized to neurons and glia, and is associated with NFTs and senile plaques (SPs) in AD brain [32]. Interestingly, population-based genetic studies of AD have identified a point mutation that changes Ala539 to threonine in the K variant of BChE, which effectively reduces serum BChE concentrations, and may be associated with cognitive decline [33]. BChE activity also increases in AD brain whereas AChE activity remains unchanged or declines [34,35].",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        },
        "MeSHAnatomy": {
          "Neuroglia": true,
          "Neurons": true
        },
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 133,
      "target": 83,
      "key": "9a8385ad0ab2543d917af1ba26eb1f3b41ee7f4bd6f4292824db17944a8227319e1e7326b463e47defbbfc1ccd5fd26a7df39bc73828355b5af1c4d312a71b14"
    },
    {
      "line": 319,
      "relation": "causesNoChange",
      "evidence": "For example, the vesicular ACh transporter (VAChT), which is co-expressed with ChAT in human CBF neurons and participates in loading ACh into synaptic vesicles in cholinergic terminals, is not severely altered in AD [40]. In this regard, pharmacological studies of VAChT in postmortem AD tissue or in vivo imaging studies using vesamicol and its analogs, suggest that VAChT levels remain steady or are minimally decreased coincident with a severe decline in ChAT activity in cortical areas [41].",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        }
      },
      "source": 133,
      "target": 122,
      "key": "3f50ffe0ca1db1fc2b6d2a16a08bfcf61102f20b75a78500ad097632f514e5fe21029b0a36da2830571d24d3325498869415b3cc1ccf0491fef4b7dd3a5e2989"
    },
    {
      "line": 332,
      "relation": "increases",
      "evidence": "Moreover, there is evidence from experimental lesions in animals [43–45] and from postmortem human brain studies [46,47] suggesting that many cholinergic neurons shrink, are depleted of phenotypic markers, and/or persist in an atrophic state after injury or during the pathological process, rather than degenerate.",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        },
        "MeSHAnatomy": {
          "Cholinergic Neurons": true
        }
      },
      "source": 133,
      "target": 136,
      "key": "7361b5e4e0f26fc1b5ac09f9c6155d1eb251aa99572e60389b46a808c7173ac435e2d9bec4a14b36df75137f3b11d4ca28fd868124381df6eea5b3dab0e499b0"
    },
    {
      "line": 371,
      "relation": "increases",
      "evidence": " In this regard, immunoblotting studies demonstrated that proNGF is the predominant form of NGF present in the cortex of aged cognitively intact humans [60]. ProNGF levels are increased in the cortex of subjects diagnosed with MCI or mild AD compared to those with NCI [61]. The biological consequences of proNGF are controversial, as is the function of its accumulation in the cortex during the prodromal stages of AD. Emerging literature suggests that recombinant proNGF binds TrkA and promotes neuronal survival and neurite outgrowth similar to mature NGF, but is approximately fivefold less active than the mature NGF peptide [62,63].",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        },
        "MeSHAnatomy": {
          "Cerebral Cortex": true
        }
      },
      "source": 133,
      "target": 18,
      "key": "c5234a5166699c46d6beaa6814fc6807aea0df1adc9580e5ec3497ec0b05aa6437c0bdb169918a2bb025ad59ba7048adf9e1fd181163d1d079a90a72cce8256d"
    },
    {
      "line": 387,
      "relation": "decreases",
      "evidence": "Significantly, while we have shown that reduced TrkA levels in the cortex were positively associated with lower cognitive performance as assessed by Mini-Mental State Exam (MMSE) test scores [64], increased cortical proNGF levels were negatively correlated with MMSE performance [61].",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        },
        "MeSHAnatomy": {
          "Cerebral Cortex": true
        },
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "source": 133,
      "target": 119,
      "key": "3a800e089a92cc8cec1d3dafb274e511e48b0c4d1e3c7076d6fc215f029cdbb9952a5620af0d1053ab1ae4cfb021cf76bdf0cd2da86c43094267d07322292303"
    },
    {
      "line": 407,
      "relation": "increases",
      "evidence": "Thus, the concomitant reduction of TrkA and accumulation of proNGF in the cortex may be an early pathobiological marker for the onset of AD (Figure 1A). In fact, significantly increased cerebrospinal fluid (CSF) levels of NGF are detectable in AD [65], demonstrating the potential utility of NGF as a diagnostic biomarker.",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        },
        "MeSHAnatomy": {
          "Cerebrospinal Fluid": true
        }
      },
      "source": 133,
      "target": 117,
      "key": "77f7c27b1779af3976eefbb4ac575f4371761fdce30b37c613b406ff88eb52949e94ed2d881cc80d412d12c29fe1b4a3302f08447173918076baa71169a9105b"
    },
    {
      "line": 456,
      "relation": "association",
      "evidence": "Recent findings indicate that the putative proapoptotic effect(s) of p75NTR-mediated proNGF signaling is dependent on interactions between p75NTR and the neurotensin receptor sortilin, a Vps10p domain trafficking protein that acts as a cell surface coreceptor with p75NTR to mediate proNGF-induced cell death. This family of receptors is acquiring increasing importance owing to its potential involvement in AD [68]. A recent study provided genetic information for a role of the proneurotrophin receptor complex comprising sortilin and p75NTR, in the mediation of neuronal viability in vivo [69]. Sortilin expression is required for p75NTR-mediated apoptosis following proNGF treatment [57], suggesting that sortilin is a p75NTR binding partner associated with the initiation of cell death [51,58]",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        }
      },
      "source": 133,
      "target": 123,
      "key": "778dc51ebda79ee490b4d42e2b58af7a21c755a3959450a2f38370c0c0e9ea787142ff7b8b09882a9e713cb51ae822a1602eccebb1db588e6abafd721f8dc62f"
    },
    {
      "line": 468,
      "relation": "decreases",
      "evidence": "Bruno and Cuello reported that a protease cascade which converts proNGF to mature NGF (mNGF) and degrades mNGF in the extracellular space by the coordinated activity of plasminogen, tissue plasminogen activator (tPA), neuroserpin, matrix metalloproteinase (MMP)-9 and tissue inhibitor of MMP (TIMP)-1 may be defective in AD, resulting in NGF dysfunction [74].",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        }
      },
      "source": 133,
      "target": 30,
      "key": "6807a7bccf98da5dbfc82fda28a806582afcc6ff4efd663510ec82906e4df0aa346475e476427beb0a07885e224ce17c35729222486a6445741ba2a606d3906d"
    },
    {
      "line": 482,
      "relation": "increases",
      "evidence": "We found an upregulation of MMP-9 protein levels and activity in both AD and MCI brains, which correlated inversely with cognitive status (Figure 1B) [75]. Since tissue alterations are often reflected in bodily fluids, determination of MMPs in blood, urine and CSF has been recommended as potential biomarkers to act as diagnostic measures to characterize the disease process that occurs in the brain [76–78]. Interestingly, plasma MMP-9 was increased in MCI and AD [77].",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        },
        "MeSHAnatomy": {
          "Plasma": true,
          "Brain": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 133,
      "target": 116,
      "key": "a20dc4fb0924c9a01019080fe93a83dd7dd6fc21d0a3f25c9b35ad3563151d902a895837913a0c11b0c7f6c9ee22211d5941ac28c29478e2b4f26699976087fb"
    },
    {
      "line": 504,
      "relation": "decreases",
      "evidence": "These studies have demonstrated a significant downregulation of trkA, trkB and trkC gene expression during the development of AD [7]. An intermediate reduction was observed in MCI, with the greatest decrement in mild AD compared to aged controls. Moreover, two separate expressed sequence tag (EST) cDNAs for each trk gene (e.g., ESTs targeted to the extracellular domain [ECD] and tyrosine kinase [TK]) domains were downregulated. By contrast, there was a lack of regulation of p75NTR expression [7] in CBF neurons. A ‘step down’ dysregulation of trk expression may, in part, underlie CBF neuron demise associated with the clinical presentation of AD. Supporting this concept is the finding that trk downregulation is associated with measures of cognitive decline [7,14]",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        },
        "MeSHAnatomy": {
          "Cholinergic Neurons": true,
          "Basal Forebrain": true
        }
      },
      "source": 133,
      "target": 61,
      "key": "f4d5a2a2bfb06c80535661a1dd3d728aad9b608eec51e97cf79813c312d4c2214c40815c1a9159b6534b8f958a83f85550d2f1d1233477bdb5f33ed268d18b97"
    },
    {
      "line": 505,
      "relation": "decreases",
      "evidence": "These studies have demonstrated a significant downregulation of trkA, trkB and trkC gene expression during the development of AD [7]. An intermediate reduction was observed in MCI, with the greatest decrement in mild AD compared to aged controls. Moreover, two separate expressed sequence tag (EST) cDNAs for each trk gene (e.g., ESTs targeted to the extracellular domain [ECD] and tyrosine kinase [TK]) domains were downregulated. By contrast, there was a lack of regulation of p75NTR expression [7] in CBF neurons. A ‘step down’ dysregulation of trk expression may, in part, underlie CBF neuron demise associated with the clinical presentation of AD. Supporting this concept is the finding that trk downregulation is associated with measures of cognitive decline [7,14]",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        },
        "MeSHAnatomy": {
          "Cholinergic Neurons": true,
          "Basal Forebrain": true
        }
      },
      "source": 133,
      "target": 62,
      "key": "2331738c4fb05b27aedfbf3883d64b765e8475cbf2d2e326d4f18edd34480f2219c993cf0215c9340c775928aed7a406d86c3c5cfcdb9c41b6f8e75af637087e"
    },
    {
      "line": 506,
      "relation": "decreases",
      "evidence": "These studies have demonstrated a significant downregulation of trkA, trkB and trkC gene expression during the development of AD [7]. An intermediate reduction was observed in MCI, with the greatest decrement in mild AD compared to aged controls. Moreover, two separate expressed sequence tag (EST) cDNAs for each trk gene (e.g., ESTs targeted to the extracellular domain [ECD] and tyrosine kinase [TK]) domains were downregulated. By contrast, there was a lack of regulation of p75NTR expression [7] in CBF neurons. A ‘step down’ dysregulation of trk expression may, in part, underlie CBF neuron demise associated with the clinical presentation of AD. Supporting this concept is the finding that trk downregulation is associated with measures of cognitive decline [7,14]",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        },
        "MeSHAnatomy": {
          "Cholinergic Neurons": true,
          "Basal Forebrain": true
        }
      },
      "source": 133,
      "target": 63,
      "key": "128c5cd360528b0c18f0816baa70bb49f11635d154054f66ef561392ed5e02ff93cca3facf52324bf56b14764894dda9084f5d587f55a2f48cc0be73445727f3"
    },
    {
      "line": 508,
      "relation": "increases",
      "evidence": "These studies have demonstrated a significant downregulation of trkA, trkB and trkC gene expression during the development of AD [7]. An intermediate reduction was observed in MCI, with the greatest decrement in mild AD compared to aged controls. Moreover, two separate expressed sequence tag (EST) cDNAs for each trk gene (e.g., ESTs targeted to the extracellular domain [ECD] and tyrosine kinase [TK]) domains were downregulated. By contrast, there was a lack of regulation of p75NTR expression [7] in CBF neurons. A ‘step down’ dysregulation of trk expression may, in part, underlie CBF neuron demise associated with the clinical presentation of AD. Supporting this concept is the finding that trk downregulation is associated with measures of cognitive decline [7,14]",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        },
        "MeSHAnatomy": {
          "Cholinergic Neurons": true,
          "Basal Forebrain": true
        }
      },
      "source": 133,
      "target": 60,
      "key": "530eced5fee21f73500960d5a641291172bf5deb296e9e8a61d8a734042d670d45a293429b5c926b920e350ba3a52952ed09cf6350aa84467bca5e5810bd8dd7"
    },
    {
      "line": 650,
      "relation": "causesNoChange",
      "evidence": "Single cell expression via microarray analysis was used to determine whether expression levels for nAChR and mAChR receptors, as well as ChAT, were differentially regulated within individual CBF neurons harvested from NCI, MCI and AD cases. ChAT mRNA expression levels did not differ across clinical conditions (Table 1). However, there was a significant upregulation of alpha7 nAChR subunit expression in AD compared with NCI and MCI.",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        },
        "MeSHAnatomy": {
          "Cholinergic Neurons": true
        }
      },
      "source": 133,
      "target": 164,
      "key": "548b4618c5cad9fafbb8766fb527e3cecdd6133c6d8ce3529f31d4bd7eb82f7af41ed83100e9833d71a4230bb38a38815418b89e977b9e6fe00d0c6c2fcd265d"
    },
    {
      "line": 652,
      "relation": "increases",
      "evidence": "Single cell expression via microarray analysis was used to determine whether expression levels for nAChR and mAChR receptors, as well as ChAT, were differentially regulated within individual CBF neurons harvested from NCI, MCI and AD cases. ChAT mRNA expression levels did not differ across clinical conditions (Table 1). However, there was a significant upregulation of alpha7 nAChR subunit expression in AD compared with NCI and MCI.",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        },
        "MeSHAnatomy": {
          "Cholinergic Neurons": true
        }
      },
      "source": 133,
      "target": 166,
      "key": "062d45682958cc4ed940f9b05978a1f874c447712a59da09a2d8ee422e218af2f1c450a5bd394f06aa5bb2c6eb19e2baddd67f9f4bb5ace90128ecaf8dd31180"
    },
    {
      "line": 672,
      "relation": "increases",
      "evidence": "This increase in alpha7 nAChR expression levels within CBF neurons was inversely associated with cognitive performance. Increased alpha7 nAChR expression in CBF neurons may signal a compensatory response to maintain basocortical cholinergic activity during the onset of AD. Upregulation of the alpha7 nAChR within individual CBF neurons is also consistent with reports of increased alpha7 nAChR mRNA and protein expression levels in hippocampal neurons, astrocytes and peripheral blood leukocytes in AD [120–122]. The observed increase in alpha7 nAChR in early AD may regulate basocortical cholinergic tone through pre- and/or postsynaptic mechanisms within cholinergic NB neurons prior to their frank degeneration in the later stages of AD.",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        },
        "Disease": {
          "Alzheimer's disease": true
        },
        "MeSHAnatomy": {
          "Astrocytes": true,
          "Hippocampus": true,
          "Leukocytes": true
        }
      },
      "source": 133,
      "target": 166,
      "key": "23d496c68febf2ee3121efe12e36245fd470b9f418d4ca38e81cee199bcec9b33fc059b9eb3011b06d302752031e54052b6e3a72316d4d062a562be81acc9f65"
    },
    {
      "line": 712,
      "relation": "causesNoChange",
      "evidence": "Conversely, M1 subunit gene expression in single CBF neurons is preserved during the progression of AD (Table 1) [119,126]. The M1 receptor is a most interesting drug target as it links several of the major hallmarks of this disorder, including cholinergic deficiency, cognitive dysfunctions, Ab and tau pathologies.",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        },
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "source": 133,
      "target": 165,
      "key": "65364f14a5542016edcf9ea974fb9ef2381ff794c27b14976011c4fe91b1dd9ff95deb11b22f84801d5fa86067f233470c32c2abcf8c2fa77efb881635a440e2"
    },
    {
      "line": 762,
      "relation": "decreases",
      "evidence": "Single cell gene array studies have shown that synaptic transcripts are selectively downregulated in CBF neurons in AD, with significant reductions in synaptophysin and synaptotagmin but not synaptobrevin or SNAP29 mRNA [134,135]. Intriguingly, synaptotagmin function is related to vesicle-presynaptic membrane fusion and neurotransmitter release, suggesting that perturbations in presynaptic vesicle trafficking comprise a common event in vulnerable neuronal populations in AD. In contrast to synaptic transcripts, mRNAs encoding APP and Notch were unchanged between control and AD subjects, whereas acid hydrolase cathepsin D mRNA was upregulated in AD [134–136].",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        }
      },
      "source": 133,
      "target": 173,
      "key": "38275d730d27176b921023cd04660a05d1b4e7423722558ee8e4e86ec9515139ae3ca736ac037b9eb455e2d2330035de2de6090082d416ac72d4585c1fa8d35b"
    },
    {
      "line": 763,
      "relation": "decreases",
      "evidence": "Single cell gene array studies have shown that synaptic transcripts are selectively downregulated in CBF neurons in AD, with significant reductions in synaptophysin and synaptotagmin but not synaptobrevin or SNAP29 mRNA [134,135]. Intriguingly, synaptotagmin function is related to vesicle-presynaptic membrane fusion and neurotransmitter release, suggesting that perturbations in presynaptic vesicle trafficking comprise a common event in vulnerable neuronal populations in AD. In contrast to synaptic transcripts, mRNAs encoding APP and Notch were unchanged between control and AD subjects, whereas acid hydrolase cathepsin D mRNA was upregulated in AD [134–136].",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        }
      },
      "source": 133,
      "target": 162,
      "key": "751a255b3b49b533b009fd643d2e6032ca0fe05e4c9eef507871ba6057db7d25a86ef29c5edc309aa9f024b1cff5132f1a58fee069354ee9614297684a58405d"
    },
    {
      "line": 764,
      "relation": "causesNoChange",
      "evidence": "Single cell gene array studies have shown that synaptic transcripts are selectively downregulated in CBF neurons in AD, with significant reductions in synaptophysin and synaptotagmin but not synaptobrevin or SNAP29 mRNA [134,135]. Intriguingly, synaptotagmin function is related to vesicle-presynaptic membrane fusion and neurotransmitter release, suggesting that perturbations in presynaptic vesicle trafficking comprise a common event in vulnerable neuronal populations in AD. In contrast to synaptic transcripts, mRNAs encoding APP and Notch were unchanged between control and AD subjects, whereas acid hydrolase cathepsin D mRNA was upregulated in AD [134–136].",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        }
      },
      "source": 133,
      "target": 174,
      "key": "82c793a1b721b082957e761b1afe5c904c1b96b2dcb96660c56c26364bc6b35a51819266494a766fe2b61099c7046f37a9e64b75aa296c5aac6865e49aa54f2c"
    },
    {
      "line": 765,
      "relation": "causesNoChange",
      "evidence": "Single cell gene array studies have shown that synaptic transcripts are selectively downregulated in CBF neurons in AD, with significant reductions in synaptophysin and synaptotagmin but not synaptobrevin or SNAP29 mRNA [134,135]. Intriguingly, synaptotagmin function is related to vesicle-presynaptic membrane fusion and neurotransmitter release, suggesting that perturbations in presynaptic vesicle trafficking comprise a common event in vulnerable neuronal populations in AD. In contrast to synaptic transcripts, mRNAs encoding APP and Notch were unchanged between control and AD subjects, whereas acid hydrolase cathepsin D mRNA was upregulated in AD [134–136].",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        }
      },
      "source": 133,
      "target": 172,
      "key": "d773c8b944d732d176b9492c5f0f21b45a62e4317b43aeaa63dc8ab1053b45558d40489a4d3cb532a77ab7664a9cde3cfcd51e6404a23e01e59e4dcb5d612db9"
    },
    {
      "line": 770,
      "relation": "causesNoChange",
      "evidence": "Single cell gene array studies have shown that synaptic transcripts are selectively downregulated in CBF neurons in AD, with significant reductions in synaptophysin and synaptotagmin but not synaptobrevin or SNAP29 mRNA [134,135]. Intriguingly, synaptotagmin function is related to vesicle-presynaptic membrane fusion and neurotransmitter release, suggesting that perturbations in presynaptic vesicle trafficking comprise a common event in vulnerable neuronal populations in AD. In contrast to synaptic transcripts, mRNAs encoding APP and Notch were unchanged between control and AD subjects, whereas acid hydrolase cathepsin D mRNA was upregulated in AD [134–136].",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        }
      },
      "source": 133,
      "target": 163,
      "key": "085754c461518132be364b62087d27a9c7368606a377c524cbe6de4ad1e450da6280223dcddb56f99ce331d2e83e492ac4c0372f4e6ec070cc86a71bec018575"
    },
    {
      "line": 771,
      "relation": "causesNoChange",
      "evidence": "Single cell gene array studies have shown that synaptic transcripts are selectively downregulated in CBF neurons in AD, with significant reductions in synaptophysin and synaptotagmin but not synaptobrevin or SNAP29 mRNA [134,135]. Intriguingly, synaptotagmin function is related to vesicle-presynaptic membrane fusion and neurotransmitter release, suggesting that perturbations in presynaptic vesicle trafficking comprise a common event in vulnerable neuronal populations in AD. In contrast to synaptic transcripts, mRNAs encoding APP and Notch were unchanged between control and AD subjects, whereas acid hydrolase cathepsin D mRNA was upregulated in AD [134–136].",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        }
      },
      "source": 133,
      "target": 169,
      "key": "7b4ac58eb04c4c4279ada63e4d1ec810b045548ddcecb2a9fd3599047a8726d7f4f4abdeaff9738df18883e6b90e216fc4aa807448537a225e2d67bd3fbfe1f2"
    },
    {
      "line": 772,
      "relation": "increases",
      "evidence": "Single cell gene array studies have shown that synaptic transcripts are selectively downregulated in CBF neurons in AD, with significant reductions in synaptophysin and synaptotagmin but not synaptobrevin or SNAP29 mRNA [134,135]. Intriguingly, synaptotagmin function is related to vesicle-presynaptic membrane fusion and neurotransmitter release, suggesting that perturbations in presynaptic vesicle trafficking comprise a common event in vulnerable neuronal populations in AD. In contrast to synaptic transcripts, mRNAs encoding APP and Notch were unchanged between control and AD subjects, whereas acid hydrolase cathepsin D mRNA was upregulated in AD [134–136].",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        }
      },
      "source": 133,
      "target": 167,
      "key": "2572c78ef3f00a1dd43df4f50b5b6b76b6c47518ab90e1be04334d67d7dc37dfe82b38f69e045881d53684209b0c0237b96188a9a39b2ef0a6db63f529dfe166"
    },
    {
      "line": 785,
      "relation": "decreases",
      "evidence": "In addition, subunits of protein phosphatase PP1 (Unigene-NCBI annotation PPP1CA and PPP1CC) mRNAs were downregulated in CBF neurons in AD [135]. This observation is interesting in light of the observation that PP1 can phosphorylate tau on several serine/threonine residues and experimental downregulation of PP1 activity leads to increased tau hyperphosphorylation [137,138], which may affect NFT formation in CBF neurons.",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        },
        "MeSHAnatomy": {
          "Cholinergic Neurons": true
        },
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "source": 133,
      "target": 170,
      "key": "5c0ea3575a4bc11d5bf68cd3fd690664365b562a7c2711aeb824ba040d7164f7b4a1416d426d9594edbba9107451f596f1b84ea8a99f9e4388f020f024f76065"
    },
    {
      "line": 786,
      "relation": "decreases",
      "evidence": "In addition, subunits of protein phosphatase PP1 (Unigene-NCBI annotation PPP1CA and PPP1CC) mRNAs were downregulated in CBF neurons in AD [135]. This observation is interesting in light of the observation that PP1 can phosphorylate tau on several serine/threonine residues and experimental downregulation of PP1 activity leads to increased tau hyperphosphorylation [137,138], which may affect NFT formation in CBF neurons.",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        },
        "MeSHAnatomy": {
          "Cholinergic Neurons": true
        },
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "source": 133,
      "target": 171,
      "key": "e08e87a077cb5591f2cf3e178fb9ed5ce09deff843f6569c9f6023d14d3323b341c7322967fadca3c50a0cc35f7faa2ec02a616a2572e8d3f39ced15aa46b3a8"
    },
    {
      "line": 809,
      "relation": "increases",
      "evidence": "Cortical and CBF neurons display NFT formation in the MCI brain [9,139,140], suggesting a concomitant alteration in tau gene expression during the early stage of AD. The adult human brain contains six tau isoforms ranging from 48 to 67 kDa, which are expressed through alternative splicing of a single tau gene on chromosome 17 [141,142]. Three of these tau isoforms contain three tandem repeats in the carboxy-terminus end of the molecule (3Rtau), while three isoforms display four tandem repeats (4Rtau) in this region. Expression levels of the six tau transcripts within CBF neurons do not differ significantly during the progression of AD [6]",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        },
        "MeSHAnatomy": {
          "Cholinergic Neurons": true,
          "Cerebral Cortex": true
        },
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "source": 133,
      "target": 155,
      "key": "87ff4618ef03e03d6c05dfcee25e68d942994257d025b20d4ea52dd51ab27c4b98e4aef1ed6dbb840b68a344c28e099d1f4eab09a6d14289547e0ffbcad3a6f3"
    },
    {
      "line": 814,
      "relation": "causesNoChange",
      "evidence": "Cortical and CBF neurons display NFT formation in the MCI brain [9,139,140], suggesting a concomitant alteration in tau gene expression during the early stage of AD. The adult human brain contains six tau isoforms ranging from 48 to 67 kDa, which are expressed through alternative splicing of a single tau gene on chromosome 17 [141,142]. Three of these tau isoforms contain three tandem repeats in the carboxy-terminus end of the molecule (3Rtau), while three isoforms display four tandem repeats (4Rtau) in this region. Expression levels of the six tau transcripts within CBF neurons do not differ significantly during the progression of AD [6]",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        },
        "MeSHAnatomy": {
          "Cholinergic Neurons": true,
          "Cerebral Cortex": true
        },
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "source": 133,
      "target": 168,
      "key": "9f0a332b75959a3dd35ab2d6b041606fab282918a25db87c4f9ebb9d7e3cb31056f38803a78f55eb37b01c2709e413553d3349c93c43b76328b36687e6fe4009"
    },
    {
      "line": 834,
      "relation": "decreases",
      "evidence": " However, a calculation of the ratio of 3Rtau/4Rtau revealed a significant shift in the 3Rtau/4Rtau ratio, with a decrement in 3Rtau in relation to 4Rtau levels for each tau transcript analyzed within CBF perikarya obtained from MCI and AD cases (Table 1) [6]. A similar shift did not occur during normal aging. These data suggest a subtle, yet pervasive shift in the gene dosage of 3Rtau and 4Rtau within vulnerable CBF neurons in MCI and AD [6]. Shifts in the ratio of tau transcripts may be a fundamental mechanism whereby normal tau function is dysregulated, not only in CBF neurons, but may be a more widespread process contributing to the selective vulnerability of neurons to NFT formation (Figure 1B) [143–145]. ",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        },
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "source": 133,
      "target": 5,
      "key": "fd9e5e5c366fb50716e53fdf0d15e7404fe8229e5284530727545a4da486647c481f041ed13fdd3ecf2d0bd42d86b88ee0787ddd457031cc10a271c077127bca"
    },
    {
      "line": 63,
      "relation": "association",
      "evidence": "Alzheimer’s disease (AD) is a progressive and fatal neurodegenerative disorder manifested by cognitive and memory decline and progressive impairment of activities of daily living, as well as a variety of neuropsychiatric symptoms and behavioral dysfunctions.",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "source": 156,
      "target": 133,
      "key": "1a605f32d51b20f6374f67bf04bbc93767e7348ed623ee0da22363e8432042f5e79ec62aa5133c7e527daa807dff68a8cec90d44bf7721144d6739630fbd1832"
    },
    {
      "line": 65,
      "relation": "association",
      "evidence": "Alzheimer’s disease (AD) is a progressive and fatal neurodegenerative disorder manifested by cognitive and memory decline and progressive impairment of activities of daily living, as well as a variety of neuropsychiatric symptoms and behavioral dysfunctions.",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "source": 148,
      "target": 133,
      "key": "3f4072cb54ad4a0fc7cd0ac2c2e690d95149b0ea48d2ae610c8e8324c4183762ef26fdc2a7d194043c02034dd811e0eb8ddc3c73427a7bd14372ff1bfd9b9e87"
    },
    {
      "line": 120,
      "relation": "association",
      "evidence": "Cholinergic neurons within the nucleus basalis (NB) and the septal diagonal band complex provide the major source of cholinergic innervation to the cerebral cortex and hippocampus, respectively, and play a key role in memory and attentional function [11–13].",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHAnatomy": {
          "Hippocampus": true,
          "Basal Nucleus of Meynert": true,
          "Cerebral Cortex": true
        }
      },
      "source": 148,
      "target": 14,
      "key": "b4169346599c88df3554f7acadf4a272ea421021e282672d618352d9e7da2f16455e2a7dda5a16c4702800c919f2adf5229791135bd62fbdac2a2499dd237e53"
    },
    {
      "line": 67,
      "relation": "association",
      "evidence": "Alzheimer’s disease (AD) is a progressive and fatal neurodegenerative disorder manifested by cognitive and memory decline and progressive impairment of activities of daily living, as well as a variety of neuropsychiatric symptoms and behavioral dysfunctions.",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "source": 140,
      "target": 133,
      "key": "d2eda74729b0cd8fa5a28e7c3fc28888f75230aaa0afc5b8c39a16aee1844ac3b800d7ec9562ae97f32272a8e6a903ff4e392be3f72eff321dc429189aa0d88a"
    },
    {
      "line": 300,
      "relation": "association",
      "evidence": "Butyrylcholinesterase (BChE) is a serine hydrolase similar to AChE that is widely distributed throughout the CNS and also catalyzes the hydrolysis of ACh. BChE is localized to neurons and glia, and is associated with NFTs and senile plaques (SPs) in AD brain [32]. Interestingly, population-based genetic studies of AD have identified a point mutation that changes Ala539 to threonine in the K variant of BChE, which effectively reduces serum BChE concentrations, and may be associated with cognitive decline [33]. BChE activity also increases in AD brain whereas AChE activity remains unchanged or declines [34,35].",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        },
        "MeSHAnatomy": {
          "Neuroglia": true,
          "Neurons": true
        },
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "source": 140,
      "target": 83,
      "key": "15a85658e08838f0b697bbf2ae1562c442a4318219f7ac0dbf35efa5869251696233f5e5dc3fcb5031083b1cfb1eb2a87b431ba2e527c3632ea75f8695286b8f"
    },
    {
      "line": 510,
      "relation": "association",
      "evidence": "These studies have demonstrated a significant downregulation of trkA, trkB and trkC gene expression during the development of AD [7]. An intermediate reduction was observed in MCI, with the greatest decrement in mild AD compared to aged controls. Moreover, two separate expressed sequence tag (EST) cDNAs for each trk gene (e.g., ESTs targeted to the extracellular domain [ECD] and tyrosine kinase [TK]) domains were downregulated. By contrast, there was a lack of regulation of p75NTR expression [7] in CBF neurons. A ‘step down’ dysregulation of trk expression may, in part, underlie CBF neuron demise associated with the clinical presentation of AD. Supporting this concept is the finding that trk downregulation is associated with measures of cognitive decline [7,14]",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        },
        "MeSHAnatomy": {
          "Cholinergic Neurons": true,
          "Basal Forebrain": true
        }
      },
      "source": 140,
      "target": 61,
      "key": "000c4e60c943878dbaf2fa2a7947b8c188a4797a0ab56fd8824f29577d9fcd76a66ec7cdce13b3220d5b5eea6da8996100e61c00da0055f283b548e3a0efead2"
    },
    {
      "line": 511,
      "relation": "association",
      "evidence": "These studies have demonstrated a significant downregulation of trkA, trkB and trkC gene expression during the development of AD [7]. An intermediate reduction was observed in MCI, with the greatest decrement in mild AD compared to aged controls. Moreover, two separate expressed sequence tag (EST) cDNAs for each trk gene (e.g., ESTs targeted to the extracellular domain [ECD] and tyrosine kinase [TK]) domains were downregulated. By contrast, there was a lack of regulation of p75NTR expression [7] in CBF neurons. A ‘step down’ dysregulation of trk expression may, in part, underlie CBF neuron demise associated with the clinical presentation of AD. Supporting this concept is the finding that trk downregulation is associated with measures of cognitive decline [7,14]",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        },
        "MeSHAnatomy": {
          "Cholinergic Neurons": true,
          "Basal Forebrain": true
        }
      },
      "source": 140,
      "target": 62,
      "key": "eaf231584d6dbb556c0a611b1b7b9e38509c387757a18eefac66eeb7728b48046193020f72f6a0a754386bde4183239fb8b316812e22c6882be2d6c27db7fff1"
    },
    {
      "line": 512,
      "relation": "association",
      "evidence": "These studies have demonstrated a significant downregulation of trkA, trkB and trkC gene expression during the development of AD [7]. An intermediate reduction was observed in MCI, with the greatest decrement in mild AD compared to aged controls. Moreover, two separate expressed sequence tag (EST) cDNAs for each trk gene (e.g., ESTs targeted to the extracellular domain [ECD] and tyrosine kinase [TK]) domains were downregulated. By contrast, there was a lack of regulation of p75NTR expression [7] in CBF neurons. A ‘step down’ dysregulation of trk expression may, in part, underlie CBF neuron demise associated with the clinical presentation of AD. Supporting this concept is the finding that trk downregulation is associated with measures of cognitive decline [7,14]",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        },
        "MeSHAnatomy": {
          "Cholinergic Neurons": true,
          "Basal Forebrain": true
        }
      },
      "source": 140,
      "target": 63,
      "key": "2aa53fc90c297bad3007c4c9a44b67b69b94ac8ea643cbb94be93d18088ffaef05d9674566c9a7cf22787ab9fe57dde28b8b9b949b0ac27740bf10e80bd3edc9"
    },
    {
      "line": 673,
      "relation": "negativeCorrelation",
      "evidence": "This increase in alpha7 nAChR expression levels within CBF neurons was inversely associated with cognitive performance. Increased alpha7 nAChR expression in CBF neurons may signal a compensatory response to maintain basocortical cholinergic activity during the onset of AD. Upregulation of the alpha7 nAChR within individual CBF neurons is also consistent with reports of increased alpha7 nAChR mRNA and protein expression levels in hippocampal neurons, astrocytes and peripheral blood leukocytes in AD [120–122]. The observed increase in alpha7 nAChR in early AD may regulate basocortical cholinergic tone through pre- and/or postsynaptic mechanisms within cholinergic NB neurons prior to their frank degeneration in the later stages of AD.",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        },
        "Disease": {
          "Alzheimer's disease": true
        },
        "MeSHAnatomy": {
          "Astrocytes": true,
          "Hippocampus": true,
          "Leukocytes": true
        }
      },
      "source": 140,
      "target": 166,
      "key": "d47b0df8bb920b625de7462dfa182680213c060bb20f7e62a5f27f3007dc819b7e67e428425f45d29290c018484c32687640cd79cd6ec735e5c9f62b006ea975"
    },
    {
      "line": 856,
      "relation": "association",
      "evidence": " For example, the neuropeptide GAL, which functions via the interaction with three G protein-coupled receptors termed GALR1, GALR2 and GALR3, has multiple biological actions, including effects on cognition and neuroplasticity [15,146,147]. In the late [148–150] but not early [151] stage of AD, fibers within the basal forebrain containing the neuropeptide GAL thicken and hyperinnervate surviving CBF neurons. Although animal and cell-culture studies have shown that GAL plays a crucial role in the regulation of CBF neuron activity [152] and rescues cholinergic cells from amyloid toxicity [153], the molecular consequences of this unique plasticity response upon CBF neurons in AD remain unclear. Gene expression studies of cholinergic transcripts have shown that GAL hyperinnervated, but not nonhyperinnervated, CBF neurons display an upregulation of ChAT expression in AD compared to controls [126]",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 140,
      "target": 111,
      "key": "209d220eb941b63cf1ce8a3b55639a4a726888c12507a6a24aba26567d9770e1cee901f1615ce224748e9b0fd61e35cd8c8dffd0975722c4a6866ecc58ff64f0"
    },
    {
      "line": 69,
      "relation": "association",
      "evidence": "Alzheimer’s disease (AD) is a progressive and fatal neurodegenerative disorder manifested by cognitive and memory decline and progressive impairment of activities of daily living, as well as a variety of neuropsychiatric symptoms and behavioral dysfunctions.",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "source": 138,
      "target": 133,
      "key": "96f34e7051f7addc07c24a9486a880690ad226166caf9b9b741623ccd12c2d0f5456d8fd4ad7cf89d31cb56e9826cf59636f6d77fff56717fcbb57cf8752c396"
    },
    {
      "line": 87,
      "relation": "association",
      "evidence": "People with a clinical diagnosis of MCI comprise a heterogeneous cohort of which those with memory deficits only are classified as amnestic MCI (aMCI) and those with impairment in other cognitive domains lacking a clinical diagnosis of dementia are designated multidomain MCI (mdMCI) [3,4]. Many individuals characterized with aMCI progress steadily to greater stages of dementia severity, and in many instances exhibit the neuropathologic, molecular and biochemical hallmarks of AD [5–9]. These clinical pathobiologic studies suggest that MCI, in general, represents a prodromal or preclinical stage of AD.",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "source": 130,
      "target": 149,
      "key": "def5963e722c8732a98d1e44b89538f9e5b19b69dea6386d6aa1305a03299760d0c62fa9d90a6637bb926e5411b3fa02051f9a86f42f823fee547a3a20f0addd"
    },
    {
      "line": 90,
      "relation": "association",
      "evidence": "People with a clinical diagnosis of MCI comprise a heterogeneous cohort of which those with memory deficits only are classified as amnestic MCI (aMCI) and those with impairment in other cognitive domains lacking a clinical diagnosis of dementia are designated multidomain MCI (mdMCI) [3,4]. Many individuals characterized with aMCI progress steadily to greater stages of dementia severity, and in many instances exhibit the neuropathologic, molecular and biochemical hallmarks of AD [5–9]. These clinical pathobiologic studies suggest that MCI, in general, represents a prodromal or preclinical stage of AD.",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "source": 130,
      "target": 142,
      "key": "ed5cc9df39ede8d42dd14ccaafb33f8d0394a0a080e5e9d008e3c4d25a34b4062f27ce6c0f1eca20de776ed00141b6d7bb095cab9dc800e9e54359305fab5659"
    },
    {
      "line": 91,
      "relation": "association",
      "evidence": "People with a clinical diagnosis of MCI comprise a heterogeneous cohort of which those with memory deficits only are classified as amnestic MCI (aMCI) and those with impairment in other cognitive domains lacking a clinical diagnosis of dementia are designated multidomain MCI (mdMCI) [3,4]. Many individuals characterized with aMCI progress steadily to greater stages of dementia severity, and in many instances exhibit the neuropathologic, molecular and biochemical hallmarks of AD [5–9]. These clinical pathobiologic studies suggest that MCI, in general, represents a prodromal or preclinical stage of AD.",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "source": 130,
      "target": 133,
      "key": "5c7d08727f884ffb6842a1c7cd5a435c67aef80770c1eafed69bebe500bab393fb306288df3cb8099839108a99507d9c1142eb459db5cbc46a03c3fe5e5196b5"
    },
    {
      "line": 87,
      "relation": "association",
      "evidence": "People with a clinical diagnosis of MCI comprise a heterogeneous cohort of which those with memory deficits only are classified as amnestic MCI (aMCI) and those with impairment in other cognitive domains lacking a clinical diagnosis of dementia are designated multidomain MCI (mdMCI) [3,4]. Many individuals characterized with aMCI progress steadily to greater stages of dementia severity, and in many instances exhibit the neuropathologic, molecular and biochemical hallmarks of AD [5–9]. These clinical pathobiologic studies suggest that MCI, in general, represents a prodromal or preclinical stage of AD.",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "source": 149,
      "target": 130,
      "key": "971894d85a6e0f026a52c33c9921ab4af5ffde8973838b120967ae3a13604ac629cf76c533ac670a12688a5109c229d5be18effeedca194538f7c43b3fe00954"
    },
    {
      "line": 88,
      "relation": "association",
      "evidence": "People with a clinical diagnosis of MCI comprise a heterogeneous cohort of which those with memory deficits only are classified as amnestic MCI (aMCI) and those with impairment in other cognitive domains lacking a clinical diagnosis of dementia are designated multidomain MCI (mdMCI) [3,4]. Many individuals characterized with aMCI progress steadily to greater stages of dementia severity, and in many instances exhibit the neuropathologic, molecular and biochemical hallmarks of AD [5–9]. These clinical pathobiologic studies suggest that MCI, in general, represents a prodromal or preclinical stage of AD.",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "source": 131,
      "target": 160,
      "key": "0d8f33816f3cb885840ce42402adf89e35ade9f0429d1f860163693c16f3ceeadf243343d16640676d73f1594f0608df770956d5ddaa34fc876600aa110f8f04"
    },
    {
      "line": 88,
      "relation": "association",
      "evidence": "People with a clinical diagnosis of MCI comprise a heterogeneous cohort of which those with memory deficits only are classified as amnestic MCI (aMCI) and those with impairment in other cognitive domains lacking a clinical diagnosis of dementia are designated multidomain MCI (mdMCI) [3,4]. Many individuals characterized with aMCI progress steadily to greater stages of dementia severity, and in many instances exhibit the neuropathologic, molecular and biochemical hallmarks of AD [5–9]. These clinical pathobiologic studies suggest that MCI, in general, represents a prodromal or preclinical stage of AD.",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "source": 160,
      "target": 131,
      "key": "0b502867100df5147ed8b7c53191d2eef0867049646dba1d69a27caa9abdafad438948a35ddbdcdcf16dd1fafd0602cd325d051c6be725390a7256ca06a796a7"
    },
    {
      "line": 95,
      "relation": "association",
      "evidence": "People with a clinical diagnosis of MCI comprise a heterogeneous cohort of which those with memory deficits only are classified as amnestic MCI (aMCI) and those with impairment in other cognitive domains lacking a clinical diagnosis of dementia are designated multidomain MCI (mdMCI) [3,4]. Many individuals characterized with aMCI progress steadily to greater stages of dementia severity, and in many instances exhibit the neuropathologic, molecular and biochemical hallmarks of AD [5–9]. These clinical pathobiologic studies suggest that MCI, in general, represents a prodromal or preclinical stage of AD.",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "source": 160,
      "target": 161,
      "key": "e4d8004f7b732303707d113d73fcbaab0115db932d5fd9621deefbfb1e439b2757eb244daef9131d986e2bd6abad0521c7789c5c38499cfd7f91566580101331"
    },
    {
      "line": 190,
      "relation": "association",
      "evidence": "Delaying or preventing cholinergic neurodegeneration or minimizing its consequences is the mechanism of action for most currently available US FDA-approved drugs for the treatment of cognitive dysfunction observed in AD [17]",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHAnatomy": {
          "Cholinergic Neurons": true
        }
      },
      "source": 160,
      "target": 43,
      "key": "8e50d4aec780fc8eeedd09990faf33cc697b9b16eda8550dae84c67325afed19c03b74ff745f982187de5936a18190f51e146ca6c675576a17cad269e49bb763"
    },
    {
      "line": 215,
      "relation": "causesNoChange",
      "evidence": " Notably, reports that physostigmine and oral anticholinesterases have beneficial effects for patients with AD suggest that the CBF system is somewhat preserved during the progression of dementia, despite well-documented loss of cholinergic biosynthetic machinery (including ChAT and AChE enzyme deficits) in patients with this disease. Interestingly, recent studies have shown that ChAT activity, which results in acetylcholine (ACh) synthesis, is preserved in the neocortex of people with MCI [18,19].",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        },
        "MeSHAnatomy": {
          "Neocortex": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 160,
      "target": 85,
      "key": "77168fb7c2fdb09df9713ee30f899bfc92fc7aa0b240426e465fcbe6158a5384e3eee392b698775cd7f3cce3b9d33810eca12997b0420625366bc1ea0a2ea30b"
    },
    {
      "line": 232,
      "relation": "increases",
      "evidence": "In fact, our group found elevated ChAT activity in the hippocampus and frontal cortex of subjects with MCI [19,20]. These results suggest that cognitive deficits in MCI and early AD are not associated with a reduction in ChAT activity. Moreover, these data indicate that select components of the hippocampal and cortical cholinergic projection system are capable of compensatory and/ or neuroplasticity responses during the early stages of AD.",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHAnatomy": {
          "Frontal Lobe": true,
          "Hippocampus": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 160,
      "target": 85,
      "key": "f5799506a19854efdd8a9953a0ea031e64fbcc9f78d094b0481258d2f12db0184b4c427c12fe4e68976518d2d6f5e4458131a1694912922df88050f9dbed83bc"
    },
    {
      "line": 257,
      "relation": "increases",
      "evidence": "In MCI, increased hippocampal and frontal cortex ChAT tone may be important for promoting biochemical activity or compensating for neurodegenerative defects, which may delay the transition of these subjects to frank AD. Hippocampal ChAT activity was increased selectively in MCI cases with high Braak scores (Braak III/IV stage) indicative of advanced disease [19], suggesting that a compensatory upregulation of ChAT may be due, at least in part, to the disconnection of glutamatergic entorhinal cortex input to the hippocampus which occurs early in the disease process [21–23]. In this scenario, upregulation of hippocampal ChAT activity may be due to reactive synaptogenesis, the filling in of denervated glutamatergic synapses by cholinergic input arising from the septum [24].",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        },
        "MeSHAnatomy": {
          "Frontal Lobe": true,
          "Hippocampus": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 160,
      "target": 85,
      "key": "9610ab1559db44f7c50990106c840076ce70c9413cbf53691a4a0655c6f6d5b7174a3a8fec1bb25ab622cd5b731a1bd1e068b4ec1bea3bdca1463fa60759cad7"
    },
    {
      "line": 256,
      "relation": "decreases",
      "evidence": "In MCI, increased hippocampal and frontal cortex ChAT tone may be important for promoting biochemical activity or compensating for neurodegenerative defects, which may delay the transition of these subjects to frank AD. Hippocampal ChAT activity was increased selectively in MCI cases with high Braak scores (Braak III/IV stage) indicative of advanced disease [19], suggesting that a compensatory upregulation of ChAT may be due, at least in part, to the disconnection of glutamatergic entorhinal cortex input to the hippocampus which occurs early in the disease process [21–23]. In this scenario, upregulation of hippocampal ChAT activity may be due to reactive synaptogenesis, the filling in of denervated glutamatergic synapses by cholinergic input arising from the septum [24].",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        },
        "MeSHAnatomy": {
          "Frontal Lobe": true,
          "Hippocampus": true
        }
      },
      "source": 160,
      "target": 12,
      "key": "60490d03620a191746dce883a2aa2c49e4e6ad6930ba703fa600d96ec3d5805ba734cb14213fd13465212317bf29b0e46ead819bfe5fc655d97a0c543546152f"
    },
    {
      "line": 370,
      "relation": "increases",
      "evidence": " In this regard, immunoblotting studies demonstrated that proNGF is the predominant form of NGF present in the cortex of aged cognitively intact humans [60]. ProNGF levels are increased in the cortex of subjects diagnosed with MCI or mild AD compared to those with NCI [61]. The biological consequences of proNGF are controversial, as is the function of its accumulation in the cortex during the prodromal stages of AD. Emerging literature suggests that recombinant proNGF binds TrkA and promotes neuronal survival and neurite outgrowth similar to mature NGF, but is approximately fivefold less active than the mature NGF peptide [62,63].",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        },
        "MeSHAnatomy": {
          "Cerebral Cortex": true
        }
      },
      "source": 160,
      "target": 18,
      "key": "682ff480b6ef4fc1d130892496a259f576c5866b66e57d0c9a693a8ef32d68cdf11ba93cab0ed8bcc64d28a23b94018e452b1fdff2c75c8a73cc30766286c81c"
    },
    {
      "line": 483,
      "relation": "increases",
      "evidence": "We found an upregulation of MMP-9 protein levels and activity in both AD and MCI brains, which correlated inversely with cognitive status (Figure 1B) [75]. Since tissue alterations are often reflected in bodily fluids, determination of MMPs in blood, urine and CSF has been recommended as potential biomarkers to act as diagnostic measures to characterize the disease process that occurs in the brain [76–78]. Interestingly, plasma MMP-9 was increased in MCI and AD [77].",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        },
        "MeSHAnatomy": {
          "Plasma": true,
          "Brain": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 160,
      "target": 116,
      "key": "80a1a346adef00371a600973c86e0e8e6fab51b517ac1249703fae570ec2a5fe52c37988dc86c0d32754d8a691c75d97b4f108a4553f070ac2977324a3110420"
    },
    {
      "line": 651,
      "relation": "causesNoChange",
      "evidence": "Single cell expression via microarray analysis was used to determine whether expression levels for nAChR and mAChR receptors, as well as ChAT, were differentially regulated within individual CBF neurons harvested from NCI, MCI and AD cases. ChAT mRNA expression levels did not differ across clinical conditions (Table 1). However, there was a significant upregulation of alpha7 nAChR subunit expression in AD compared with NCI and MCI.",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        },
        "MeSHAnatomy": {
          "Cholinergic Neurons": true
        }
      },
      "source": 160,
      "target": 164,
      "key": "46b3f3bec87da53c86718638e33bad7b26476fef86c894259a952807dbad12779986baf56b44315be2cedd18f76619c8e4e87f680473b94553c9048c852b9f9c"
    },
    {
      "line": 713,
      "relation": "association",
      "evidence": "Conversely, M1 subunit gene expression in single CBF neurons is preserved during the progression of AD (Table 1) [119,126]. The M1 receptor is a most interesting drug target as it links several of the major hallmarks of this disorder, including cholinergic deficiency, cognitive dysfunctions, Ab and tau pathologies.",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        },
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "source": 160,
      "target": 86,
      "key": "f8d7157e04fd261e512cf366b370074585433b52fed45454885cfa3edd175095838899f55af1e30ef72f27c1acf879c79107fa9dc44c5c1991ef9f7d66501a08"
    },
    {
      "line": 835,
      "relation": "decreases",
      "evidence": " However, a calculation of the ratio of 3Rtau/4Rtau revealed a significant shift in the 3Rtau/4Rtau ratio, with a decrement in 3Rtau in relation to 4Rtau levels for each tau transcript analyzed within CBF perikarya obtained from MCI and AD cases (Table 1) [6]. A similar shift did not occur during normal aging. These data suggest a subtle, yet pervasive shift in the gene dosage of 3Rtau and 4Rtau within vulnerable CBF neurons in MCI and AD [6]. Shifts in the ratio of tau transcripts may be a fundamental mechanism whereby normal tau function is dysregulated, not only in CBF neurons, but may be a more widespread process contributing to the selective vulnerability of neurons to NFT formation (Figure 1B) [143–145]. ",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        },
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "source": 160,
      "target": 5,
      "key": "bcb7db4208fc102c564965fe753c10cad7843995481dc1961714c503ab039f70faa985be1e406e019762ebbd3681a7672ee4b6cd40a9326d6b8684593a337dbe"
    },
    {
      "line": 90,
      "relation": "association",
      "evidence": "People with a clinical diagnosis of MCI comprise a heterogeneous cohort of which those with memory deficits only are classified as amnestic MCI (aMCI) and those with impairment in other cognitive domains lacking a clinical diagnosis of dementia are designated multidomain MCI (mdMCI) [3,4]. Many individuals characterized with aMCI progress steadily to greater stages of dementia severity, and in many instances exhibit the neuropathologic, molecular and biochemical hallmarks of AD [5–9]. These clinical pathobiologic studies suggest that MCI, in general, represents a prodromal or preclinical stage of AD.",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "source": 142,
      "target": 130,
      "key": "95c27a5c7cdc18f73d65556dc3eeff2ad289c45a8251feacb289e195d1cee48f3d986f669ae52552b36d6ceb02018fc0344b9bdd1e594fc65eab8573f5be41b7"
    },
    {
      "line": 208,
      "relation": "association",
      "evidence": " Notably, reports that physostigmine and oral anticholinesterases have beneficial effects for patients with AD suggest that the CBF system is somewhat preserved during the progression of dementia, despite well-documented loss of cholinergic biosynthetic machinery (including ChAT and AChE enzyme deficits) in patients with this disease. Interestingly, recent studies have shown that ChAT activity, which results in acetylcholine (ACh) synthesis, is preserved in the neocortex of people with MCI [18,19].",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "source": 142,
      "target": 14,
      "key": "139e89a47a084c643273dedab59f8fd9badce4c82749fdd78078ef8b7dcdacdf70ac52d8dbb8084d30d6cd8349efe6bbcaced3b6093f4d64d7cca3754f847945"
    },
    {
      "line": 266,
      "relation": "decreases",
      "evidence": "The enzyme that hydrolyzes ACh at the synapse, AChE, does not show a decline in cortical areas until at least moderately severe levels of dementia [28]. ",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "source": 142,
      "target": 80,
      "key": "9646f5c09346a22a57cf63919d9b8fbf9f597e1ce40fa9eb8cdc4ba33aa58e2d5d023d63e47fca20c1575311436155d360fa102ba7022cf6dc4c3d165855b737"
    },
    {
      "line": 95,
      "relation": "association",
      "evidence": "People with a clinical diagnosis of MCI comprise a heterogeneous cohort of which those with memory deficits only are classified as amnestic MCI (aMCI) and those with impairment in other cognitive domains lacking a clinical diagnosis of dementia are designated multidomain MCI (mdMCI) [3,4]. Many individuals characterized with aMCI progress steadily to greater stages of dementia severity, and in many instances exhibit the neuropathologic, molecular and biochemical hallmarks of AD [5–9]. These clinical pathobiologic studies suggest that MCI, in general, represents a prodromal or preclinical stage of AD.",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "source": 161,
      "target": 160,
      "key": "56b0011b9febdd61c9ae65d433c68d1f0ec560e28d89b3cfd82a3dbf207a29692318cb0eec6b49ae5ae4547861696d41cb396b67fff23c6af324cfc61d515942"
    },
    {
      "line": 119,
      "relation": "directlyIncreases",
      "evidence": "Cholinergic neurons within the nucleus basalis (NB) and the septal diagonal band complex provide the major source of cholinergic innervation to the cerebral cortex and hippocampus, respectively, and play a key role in memory and attentional function [11–13].",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHAnatomy": {
          "Hippocampus": true,
          "Basal Nucleus of Meynert": true,
          "Cerebral Cortex": true
        }
      },
      "source": 14,
      "target": 37,
      "key": "2a04b96dcedd3f2158fc0a65a9187702ed354210ad1ef33dc68db5465bb66cdf68cb5d878e8ac3d32db5cf7ca98866fd86a3c97032a86fc18a41b2273245632b"
    },
    {
      "line": 120,
      "relation": "association",
      "evidence": "Cholinergic neurons within the nucleus basalis (NB) and the septal diagonal band complex provide the major source of cholinergic innervation to the cerebral cortex and hippocampus, respectively, and play a key role in memory and attentional function [11–13].",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHAnatomy": {
          "Hippocampus": true,
          "Basal Nucleus of Meynert": true,
          "Cerebral Cortex": true
        }
      },
      "source": 14,
      "target": 148,
      "key": "aaf0dd725ad9f67eabf5069113d568cefac1899f68ff9622710e6c2f49d73f79c48236676650e933c2f19b4d3197f8b9952d18b290b2707bcba73239caf6c542"
    },
    {
      "line": 122,
      "relation": "association",
      "evidence": "Cholinergic neurons within the nucleus basalis (NB) and the septal diagonal band complex provide the major source of cholinergic innervation to the cerebral cortex and hippocampus, respectively, and play a key role in memory and attentional function [11–13].",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHAnatomy": {
          "Hippocampus": true,
          "Basal Nucleus of Meynert": true,
          "Cerebral Cortex": true
        }
      },
      "source": 14,
      "target": 137,
      "key": "079ed97ba43e59c6c937fbde1a1737601e976434687c911180b11c76d71161f2ea8200bd81b1badefa7d3c332309e6d3076c606adc3be37b4791c23bfc818530"
    },
    {
      "line": 139,
      "relation": "association",
      "evidence": "Cholinergic basal forebrain (CBF) cortical projection neurons contain the pathological AD hallmark, neurofibrillary tangles (NFTs), and undergo chemical phenotypic alterations during the progression of AD, making them an excellent natural model for studying mechanisms of cell death, survival and treatment approaches both in vitro and in vivo, including relevant animal models of neurodegeneration as well as human postmortem clinical pathological tissue studies [14].",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHAnatomy": {
          "Basal Forebrain": true
        },
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "source": 14,
      "target": 13,
      "key": "ec83583d31b956d2d6eda92bcbbadc9fc4784cd803179e13039749c00fbed54906bc45b52db8f3b139033c9048cb2234b754daeb04fb42d8ed3de5e119631162"
    },
    {
      "line": 141,
      "relation": "association",
      "evidence": "Cholinergic basal forebrain (CBF) cortical projection neurons contain the pathological AD hallmark, neurofibrillary tangles (NFTs), and undergo chemical phenotypic alterations during the progression of AD, making them an excellent natural model for studying mechanisms of cell death, survival and treatment approaches both in vitro and in vivo, including relevant animal models of neurodegeneration as well as human postmortem clinical pathological tissue studies [14].",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHAnatomy": {
          "Basal Forebrain": true
        },
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "source": 14,
      "target": 133,
      "key": "5e4d1ba0ca008c647ada06643c39b9d5fecc37caa64675a7e0e95bc23ed03cd4b42538ddca2012a9c8e50533c320766d1a79173a22e0add40211781b78ce4a11"
    },
    {
      "line": 158,
      "relation": "association",
      "evidence": " The regions of the forebrain that contain cholinobasal and septohippocampal CBF neurons also display various non-cholinergic neurons, including GABAergic interneurons that innervate cholinergic perikarya [11]. In addition, neuropeptides often co-localize with CBF neurons. For example, the inhibitory neuropeptide galanin (GAL) is found in septohippocampal and NB neurons in rodents, but not in higher apes or humans where GAL fibers innvervate CBF neurons. [15].",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHAnatomy": {
          "Basal Forebrain": true
        }
      },
      "source": 14,
      "target": 11,
      "key": "6873008c72ca5ef6a6a6962c0d9cb8246b6d6585e63718179b909e91e448e6b78c1f23ec5f7183cfac811908c619b00e06ec3c7d126127eda586f38c2a52a1bf"
    },
    {
      "line": 160,
      "relation": "association",
      "evidence": " The regions of the forebrain that contain cholinobasal and septohippocampal CBF neurons also display various non-cholinergic neurons, including GABAergic interneurons that innervate cholinergic perikarya [11]. In addition, neuropeptides often co-localize with CBF neurons. For example, the inhibitory neuropeptide galanin (GAL) is found in septohippocampal and NB neurons in rodents, but not in higher apes or humans where GAL fibers innvervate CBF neurons. [15].",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHAnatomy": {
          "Basal Forebrain": true
        }
      },
      "source": 14,
      "target": 15,
      "key": "e98e4453a2d92cac767e652c3865f0d25e9a091b62e768c8c05a6a9d435c823ad2466ee7be6e5a7f7db2e695256f9b05fe5de4610b3a6c285ec027f8ff9ddd4a"
    },
    {
      "line": 164,
      "relation": "association",
      "evidence": " The regions of the forebrain that contain cholinobasal and septohippocampal CBF neurons also display various non-cholinergic neurons, including GABAergic interneurons that innervate cholinergic perikarya [11]. In addition, neuropeptides often co-localize with CBF neurons. For example, the inhibitory neuropeptide galanin (GAL) is found in septohippocampal and NB neurons in rodents, but not in higher apes or humans where GAL fibers innvervate CBF neurons. [15].",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHAnatomy": {
          "Basal Forebrain": true
        },
        "Species": {
          "10116": true
        }
      },
      "source": 14,
      "target": 128,
      "key": "4f3cc4c581ad9cf42f2bd95e0230a57ed1c75ee2c00e95b0a92408fe10602ce4d925430c5ec0a8b81e32347252410b2b85ad97b0f4700762e579d1991d17d729"
    },
    {
      "line": 181,
      "relation": "association",
      "evidence": "Specifically, progressive phenotypic downregulation of markers within CBF neurons as well as frank CBF cell loss has been observed consistently, along with an associated reduction of choline acetyltransferase (ChAT) and acetylcholinesterase (AChE) activity within the cortex in AD [16]. Most researchers presumed that progressive disruption of cholinergic function underlies much of the short-term memory loss seen in AD",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "source": 14,
      "target": 150,
      "key": "3d03edc5e9c22a755659ae868c29acec41888e3a1da5842736123d0ffcfc47a8512697ae35a2a289cbf3536c63ad836f0ec18f98baf5fa62148988e7adeba834"
    },
    {
      "line": 208,
      "relation": "association",
      "evidence": " Notably, reports that physostigmine and oral anticholinesterases have beneficial effects for patients with AD suggest that the CBF system is somewhat preserved during the progression of dementia, despite well-documented loss of cholinergic biosynthetic machinery (including ChAT and AChE enzyme deficits) in patients with this disease. Interestingly, recent studies have shown that ChAT activity, which results in acetylcholine (ACh) synthesis, is preserved in the neocortex of people with MCI [18,19].",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "source": 14,
      "target": 142,
      "key": "c4224319499b5de13aac9141bfafbc57ca69d2f0b3aab8b5eedf25ee2f7ac3a2b0bcbc69f85892f630f09eca19c21934cbfe169891df0bc77c06a71da8a4d2ea"
    },
    {
      "line": 972,
      "relation": "association",
      "evidence": "In addition, indirect effects and unwanted side effects appeared with systemic administration including unregulated neurotransmitter release, hyperinnervation, sprouting of neurons, sympathetic stimulation, induction of antibodies, cachexia and hyperalgesia [178–181].",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        }
      },
      "source": 37,
      "target": 117,
      "key": "7601cde8989a9136cd0de3dcfa78ebf692916476b12f878328d3fee7a22d2959daa2dd48a0e16b60c0061c7841851be22a87ce495dda3a7bed0f597d9958d0a4"
    },
    {
      "line": 122,
      "relation": "association",
      "evidence": "Cholinergic neurons within the nucleus basalis (NB) and the septal diagonal band complex provide the major source of cholinergic innervation to the cerebral cortex and hippocampus, respectively, and play a key role in memory and attentional function [11–13].",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHAnatomy": {
          "Hippocampus": true,
          "Basal Nucleus of Meynert": true,
          "Cerebral Cortex": true
        }
      },
      "source": 137,
      "target": 14,
      "key": "e7eec8c2a3830eb22c5c9da65ecac98481c5eb3d2b4aa4d8381ebc7521383a2dff36eff132c89e08e46bc38c71d23892475d6418548eeb7228f850d65f83e82e"
    },
    {
      "line": 139,
      "relation": "association",
      "evidence": "Cholinergic basal forebrain (CBF) cortical projection neurons contain the pathological AD hallmark, neurofibrillary tangles (NFTs), and undergo chemical phenotypic alterations during the progression of AD, making them an excellent natural model for studying mechanisms of cell death, survival and treatment approaches both in vitro and in vivo, including relevant animal models of neurodegeneration as well as human postmortem clinical pathological tissue studies [14].",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHAnatomy": {
          "Basal Forebrain": true
        },
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "source": 13,
      "target": 14,
      "key": "fd90743e8545977a27ec4206fa1cab2d48baa344321b3624839c3f9e5302437c881b4188d76b26221bb4af3620c5dc1315f4618598cc7e1199e6d0dd66737b1e"
    },
    {
      "line": 140,
      "relation": "association",
      "evidence": "Cholinergic basal forebrain (CBF) cortical projection neurons contain the pathological AD hallmark, neurofibrillary tangles (NFTs), and undergo chemical phenotypic alterations during the progression of AD, making them an excellent natural model for studying mechanisms of cell death, survival and treatment approaches both in vitro and in vivo, including relevant animal models of neurodegeneration as well as human postmortem clinical pathological tissue studies [14].",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHAnatomy": {
          "Basal Forebrain": true
        },
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "source": 13,
      "target": 133,
      "key": "c90be787b757e418bb87a1d68c1b2da36ca6a86cf5d37712907264932b0ca7998ac1b8eb2aa62ee4755a134acfc5004965b184594141b09e77a469231fd8cdac"
    },
    {
      "line": 296,
      "relation": "association",
      "evidence": "Butyrylcholinesterase (BChE) is a serine hydrolase similar to AChE that is widely distributed throughout the CNS and also catalyzes the hydrolysis of ACh. BChE is localized to neurons and glia, and is associated with NFTs and senile plaques (SPs) in AD brain [32]. Interestingly, population-based genetic studies of AD have identified a point mutation that changes Ala539 to threonine in the K variant of BChE, which effectively reduces serum BChE concentrations, and may be associated with cognitive decline [33]. BChE activity also increases in AD brain whereas AChE activity remains unchanged or declines [34,35].",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        },
        "MeSHAnatomy": {
          "Neuroglia": true,
          "Neurons": true
        },
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "source": 13,
      "target": 83,
      "key": "7e5f748831a2bc5f09c5a6ab50ec9323967274371f3bda0d9cd7da0aceda57249bf3184529138ade73f52e145029bb7f4502bbb2c9e6c2f9ed09a4372f5744f6"
    },
    {
      "line": 158,
      "relation": "association",
      "evidence": " The regions of the forebrain that contain cholinobasal and septohippocampal CBF neurons also display various non-cholinergic neurons, including GABAergic interneurons that innervate cholinergic perikarya [11]. In addition, neuropeptides often co-localize with CBF neurons. For example, the inhibitory neuropeptide galanin (GAL) is found in septohippocampal and NB neurons in rodents, but not in higher apes or humans where GAL fibers innvervate CBF neurons. [15].",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHAnatomy": {
          "Basal Forebrain": true
        }
      },
      "source": 11,
      "target": 14,
      "key": "39bd5ccce75157d5f42889edea76a3be6bbba7a1d48d5ceb3aa31ca52cda3c573f4ed9c396c8fc8c6876c169284a6b5dd1c5abc78420b7941a32b60baedc0be6"
    },
    {
      "line": 160,
      "relation": "association",
      "evidence": " The regions of the forebrain that contain cholinobasal and septohippocampal CBF neurons also display various non-cholinergic neurons, including GABAergic interneurons that innervate cholinergic perikarya [11]. In addition, neuropeptides often co-localize with CBF neurons. For example, the inhibitory neuropeptide galanin (GAL) is found in septohippocampal and NB neurons in rodents, but not in higher apes or humans where GAL fibers innvervate CBF neurons. [15].",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHAnatomy": {
          "Basal Forebrain": true
        }
      },
      "source": 15,
      "target": 14,
      "key": "c3384054ba49bd032d75583c8f8f23c2940e40aa7850fc147531c98e8573c6645bac41f072b9d0d27bbc4122440ad2565e2164fdab10001e13f32e0e570f5552"
    },
    {
      "line": 164,
      "relation": "association",
      "evidence": " The regions of the forebrain that contain cholinobasal and septohippocampal CBF neurons also display various non-cholinergic neurons, including GABAergic interneurons that innervate cholinergic perikarya [11]. In addition, neuropeptides often co-localize with CBF neurons. For example, the inhibitory neuropeptide galanin (GAL) is found in septohippocampal and NB neurons in rodents, but not in higher apes or humans where GAL fibers innvervate CBF neurons. [15].",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHAnatomy": {
          "Basal Forebrain": true
        },
        "Species": {
          "10116": true
        }
      },
      "source": 128,
      "target": 14,
      "key": "d2cee8f9eb1fc868356fe0923426fb6ed2235f750e8c04e5ce5fbda9510adab8e51d2c17bf20cd4a56a61a7fbdf278508d203e52ad5805317096ff19b8ba62b5"
    },
    {
      "line": 216,
      "relation": "directlyIncreases",
      "evidence": " Notably, reports that physostigmine and oral anticholinesterases have beneficial effects for patients with AD suggest that the CBF system is somewhat preserved during the progression of dementia, despite well-documented loss of cholinergic biosynthetic machinery (including ChAT and AChE enzyme deficits) in patients with this disease. Interestingly, recent studies have shown that ChAT activity, which results in acetylcholine (ACh) synthesis, is preserved in the neocortex of people with MCI [18,19].",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        },
        "MeSHAnatomy": {
          "Neocortex": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 85,
      "target": 2,
      "key": "9d3d382803b7b6368cec81bac47f9bd0d0945cefca704cb43ddb71e4d9579047cf04271e6d2f3bfaf7dd20dff0ca3aac2f55e2080153819e06152a3a830fd5e5"
    },
    {
      "line": 254,
      "relation": "decreases",
      "evidence": "In MCI, increased hippocampal and frontal cortex ChAT tone may be important for promoting biochemical activity or compensating for neurodegenerative defects, which may delay the transition of these subjects to frank AD. Hippocampal ChAT activity was increased selectively in MCI cases with high Braak scores (Braak III/IV stage) indicative of advanced disease [19], suggesting that a compensatory upregulation of ChAT may be due, at least in part, to the disconnection of glutamatergic entorhinal cortex input to the hippocampus which occurs early in the disease process [21–23]. In this scenario, upregulation of hippocampal ChAT activity may be due to reactive synaptogenesis, the filling in of denervated glutamatergic synapses by cholinergic input arising from the septum [24].",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        },
        "MeSHAnatomy": {
          "Frontal Lobe": true,
          "Hippocampus": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 85,
      "target": 43,
      "key": "dfce1520fc324d618f43ef860549cbfdbfb803fd51cf9ecd21bdcc47cd1032c0be9782a90648b945f2034eb5e162970748d62b01ee3ae69d0cefa3de7de2309b"
    },
    {
      "line": 927,
      "relation": "association",
      "evidence": "In this regard, AChE has been localized to SPs in the vicinity of cholinergic synapses, and experimental evidence suggests that AChE promotes Ab fibrillization [164], suggesting that a further benefit from AChE inhibitor therapy may be to prevent continued Ab deposition in cholinergic projection sites. ",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        }
      },
      "source": 80,
      "target": 158,
      "key": "5fff8a0f0c50ad5438b25e97217b802f9b0f7bcc2c11f2577116439f2a622e4c977494c21fd8dc6785e8d258d86d1d9f6f7737db337bcc869b007eb40da327d5"
    },
    {
      "line": 929,
      "relation": "increases",
      "evidence": "In this regard, AChE has been localized to SPs in the vicinity of cholinergic synapses, and experimental evidence suggests that AChE promotes Ab fibrillization [164], suggesting that a further benefit from AChE inhibitor therapy may be to prevent continued Ab deposition in cholinergic projection sites. ",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        }
      },
      "source": 80,
      "target": 40,
      "key": "f3592765ffb4a566638ff3b07cf9772499d867d5b645d945d2028c9e2ff4dae8183a7307e0e90b1400df50af7824a7f76c591ffecbeade53272408560982e86e"
    },
    {
      "line": 181,
      "relation": "association",
      "evidence": "Specifically, progressive phenotypic downregulation of markers within CBF neurons as well as frank CBF cell loss has been observed consistently, along with an associated reduction of choline acetyltransferase (ChAT) and acetylcholinesterase (AChE) activity within the cortex in AD [16]. Most researchers presumed that progressive disruption of cholinergic function underlies much of the short-term memory loss seen in AD",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "source": 150,
      "target": 14,
      "key": "7d36b1cae5076b92cefb8dd4f64798c1a26c8ac55519f2bb55b3058654b5bff1999b12c673973d6c7252114c21303b14782766cb5a04cd3d0bd3fa30ca38f74e"
    },
    {
      "line": 190,
      "relation": "association",
      "evidence": "Delaying or preventing cholinergic neurodegeneration or minimizing its consequences is the mechanism of action for most currently available US FDA-approved drugs for the treatment of cognitive dysfunction observed in AD [17]",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHAnatomy": {
          "Cholinergic Neurons": true
        }
      },
      "source": 43,
      "target": 160,
      "key": "144071661076dcc3a0f137a9e3f4aac0551c5d248fec6c1e6ca237a8fe5edfe09be35c852ebb862120c3ba92ad79c9f112b8af491058abef10edf0b143a9c96b"
    },
    {
      "line": 205,
      "relation": "decreases",
      "evidence": " Notably, reports that physostigmine and oral anticholinesterases have beneficial effects for patients with AD suggest that the CBF system is somewhat preserved during the progression of dementia, despite well-documented loss of cholinergic biosynthetic machinery (including ChAT and AChE enzyme deficits) in patients with this disease. Interestingly, recent studies have shown that ChAT activity, which results in acetylcholine (ACh) synthesis, is preserved in the neocortex of people with MCI [18,19].",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "source": 4,
      "target": 133,
      "key": "da7c830e1d8d620562fede07fa4f46c1e1d450603d4659bf9fb06ee80cd670abdd532ab1c577e434ada477bd3b8fcda17575b8b814567896ec4efebf0b08ba63"
    },
    {
      "line": 207,
      "relation": "decreases",
      "evidence": " Notably, reports that physostigmine and oral anticholinesterases have beneficial effects for patients with AD suggest that the CBF system is somewhat preserved during the progression of dementia, despite well-documented loss of cholinergic biosynthetic machinery (including ChAT and AChE enzyme deficits) in patients with this disease. Interestingly, recent studies have shown that ChAT activity, which results in acetylcholine (ACh) synthesis, is preserved in the neocortex of people with MCI [18,19].",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "source": 8,
      "target": 133,
      "key": "0c648d12368fe3dab881d07895e72b9ac31031997a82d89ca88ed98fa388689deff49ba11f475eec377f64d89dbce5e0a68478b9596dfcc79478ec89ff8d5eab"
    },
    {
      "line": 912,
      "relation": "decreases",
      "evidence": "Recent studies report that anticholinesterase drugs reduce circulating Ab deposition in several dementia types, including AD [159]. Evidence from clinical trials [160], noninvasive functional imaging [161] and basic science research suggest that cholinesterase inhibitors might alter APP processing and therefore provide some degree of neuroprotection [162,163]",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        },
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "source": 8,
      "target": 1,
      "key": "b55b2b3d9e635b4bd3c03076c4d5c14f2837aefbb9acbd0bfbddea5efc282911c9152da80f7fa708b9f53ddddee02356852b09631ea3d13ab2f5e611645c81bf"
    },
    {
      "line": 914,
      "relation": "increases",
      "evidence": "Recent studies report that anticholinesterase drugs reduce circulating Ab deposition in several dementia types, including AD [159]. Evidence from clinical trials [160], noninvasive functional imaging [161] and basic science research suggest that cholinesterase inhibitors might alter APP processing and therefore provide some degree of neuroprotection [162,163]",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        },
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "source": 8,
      "target": 45,
      "key": "6b010ef045aa02a7352285ce4b1496381379dbe7d2e2d73c4cbe63254b07caf10bbd5f1c8b84f7d4151a2f57a2371c3dabb65b28bbc40e207e99c28dde1f0a0f"
    },
    {
      "line": 916,
      "relation": "association",
      "evidence": "Recent studies report that anticholinesterase drugs reduce circulating Ab deposition in several dementia types, including AD [159]. Evidence from clinical trials [160], noninvasive functional imaging [161] and basic science research suggest that cholinesterase inhibitors might alter APP processing and therefore provide some degree of neuroprotection [162,163]",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        },
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "source": 8,
      "target": 36,
      "key": "d1386e7ad98c5dac193ed987c793e15fad77ac98f813dd5d5d9a89b36c25002b40f03cc1d4f5f2112bad178785c937439cdb61f94a8300a83ae374ba7749c6e3"
    },
    {
      "line": 943,
      "relation": "association",
      "evidence": "Since the cholinergic deficit is not an early defect in the progression of AD [18–20], the use of these drugs in the prodromal stages of AD should be continued. However, the limited effect of cholinesterase inhibitors for the treatment of cognitive decline in AD coupled with unwanted side effects such as diarrhea, nausea, insomnia, fatigue and loss of appetite indicates the need to move beyond this conventional drug treatment with somewhat circumscribed efficacy.",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        },
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "source": 8,
      "target": 147,
      "key": "8767d28edfb8ef13d66e60b0a4e8632c7f8c432b5f43c70d6439154d411f738adad40b3314e9034a51be957c82f01f51b9758b8334426eabf35bbac1a9ab0d4b"
    },
    {
      "line": 945,
      "relation": "association",
      "evidence": "Since the cholinergic deficit is not an early defect in the progression of AD [18–20], the use of these drugs in the prodromal stages of AD should be continued. However, the limited effect of cholinesterase inhibitors for the treatment of cognitive decline in AD coupled with unwanted side effects such as diarrhea, nausea, insomnia, fatigue and loss of appetite indicates the need to move beyond this conventional drug treatment with somewhat circumscribed efficacy.",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        },
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "source": 8,
      "target": 144,
      "key": "1743390f0bd9c6a2feeea619e5dfcf7808c32f726a7eb4ecbcdb64d259ef4c518958cb329ceebca6bbc95930537da64db2afb6cfee7d542c7ebc114ec73ea34e"
    },
    {
      "line": 947,
      "relation": "association",
      "evidence": "Since the cholinergic deficit is not an early defect in the progression of AD [18–20], the use of these drugs in the prodromal stages of AD should be continued. However, the limited effect of cholinesterase inhibitors for the treatment of cognitive decline in AD coupled with unwanted side effects such as diarrhea, nausea, insomnia, fatigue and loss of appetite indicates the need to move beyond this conventional drug treatment with somewhat circumscribed efficacy.",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        },
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "source": 8,
      "target": 151,
      "key": "434146a3ba15c250621d27d8568371d25c02b089012a22fa20a50edae6c8a2c420c0263c79404229da6263768205341f036c4d75ab0d2deb2ed65fc7c89989ad"
    },
    {
      "line": 949,
      "relation": "association",
      "evidence": "Since the cholinergic deficit is not an early defect in the progression of AD [18–20], the use of these drugs in the prodromal stages of AD should be continued. However, the limited effect of cholinesterase inhibitors for the treatment of cognitive decline in AD coupled with unwanted side effects such as diarrhea, nausea, insomnia, fatigue and loss of appetite indicates the need to move beyond this conventional drug treatment with somewhat circumscribed efficacy.",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        },
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "source": 8,
      "target": 145,
      "key": "3ad5c820aac0b033c472601d176fef3af9e0eca2203016ed69df23a7bc7fb5342c7ebbaa5fd0dd65ede8fbea1c5ddea9fdc7efc8b5698a700932ee1eee94e331"
    },
    {
      "line": 951,
      "relation": "association",
      "evidence": "Since the cholinergic deficit is not an early defect in the progression of AD [18–20], the use of these drugs in the prodromal stages of AD should be continued. However, the limited effect of cholinesterase inhibitors for the treatment of cognitive decline in AD coupled with unwanted side effects such as diarrhea, nausea, insomnia, fatigue and loss of appetite indicates the need to move beyond this conventional drug treatment with somewhat circumscribed efficacy.",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        },
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "source": 8,
      "target": 135,
      "key": "bfe784a2284e49ddefd4d1e623d6f8a4c69625f1a4388fc1d815df74c0b2bbbd5aa1104fa2f9d311d8a91b88b1ef69d63dabd4c741f7c171b38df2af92498c26"
    },
    {
      "line": 277,
      "relation": "increases",
      "evidence": "A recent functional MRI study demonstrated that people with MCI treated with the FDA-approved anticholinesterase donepezil demonstrated increased frontal cortex activation relative to untreated controls, which was positively correlated with task performance [31].",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 3,
      "target": 9,
      "key": "303c8d4537719e9ed01f8001d72f75e41eacddf67e81a868bf9a85b60099c95ba12ac805777d5bf7414ae33cbaadac0e7986f0dab143763d996d16b26a50795b"
    },
    {
      "line": 279,
      "relation": "positiveCorrelation",
      "evidence": "A recent functional MRI study demonstrated that people with MCI treated with the FDA-approved anticholinesterase donepezil demonstrated increased frontal cortex activation relative to untreated controls, which was positively correlated with task performance [31].",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        }
      },
      "source": 9,
      "target": 153,
      "key": "6cbc3c45ae1bc75a3461db115b814ea2b0e3a72eb6bb2f32849352af8fe967c0b2284b91cf362d6b7e260a1a80c5ec2a38ed433a99d064f4df0b02915af9aa7f"
    },
    {
      "line": 279,
      "relation": "positiveCorrelation",
      "evidence": "A recent functional MRI study demonstrated that people with MCI treated with the FDA-approved anticholinesterase donepezil demonstrated increased frontal cortex activation relative to untreated controls, which was positively correlated with task performance [31].",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        }
      },
      "source": 153,
      "target": 9,
      "key": "854324a685353566c5f7d5f8e96a23553b30c84648b57b0b4e6634c9936d02ced525ef785ee0c86a59f05d283ddb4a36c6ae39b0dbdd2885fd4236ee05427e37"
    },
    {
      "line": 295,
      "relation": "directlyIncreases",
      "evidence": "Butyrylcholinesterase (BChE) is a serine hydrolase similar to AChE that is widely distributed throughout the CNS and also catalyzes the hydrolysis of ACh. BChE is localized to neurons and glia, and is associated with NFTs and senile plaques (SPs) in AD brain [32]. Interestingly, population-based genetic studies of AD have identified a point mutation that changes Ala539 to threonine in the K variant of BChE, which effectively reduces serum BChE concentrations, and may be associated with cognitive decline [33]. BChE activity also increases in AD brain whereas AChE activity remains unchanged or declines [34,35].",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        },
        "MeSHAnatomy": {
          "Neuroglia": true,
          "Neurons": true
        },
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "subject": {
        "modifier": "Activity",
        "effect": {
          "namespace": "bel",
          "name": "cat"
        }
      },
      "object": {
        "modifier": "Degradation"
      },
      "source": 83,
      "target": 2,
      "key": "5a93b8c6c086dd5646f2f79cf30f6a2cdc1d9d3ab20c4575c5e7e75871f5d49eebdd1db48b32213d0ef6c49b4c2be5a18e1d664fdc3a2b08c516689f06e6be2e"
    },
    {
      "line": 296,
      "relation": "association",
      "evidence": "Butyrylcholinesterase (BChE) is a serine hydrolase similar to AChE that is widely distributed throughout the CNS and also catalyzes the hydrolysis of ACh. BChE is localized to neurons and glia, and is associated with NFTs and senile plaques (SPs) in AD brain [32]. Interestingly, population-based genetic studies of AD have identified a point mutation that changes Ala539 to threonine in the K variant of BChE, which effectively reduces serum BChE concentrations, and may be associated with cognitive decline [33]. BChE activity also increases in AD brain whereas AChE activity remains unchanged or declines [34,35].",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        },
        "MeSHAnatomy": {
          "Neuroglia": true,
          "Neurons": true
        },
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "source": 83,
      "target": 13,
      "key": "0c1dad7a57c806f3029026fab0e6e9a948671ea1430d89d7dda9d01a8b9bff31a92b53f64f583e414819e1d19928656ced4d3a0a3328bda5068ec67c3b001c3c"
    },
    {
      "line": 298,
      "relation": "association",
      "evidence": "Butyrylcholinesterase (BChE) is a serine hydrolase similar to AChE that is widely distributed throughout the CNS and also catalyzes the hydrolysis of ACh. BChE is localized to neurons and glia, and is associated with NFTs and senile plaques (SPs) in AD brain [32]. Interestingly, population-based genetic studies of AD have identified a point mutation that changes Ala539 to threonine in the K variant of BChE, which effectively reduces serum BChE concentrations, and may be associated with cognitive decline [33]. BChE activity also increases in AD brain whereas AChE activity remains unchanged or declines [34,35].",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        },
        "MeSHAnatomy": {
          "Neuroglia": true,
          "Neurons": true
        },
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "source": 83,
      "target": 158,
      "key": "0e5f78e7762eef5fd227dad0ccbeddeca68dca40c56b4020578828375fb97ee5f333afa403084eb16c28e6767f61453882ee5cf15a2d63bbca23c7900c926448"
    },
    {
      "relation": "hasVariant",
      "source": 83,
      "target": 84,
      "key": "5b9da80d4fbd81f66475185596fc7b67c4db42fa2d79f6971b9974c3948f21090bf5b9341aebd0c1786ed51819751a8f627ee9e0ec3e9c3fb955f43e19a2bd03"
    },
    {
      "line": 300,
      "relation": "association",
      "evidence": "Butyrylcholinesterase (BChE) is a serine hydrolase similar to AChE that is widely distributed throughout the CNS and also catalyzes the hydrolysis of ACh. BChE is localized to neurons and glia, and is associated with NFTs and senile plaques (SPs) in AD brain [32]. Interestingly, population-based genetic studies of AD have identified a point mutation that changes Ala539 to threonine in the K variant of BChE, which effectively reduces serum BChE concentrations, and may be associated with cognitive decline [33]. BChE activity also increases in AD brain whereas AChE activity remains unchanged or declines [34,35].",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        },
        "MeSHAnatomy": {
          "Neuroglia": true,
          "Neurons": true
        },
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "source": 83,
      "target": 140,
      "key": "7dee348f3bdd41733ec144d4d056e1313c85c13edca42221ab2d0a0b3c28d734451bf151ac12db709d0f4d3898628b7adbcd2f31ddb447747deb3e0f4ee5cb5f"
    },
    {
      "line": 298,
      "relation": "association",
      "evidence": "Butyrylcholinesterase (BChE) is a serine hydrolase similar to AChE that is widely distributed throughout the CNS and also catalyzes the hydrolysis of ACh. BChE is localized to neurons and glia, and is associated with NFTs and senile plaques (SPs) in AD brain [32]. Interestingly, population-based genetic studies of AD have identified a point mutation that changes Ala539 to threonine in the K variant of BChE, which effectively reduces serum BChE concentrations, and may be associated with cognitive decline [33]. BChE activity also increases in AD brain whereas AChE activity remains unchanged or declines [34,35].",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        },
        "MeSHAnatomy": {
          "Neuroglia": true,
          "Neurons": true
        },
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "source": 158,
      "target": 83,
      "key": "6eb10e7335b79e47167272cdba92df0258c66b30eec25c8521d1e8455ced7eed73a0f2a0484b5555cd13bc2692d595c41a5c0625d955d9c51b2e85436d8ebdd0"
    },
    {
      "line": 927,
      "relation": "association",
      "evidence": "In this regard, AChE has been localized to SPs in the vicinity of cholinergic synapses, and experimental evidence suggests that AChE promotes Ab fibrillization [164], suggesting that a further benefit from AChE inhibitor therapy may be to prevent continued Ab deposition in cholinergic projection sites. ",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        }
      },
      "source": 158,
      "target": 80,
      "key": "70459fac1f281a21bfa78ca3f18ebf84c4c8027e43780c4bad34ef920ca3aad05d92924cca7710cb1c2b8670bfbcbbb3cd18c0b97b3a8477ea1fdec89b54919a"
    },
    {
      "line": 299,
      "relation": "decreases",
      "evidence": "Butyrylcholinesterase (BChE) is a serine hydrolase similar to AChE that is widely distributed throughout the CNS and also catalyzes the hydrolysis of ACh. BChE is localized to neurons and glia, and is associated with NFTs and senile plaques (SPs) in AD brain [32]. Interestingly, population-based genetic studies of AD have identified a point mutation that changes Ala539 to threonine in the K variant of BChE, which effectively reduces serum BChE concentrations, and may be associated with cognitive decline [33]. BChE activity also increases in AD brain whereas AChE activity remains unchanged or declines [34,35].",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        },
        "MeSHAnatomy": {
          "Neuroglia": true,
          "Neurons": true
        },
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "source": 84,
      "target": 83,
      "key": "241e3e5f756587556e32ad49f7b50e4bc1a36426c0c97371ec5d60838071b530888ea0833c8158f10ac3d0f92ea85896ceb62017457726085179453cea151a02"
    },
    {
      "line": 347,
      "relation": "isA",
      "evidence": "NGF is synthesized as a precursor (proNGF) molecule that is proteolytically cleaved to a mature biologically active neurotrophin peptide [49]. Mature NGF binds to the TrkA receptor, which stimulates signal transduction pathways mediating the majority of the survival and growth effects of NGF [50], and to the p75NTR receptor, which is a positive modulator of NGF/TrkA binding [50]. However, p75NTR has multiple functions, including apoptotic or cell death actions [51–56], which are dependent upon its interaction with various receptor chaperones [57–59].",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        }
      },
      "source": 117,
      "target": 10,
      "key": "9fc6a1092ea1b1a4baac2a7d424985ba378bd9bfe1f43716ab395798840824bc43a12e10760a004c32b2941e178fd51a6eb42f32779c98b73e391ecd7c1de0d4"
    },
    {
      "line": 524,
      "relation": "increases",
      "evidence": " For example, NGF signal transduction activates the MAPK pathway, which participates in a wide array of biologic functions, including cell survival, differentiation and apoptosis [82–84]. MAPK is a serine/ threonine protein kinase which becomes activated upon phosphorylation and affects a wide variety of transcription factors [85].",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 117,
      "target": 20,
      "key": "8294f7cf886a5d82c52b7e6901c48a0bdfebed23c149cac237c3537d6c7f4609937ea16ace0dede38bb374d6d89e676058f017cba03be48a5d8674ec595fcb88"
    },
    {
      "line": 961,
      "relation": "causesNoChange",
      "evidence": "NGF therapy has been tested in clinical trials of diabetic peripheral neuropathy and HIV-associated neuropathy, as well as patients with AD [177]. Each of these clinical trials met with disappointment owing to lack of efficacy, toxicity or both. ",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        }
      },
      "source": 117,
      "target": 143,
      "key": "3a7dcfd750bb31e2ab16f577670b370e8cc0a5d43bfac9b23618a5a3e2f2eba3247b8a9648575fa4a41b24c470152f66b500fdb1afc0ef8575c76f17df81057e"
    },
    {
      "line": 963,
      "relation": "causesNoChange",
      "evidence": "NGF therapy has been tested in clinical trials of diabetic peripheral neuropathy and HIV-associated neuropathy, as well as patients with AD [177]. Each of these clinical trials met with disappointment owing to lack of efficacy, toxicity or both. ",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        }
      },
      "source": 117,
      "target": 154,
      "key": "c01fbf33af22649abe2096a77d09ab831b21f604b1f05b845370d83090d713e98afce20965456428eb18f0368a50d4cc835d6e03f02e7200e4151b89696aa818"
    },
    {
      "line": 964,
      "relation": "causesNoChange",
      "evidence": "NGF therapy has been tested in clinical trials of diabetic peripheral neuropathy and HIV-associated neuropathy, as well as patients with AD [177]. Each of these clinical trials met with disappointment owing to lack of efficacy, toxicity or both. ",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        }
      },
      "source": 117,
      "target": 133,
      "key": "74587827653a6c4eda57cf47564130bfadae82878b13a5088c8a27ad770d0569dc5b81336d8d2554f3f79fcd1c1553870d5849212ca236e709c0374502f8d5d1"
    },
    {
      "line": 972,
      "relation": "association",
      "evidence": "In addition, indirect effects and unwanted side effects appeared with systemic administration including unregulated neurotransmitter release, hyperinnervation, sprouting of neurons, sympathetic stimulation, induction of antibodies, cachexia and hyperalgesia [178–181].",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        }
      },
      "source": 117,
      "target": 37,
      "key": "1cecce216b51abc6d259968de77e49d788fa001e7472f0b687d85263505f30616aa045b183e11f59c18f9854ccac93c106efc69f23bf5cc983581e3045725036"
    },
    {
      "line": 974,
      "relation": "association",
      "evidence": "In addition, indirect effects and unwanted side effects appeared with systemic administration including unregulated neurotransmitter release, hyperinnervation, sprouting of neurons, sympathetic stimulation, induction of antibodies, cachexia and hyperalgesia [178–181].",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        }
      },
      "source": 117,
      "target": 24,
      "key": "78bb91d51e43419e6fc0111869b425c8114bc0377b890f685bcb94a315a501172839360c9a48c432d943feb0a3c9310ad0ddccd971e00e130309b482e5322386"
    },
    {
      "line": 976,
      "relation": "association",
      "evidence": "In addition, indirect effects and unwanted side effects appeared with systemic administration including unregulated neurotransmitter release, hyperinnervation, sprouting of neurons, sympathetic stimulation, induction of antibodies, cachexia and hyperalgesia [178–181].",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        }
      },
      "source": 117,
      "target": 35,
      "key": "b7ef9cae21cb56ad4040df84ca5821150d4e5735bba72b448c7313a043580c3f119e04ab80e274bc4c29a29053015152d95c3713f1e36e143b904883f97952ae"
    },
    {
      "line": 978,
      "relation": "association",
      "evidence": "In addition, indirect effects and unwanted side effects appeared with systemic administration including unregulated neurotransmitter release, hyperinnervation, sprouting of neurons, sympathetic stimulation, induction of antibodies, cachexia and hyperalgesia [178–181].",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        }
      },
      "source": 117,
      "target": 139,
      "key": "97efaeab88f9fcbe3e67a8dd6d7656fd01de24cf721b588ddd8f301b2f34c209866a38d06e608a4cac4efc1e0da17f1aec6008e7c8bf7b80c936f5574071048f"
    },
    {
      "line": 980,
      "relation": "association",
      "evidence": "In addition, indirect effects and unwanted side effects appeared with systemic administration including unregulated neurotransmitter release, hyperinnervation, sprouting of neurons, sympathetic stimulation, induction of antibodies, cachexia and hyperalgesia [178–181].",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        }
      },
      "source": 117,
      "target": 146,
      "key": "ee9ce93375d30c5c710574e77a7278b517748da1e2632b0414a80c8baf363566a7a11d013e48b0b1972e69c1f588a482822d87d47bf4964a7fac3f754699c93f"
    },
    {
      "line": 999,
      "relation": "decreases",
      "evidence": "The ex vivo Phase I trial attempted to move beyond currently available treatments for AD [113]. The goal of this NGF trial was to protect CBF neurons from degeneration, as well as augment the function of remaining cholinergic neurons by delivery of human NGF. After obtaining informed consent, skin biopsies were attained to generate primary cultures of autologous fibroblasts that were transfected to produce human NGF [184]. If fibroblasts were found to be acceptable based on NGF production rates, then grafts were stereotaxically placed into multiple locations within the region of the CBF neurons. Following a period of 22 months, no long-term post-surgical adverse effects were found and the rate of cognitive decline appeared to be reduced [113]. ",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        },
        "MeSHAnatomy": {
          "Fibroblasts": true
        }
      },
      "source": 117,
      "target": 160,
      "key": "fb92cd22981e253bb2869edb03781cd54094f86e8be10c3870cce9d3ac23dca4c7418793df7d4f4a721fc01de6ce7aa845d188965b9f23d7f88b32d5fec75b57"
    },
    {
      "relation": "hasComponent",
      "source": 56,
      "target": 117,
      "key": "1c15a13f2ff9aab0599596c4994c847b242c859b1c7956697c759e0a74d0554ac0f00d7f73f3ef8324cfedc7c31a670c33503fd5c4cf7be546e91121ccb0ecb1"
    },
    {
      "relation": "hasComponent",
      "source": 56,
      "target": 119,
      "key": "6fe9d1f42202bfbd6b9305ddd9a57f64ae0ac4aca0513205e7f4b32b6645ab8b749be259612118d4d29518306d09583ffeefd24581ed834b5e3faef0c2339d26"
    },
    {
      "line": 349,
      "relation": "increases",
      "evidence": "NGF is synthesized as a precursor (proNGF) molecule that is proteolytically cleaved to a mature biologically active neurotrophin peptide [49]. Mature NGF binds to the TrkA receptor, which stimulates signal transduction pathways mediating the majority of the survival and growth effects of NGF [50], and to the p75NTR receptor, which is a positive modulator of NGF/TrkA binding [50]. However, p75NTR has multiple functions, including apoptotic or cell death actions [51–56], which are dependent upon its interaction with various receptor chaperones [57–59].",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        }
      },
      "source": 56,
      "target": 32,
      "key": "af80e14a39eb178d7f0fa248402cb13af2e55435e1804b48f3e09b17846d6ab47d27dbb2636e9cafec85415ec3024e3645c8889341b3a88d88939f5ed2d41f4a"
    },
    {
      "line": 374,
      "relation": "increases",
      "evidence": " In this regard, immunoblotting studies demonstrated that proNGF is the predominant form of NGF present in the cortex of aged cognitively intact humans [60]. ProNGF levels are increased in the cortex of subjects diagnosed with MCI or mild AD compared to those with NCI [61]. The biological consequences of proNGF are controversial, as is the function of its accumulation in the cortex during the prodromal stages of AD. Emerging literature suggests that recombinant proNGF binds TrkA and promotes neuronal survival and neurite outgrowth similar to mature NGF, but is approximately fivefold less active than the mature NGF peptide [62,63].",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        },
        "MeSHAnatomy": {
          "Cerebral Cortex": true
        }
      },
      "source": 56,
      "target": 28,
      "key": "52a3bb50d87a50d28cfbf37ba819f9951f4b6831009a3be7b62e116109c0078cb81b40c1a95da7c3bb1e831daf0fccf3532ed07387c19fbf7723bc6b724f4355"
    },
    {
      "line": 389,
      "relation": "negativeCorrelation",
      "evidence": "Significantly, while we have shown that reduced TrkA levels in the cortex were positively associated with lower cognitive performance as assessed by Mini-Mental State Exam (MMSE) test scores [64], increased cortical proNGF levels were negatively correlated with MMSE performance [61].",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        },
        "MeSHAnatomy": {
          "Cerebral Cortex": true
        },
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "source": 119,
      "target": 141,
      "key": "13968b52e664455e3d5985d8775bf709bf3e2ab021f8804ac4ca6ef11ff78766775cc12d9f3ff7bc57107eb588c91abe2690511f9cbc563b563eaa9cc3f2548b"
    },
    {
      "line": 402,
      "relation": "biomarkerFor",
      "evidence": "Thus, the concomitant reduction of TrkA and accumulation of proNGF in the cortex may be an early pathobiological marker for the onset of AD (Figure 1A). In fact, significantly increased cerebrospinal fluid (CSF) levels of NGF are detectable in AD [65], demonstrating the potential utility of NGF as a diagnostic biomarker.",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        }
      },
      "source": 119,
      "target": 133,
      "key": "8eda6971f7f23e8400e032a653b8189060b06f6a5ba9c467e82c4843649e55a1eb71e56fe4f0f434366c83a0c25e5970f454c79ce6a224b2e095530a1257b07b"
    },
    {
      "line": 433,
      "relation": "decreases",
      "evidence": "It is also important to note that TrkA reduces and p75NTR activates β-secretase strike (BACE) cleavage of the amyloid precursor protein (APP), which requires NGF binding and activation of the second messenger ceramide [66]. Aging may activate beta-amyloid (Ab) generation in the brain by ‘switching’ from TrkA to p75NTR, suggesting that NGF receptor balance is a molecular link between normal aging of the brain and AD in relation to amyloid processing.",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        },
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 119,
      "target": 82,
      "key": "ce59eccc088a587d60d48ad58dfcca1e56a9da29faedf2340f5aab9bc4ccf3285d1b0f6d649be13aa9dfd4d19c25a3d9ca1671d74073cfabeac643118fe073f4"
    },
    {
      "relation": "hasVariant",
      "source": 119,
      "target": 120,
      "key": "3f77adcc3241e87b8b96fdc4bfcc50c9197384b942ec8d1fb3385834faded26568c37abed9eae35e2eac0928956d33a912ddd3a51ebcf2b06be6610f2ed917e2"
    },
    {
      "line": 351,
      "relation": "increases",
      "evidence": "NGF is synthesized as a precursor (proNGF) molecule that is proteolytically cleaved to a mature biologically active neurotrophin peptide [49]. Mature NGF binds to the TrkA receptor, which stimulates signal transduction pathways mediating the majority of the survival and growth effects of NGF [50], and to the p75NTR receptor, which is a positive modulator of NGF/TrkA binding [50]. However, p75NTR has multiple functions, including apoptotic or cell death actions [51–56], which are dependent upon its interaction with various receptor chaperones [57–59].",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        }
      },
      "source": 32,
      "target": 41,
      "key": "75f23ca7b6f31928427c0a6a3b576c3953fc616bbc662b628d26817f2506c533cf2866c7ce595375bb42103497baca589c027c85970e2747c056df95d3ce364b"
    },
    {
      "relation": "hasComponent",
      "source": 55,
      "target": 117,
      "key": "4919da736a9cea142bc0a2b4b3d197fa1d6a118ec340618f53d75664ca4018c99b9677dbe3a7d01078a4c50756fff18dfec76aa6507ddbda398de5f0b70531d8"
    },
    {
      "relation": "hasComponent",
      "source": 55,
      "target": 118,
      "key": "fa5a77f89d8d71b079dbf7b6d5a52271825a0fcdb7dae6875203d95a23a8fa80f4167e3a794b3aba49e1f71c7077899c9dce56b8aa0e5e4828bb71581f26090c"
    },
    {
      "line": 353,
      "relation": "increases",
      "evidence": "NGF is synthesized as a precursor (proNGF) molecule that is proteolytically cleaved to a mature biologically active neurotrophin peptide [49]. Mature NGF binds to the TrkA receptor, which stimulates signal transduction pathways mediating the majority of the survival and growth effects of NGF [50], and to the p75NTR receptor, which is a positive modulator of NGF/TrkA binding [50]. However, p75NTR has multiple functions, including apoptotic or cell death actions [51–56], which are dependent upon its interaction with various receptor chaperones [57–59].",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        }
      },
      "source": 55,
      "target": 56,
      "key": "670a3fa10d177747bc8625f32b053a91c6ca08f75a5e42d9a9201715ad246e2b981bb1cfd2496e2a3bdce6894282937a6348b3bc0b8683e77561feefdae6c8e1"
    },
    {
      "line": 355,
      "relation": "association",
      "evidence": "NGF is synthesized as a precursor (proNGF) molecule that is proteolytically cleaved to a mature biologically active neurotrophin peptide [49]. Mature NGF binds to the TrkA receptor, which stimulates signal transduction pathways mediating the majority of the survival and growth effects of NGF [50], and to the p75NTR receptor, which is a positive modulator of NGF/TrkA binding [50]. However, p75NTR has multiple functions, including apoptotic or cell death actions [51–56], which are dependent upon its interaction with various receptor chaperones [57–59].",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        }
      },
      "source": 118,
      "target": 39,
      "key": "e75799cc603ec8e1dd95c88ba29db2137e33478dde98f467a8558310bb6f29aab484123b0ec26d49ae9331b05793824e8c22b5a03255735f94e593e6ffa29201"
    },
    {
      "line": 434,
      "relation": "increases",
      "evidence": "It is also important to note that TrkA reduces and p75NTR activates β-secretase strike (BACE) cleavage of the amyloid precursor protein (APP), which requires NGF binding and activation of the second messenger ceramide [66]. Aging may activate beta-amyloid (Ab) generation in the brain by ‘switching’ from TrkA to p75NTR, suggesting that NGF receptor balance is a molecular link between normal aging of the brain and AD in relation to amyloid processing.",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        },
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 118,
      "target": 82,
      "key": "07b06c2bbfa0f765e1cf87ec80bbfa2bbd4c9e1548509ee371165f90a40f5a5cfc2b08ccc2f89b70faa4bd88243c29bb4cd4c2a4ef1cfa9742297bdf8ef5d7fe"
    },
    {
      "line": 437,
      "relation": "increases",
      "evidence": "It is also important to note that TrkA reduces and p75NTR activates β-secretase strike (BACE) cleavage of the amyloid precursor protein (APP), which requires NGF binding and activation of the second messenger ceramide [66]. Aging may activate beta-amyloid (Ab) generation in the brain by ‘switching’ from TrkA to p75NTR, suggesting that NGF receptor balance is a molecular link between normal aging of the brain and AD in relation to amyloid processing.",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        },
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "source": 118,
      "target": 1,
      "key": "9a063e9505a5f389aa4699fe398bdc17a3812af27926b47017ef0f0aef62f1b6da4b798c78314c860188fea328d4e5e3208a9c522853ec34e742468785688bc4"
    },
    {
      "line": 591,
      "relation": "association",
      "evidence": "Recent evidence supports the notion that p75NTR has an intrinsic signaling capacity including: •   Sphingolipid metabolism [98–100] •      Activation of the JNK pathway [52,54,56,101–103] •      Activation of the NF-kappaB pathway [104–109] •         Activation of the Akt pathway [110] •   Activation of the MAPK pathway [97,111]",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 118,
      "target": 21,
      "key": "fddca8071366601f000f772c359a31bc30062ae2296cabcbfd0f0f52e2352573c97ed5accee1caea9bab3df7095ef1466eaa169604a2faeb1291252e718dfe49"
    },
    {
      "line": 593,
      "relation": "increases",
      "evidence": "Recent evidence supports the notion that p75NTR has an intrinsic signaling capacity including: •   Sphingolipid metabolism [98–100] •      Activation of the JNK pathway [52,54,56,101–103] •      Activation of the NF-kappaB pathway [104–109] •         Activation of the Akt pathway [110] •   Activation of the MAPK pathway [97,111]",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 118,
      "target": 23,
      "key": "97f5a389975296f277beca5a9ffc49d3a195baf6cc348e519fa0fa475fed90d325d60a0640e609ac826a4c3460563e463dbebd42ef6708878852d6dde047f6ae"
    },
    {
      "line": 595,
      "relation": "increases",
      "evidence": "Recent evidence supports the notion that p75NTR has an intrinsic signaling capacity including: •   Sphingolipid metabolism [98–100] •      Activation of the JNK pathway [52,54,56,101–103] •      Activation of the NF-kappaB pathway [104–109] •         Activation of the Akt pathway [110] •   Activation of the MAPK pathway [97,111]",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 118,
      "target": 31,
      "key": "f9ac78f083d234b48dcc6e82e14d689ba5a8ba8ec34661668732383471f8b4c685774c1603d0889720ce44d33ac5607f1346633db841e871acdf123bd8691446"
    },
    {
      "line": 596,
      "relation": "increases",
      "evidence": "Recent evidence supports the notion that p75NTR has an intrinsic signaling capacity including: •   Sphingolipid metabolism [98–100] •      Activation of the JNK pathway [52,54,56,101–103] •      Activation of the NF-kappaB pathway [104–109] •         Activation of the Akt pathway [110] •   Activation of the MAPK pathway [97,111]",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 118,
      "target": 33,
      "key": "6ab3d59e77713496f43eca34c33b2a0160ab6ce3d5778a04e5f09a99290aaaebb1ba5d8a5d04d5b87a547efc032cd33d33b0d2b072b4e93709deaced4d6673f6"
    },
    {
      "line": 597,
      "relation": "increases",
      "evidence": "Recent evidence supports the notion that p75NTR has an intrinsic signaling capacity including: •   Sphingolipid metabolism [98–100] •      Activation of the JNK pathway [52,54,56,101–103] •      Activation of the NF-kappaB pathway [104–109] •         Activation of the Akt pathway [110] •   Activation of the MAPK pathway [97,111]",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 118,
      "target": 20,
      "key": "f901dac0ad289e4190b17f3de221c1edf718ba98c6a67bd6bca65be2964f9bf471ca827ca1850f6a4faa0965f79747b09c7c7ffb62ec5cf5097a22a3716c4f67"
    },
    {
      "line": 355,
      "relation": "association",
      "evidence": "NGF is synthesized as a precursor (proNGF) molecule that is proteolytically cleaved to a mature biologically active neurotrophin peptide [49]. Mature NGF binds to the TrkA receptor, which stimulates signal transduction pathways mediating the majority of the survival and growth effects of NGF [50], and to the p75NTR receptor, which is a positive modulator of NGF/TrkA binding [50]. However, p75NTR has multiple functions, including apoptotic or cell death actions [51–56], which are dependent upon its interaction with various receptor chaperones [57–59].",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        }
      },
      "source": 39,
      "target": 118,
      "key": "6a3235f733e7268ddff890fa8f2ac887219aa3bcec402c5dc243733e9f56fd77a8627674e9efb38d795d41022b813a04b638e3c3070e38281910009bfe243c16"
    },
    {
      "line": 390,
      "relation": "positiveCorrelation",
      "evidence": "Significantly, while we have shown that reduced TrkA levels in the cortex were positively associated with lower cognitive performance as assessed by Mini-Mental State Exam (MMSE) test scores [64], increased cortical proNGF levels were negatively correlated with MMSE performance [61].",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        },
        "MeSHAnatomy": {
          "Cerebral Cortex": true
        },
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "source": 18,
      "target": 141,
      "key": "d6215b10fdb89d4d8cd81cd99eeb846f110fd343928d2074b93dc2c028f96e1b6b7f4947fe941b250b1596ac34ca88290e567314943d72a4e88ceb2106284e07"
    },
    {
      "line": 403,
      "relation": "biomarkerFor",
      "evidence": "Thus, the concomitant reduction of TrkA and accumulation of proNGF in the cortex may be an early pathobiological marker for the onset of AD (Figure 1A). In fact, significantly increased cerebrospinal fluid (CSF) levels of NGF are detectable in AD [65], demonstrating the potential utility of NGF as a diagnostic biomarker.",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        }
      },
      "source": 18,
      "target": 133,
      "key": "c811ca1fe098c7e1d2553ebe90eea317b9e6148bd5e27983470ac2b0046f32e3981c2a1f8ba4b761a6d94fece87a350ae3606ae87785bb741b3522a8efb56026"
    },
    {
      "relation": "hasComponent",
      "source": 53,
      "target": 18,
      "key": "1f29fc64412f38da2cfa394c42694a44c71b6d5e0c00f16445bff25c25bb21f982a29502845894a76c0bf723222df647efd967dd1152c3fbd563d5e5746a0dbd"
    },
    {
      "relation": "hasComponent",
      "source": 53,
      "target": 119,
      "key": "ac55c621c376b9c15e3ea4bf218bdb971cf2e8525b827f0bd669db1be52b08ae8189427809d281a7ebebbf20385512951e6a8af18300dae840b1b2b60d23f153"
    },
    {
      "line": 373,
      "relation": "increases",
      "evidence": " In this regard, immunoblotting studies demonstrated that proNGF is the predominant form of NGF present in the cortex of aged cognitively intact humans [60]. ProNGF levels are increased in the cortex of subjects diagnosed with MCI or mild AD compared to those with NCI [61]. The biological consequences of proNGF are controversial, as is the function of its accumulation in the cortex during the prodromal stages of AD. Emerging literature suggests that recombinant proNGF binds TrkA and promotes neuronal survival and neurite outgrowth similar to mature NGF, but is approximately fivefold less active than the mature NGF peptide [62,63].",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        },
        "MeSHAnatomy": {
          "Cerebral Cortex": true
        }
      },
      "source": 53,
      "target": 28,
      "key": "d9c0674cef7878099ea62b328a7361e3b7eb027e89a5c104515980298f862c44cdc27b35a9c9917c0e042b259469677c27a6e8c09e9db5a091706b75989ff565"
    },
    {
      "line": 549,
      "relation": "association",
      "evidence": "The classic MAPK cascade involves activation of the small GTPase Ras, and the kinases Raf and MEK [86,87]. Downstream consequences of MAPK activation include activation of the ribosomal S6 kinases (Rsk) and the MAPK-activated protein kinase 2 (MAPKAP2), which phosphorylates several transcription factors including Elk-1 and cAMP-regulated response element binding protein (CREB) [85]. The physiological significance of this elaborate NGF-induced network remains unclear, but the sustained activation of MAPK is linked to neurotrophin-mediated neurite outgrowth [88,89]",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 28,
      "target": 70,
      "key": "d58b6342c1c2e8018374719a7c436160108daa346a66ae0c197ffd25d4b14a5ff458968ba83f28440be56844fbd6a340fcb8a5194dc518dca7e0c4952192550e"
    },
    {
      "line": 389,
      "relation": "negativeCorrelation",
      "evidence": "Significantly, while we have shown that reduced TrkA levels in the cortex were positively associated with lower cognitive performance as assessed by Mini-Mental State Exam (MMSE) test scores [64], increased cortical proNGF levels were negatively correlated with MMSE performance [61].",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        },
        "MeSHAnatomy": {
          "Cerebral Cortex": true
        },
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "source": 141,
      "target": 119,
      "key": "024e6ce26cb71dc7dff83d6d9bc8ebb1407ae60524d1857b7137e9d7f54c8463823e3f339b8fafe5d7284478470ed721234b125fdfecb56bea4bcd79238c917c"
    },
    {
      "line": 390,
      "relation": "positiveCorrelation",
      "evidence": "Significantly, while we have shown that reduced TrkA levels in the cortex were positively associated with lower cognitive performance as assessed by Mini-Mental State Exam (MMSE) test scores [64], increased cortical proNGF levels were negatively correlated with MMSE performance [61].",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        },
        "MeSHAnatomy": {
          "Cerebral Cortex": true
        },
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "source": 141,
      "target": 18,
      "key": "24e74c71584465e695ddc9d710d46cfb10e3ccfca374b9c5e1653e1ea47764448147523c6452f2cf363b8e6df3868984fd033747824def016e3204ca5746c3cc"
    },
    {
      "line": 484,
      "relation": "positiveCorrelation",
      "evidence": "We found an upregulation of MMP-9 protein levels and activity in both AD and MCI brains, which correlated inversely with cognitive status (Figure 1B) [75]. Since tissue alterations are often reflected in bodily fluids, determination of MMPs in blood, urine and CSF has been recommended as potential biomarkers to act as diagnostic measures to characterize the disease process that occurs in the brain [76–78]. Interestingly, plasma MMP-9 was increased in MCI and AD [77].",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        },
        "MeSHAnatomy": {
          "Plasma": true,
          "Brain": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 141,
      "target": 116,
      "key": "79886e2b72d448af0b164fcfc1caecd4df7543c49f4705a03c6891e71dbb8e609d7bafcef64d2dc10acc0c0dd74168a148bcf9564ac42809dd07fb1449a7253a"
    },
    {
      "relation": "hasComponent",
      "source": 52,
      "target": 18,
      "key": "54a80bf402c89dc889384ff7af89e1305c943873390d6d286bc50963ede2b43af9f4ea1caff0fa80a5eb9aadc3c988bcab091beb0645870aab33b16c60cec4ff"
    },
    {
      "relation": "hasComponent",
      "source": 52,
      "target": 118,
      "key": "e14bf3d0d0ac2f27fd009df1930ccee64f786f1d22800ceed2afee73fd0a83bde5b321186e692f0f70e0f97f76391b738ef498f52624462f4a6c18a9cdfd4f1a"
    },
    {
      "line": 419,
      "relation": "increases",
      "evidence": "By contrast, several studies indicate that increases in cortical proNGF may result in proapoptotic signaling through binding to the p75NTR receptor. In support of this, a different form of recombinant proNGF was shown to bind p75NTR with high affinity and promote neuronal apoptosis [55].",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        }
      },
      "source": 52,
      "target": 22,
      "key": "0712aa2bcdb9438081f65b50aa6ca3256d2c92d98c69215bf187ae2d23472d8e5d5a8ee7e045aa18744d68285b765f9ae45cc9df1a03a8a5e1e2ee7d5d1a4054"
    },
    {
      "line": 525,
      "relation": "association",
      "evidence": " For example, NGF signal transduction activates the MAPK pathway, which participates in a wide array of biologic functions, including cell survival, differentiation and apoptosis [82–84]. MAPK is a serine/ threonine protein kinase which becomes activated upon phosphorylation and affects a wide variety of transcription factors [85].",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        }
      },
      "source": 22,
      "target": 20,
      "key": "bb054567feb19dcc57c54b3a9d33c5a07a241fdf2f565401bf3afb93ad8e081ce93964d4012558957901f0be882d611d13146ce99f1a7e56d5f5260275e63ebe"
    },
    {
      "line": 432,
      "relation": "increases",
      "evidence": "It is also important to note that TrkA reduces and p75NTR activates β-secretase strike (BACE) cleavage of the amyloid precursor protein (APP), which requires NGF binding and activation of the second messenger ceramide [66]. Aging may activate beta-amyloid (Ab) generation in the brain by ‘switching’ from TrkA to p75NTR, suggesting that NGF receptor balance is a molecular link between normal aging of the brain and AD in relation to amyloid processing.",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        },
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 82,
      "target": 1,
      "key": "07304223a73acbfaf0afdd7de8bb76842bada6c4b08c65c5ff183d30debb0ef711fcb67be0bdb40733cfdce12323c184b52f28a626a2719ac91dcc1b7e92ee8c"
    },
    {
      "line": 436,
      "relation": "increases",
      "evidence": "It is also important to note that TrkA reduces and p75NTR activates β-secretase strike (BACE) cleavage of the amyloid precursor protein (APP), which requires NGF binding and activation of the second messenger ceramide [66]. Aging may activate beta-amyloid (Ab) generation in the brain by ‘switching’ from TrkA to p75NTR, suggesting that NGF receptor balance is a molecular link between normal aging of the brain and AD in relation to amyloid processing.",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        },
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "source": 46,
      "target": 118,
      "key": "3cbdd41ad3ba8563644e93455ef05a55b5da801d84226b8d8f1a9252e6b47b5f59f86952afa6e628e918bb80fb4dc762ac6b8a63c120ea64ff9805d6c5455336"
    },
    {
      "relation": "hasComponent",
      "source": 58,
      "target": 18,
      "key": "309dc4b5dc6359575c93e54d0084fa863256156ef434675f7ff975e5d0d585bc2aa43e94519bc401ff5673c9805b1e4b33eabff0dbcfe6039dcc877401255407"
    },
    {
      "relation": "hasComponent",
      "source": 58,
      "target": 57,
      "key": "df86038b92580b5d87ee02ff06ec2329695b721b7d75f2d58e89f478c5a4a322422428d8fda5c0747ce9078f2c66b98b0027c8b956d15bbc4f4b698938c7fa8a"
    },
    {
      "line": 455,
      "relation": "increases",
      "evidence": "Recent findings indicate that the putative proapoptotic effect(s) of p75NTR-mediated proNGF signaling is dependent on interactions between p75NTR and the neurotensin receptor sortilin, a Vps10p domain trafficking protein that acts as a cell surface coreceptor with p75NTR to mediate proNGF-induced cell death. This family of receptors is acquiring increasing importance owing to its potential involvement in AD [68]. A recent study provided genetic information for a role of the proneurotrophin receptor complex comprising sortilin and p75NTR, in the mediation of neuronal viability in vivo [69]. Sortilin expression is required for p75NTR-mediated apoptosis following proNGF treatment [57], suggesting that sortilin is a p75NTR binding partner associated with the initiation of cell death [51,58]",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        }
      },
      "source": 58,
      "target": 22,
      "key": "425f145da1fbce165f84f7d3506fef9fdfb8e959cf9b998566e426bb0759445ec298b036acb37cb60149f9e8d56f6bc7bfe457cea73c28eac376531991ebf6b1"
    },
    {
      "relation": "hasComponent",
      "source": 57,
      "target": 118,
      "key": "0a54ec9c37d78979566b6315df97edd8327ff66f2b463386bed50372d9ad35824169db211a1133a9169d870428812ef079a879bf096442eae9397b2e39c0dad2"
    },
    {
      "relation": "hasComponent",
      "source": 57,
      "target": 123,
      "key": "7a79e1ba6bb0bf686fbb03dcb15137e194673001719e75cac5df36e63f89b321cd61ce5838af5160d79efcbdd2df5d6c316a9c7a98749e5ad6cf2f4954baa652"
    },
    {
      "line": 456,
      "relation": "association",
      "evidence": "Recent findings indicate that the putative proapoptotic effect(s) of p75NTR-mediated proNGF signaling is dependent on interactions between p75NTR and the neurotensin receptor sortilin, a Vps10p domain trafficking protein that acts as a cell surface coreceptor with p75NTR to mediate proNGF-induced cell death. This family of receptors is acquiring increasing importance owing to its potential involvement in AD [68]. A recent study provided genetic information for a role of the proneurotrophin receptor complex comprising sortilin and p75NTR, in the mediation of neuronal viability in vivo [69]. Sortilin expression is required for p75NTR-mediated apoptosis following proNGF treatment [57], suggesting that sortilin is a p75NTR binding partner associated with the initiation of cell death [51,58]",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        }
      },
      "source": 123,
      "target": 133,
      "key": "68f897b61a54406ee11c5ceeebcab7989dcce3689e8283ae7e95db28bd4620fceb65f1142a85ffa388008f1a634e74ca2723f99a9f497ed0a186bd96f9f79158"
    },
    {
      "line": 484,
      "relation": "positiveCorrelation",
      "evidence": "We found an upregulation of MMP-9 protein levels and activity in both AD and MCI brains, which correlated inversely with cognitive status (Figure 1B) [75]. Since tissue alterations are often reflected in bodily fluids, determination of MMPs in blood, urine and CSF has been recommended as potential biomarkers to act as diagnostic measures to characterize the disease process that occurs in the brain [76–78]. Interestingly, plasma MMP-9 was increased in MCI and AD [77].",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        },
        "MeSHAnatomy": {
          "Plasma": true,
          "Brain": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 116,
      "target": 141,
      "key": "3e2037fb596197aeddc725ab0524fbd6f69ef35cefbf274d88a0ac7294001b85b9a851332b48e2c74402919c8b16d0b19de21bb6cdf53e24cf678ece0bb2368f"
    },
    {
      "line": 510,
      "relation": "association",
      "evidence": "These studies have demonstrated a significant downregulation of trkA, trkB and trkC gene expression during the development of AD [7]. An intermediate reduction was observed in MCI, with the greatest decrement in mild AD compared to aged controls. Moreover, two separate expressed sequence tag (EST) cDNAs for each trk gene (e.g., ESTs targeted to the extracellular domain [ECD] and tyrosine kinase [TK]) domains were downregulated. By contrast, there was a lack of regulation of p75NTR expression [7] in CBF neurons. A ‘step down’ dysregulation of trk expression may, in part, underlie CBF neuron demise associated with the clinical presentation of AD. Supporting this concept is the finding that trk downregulation is associated with measures of cognitive decline [7,14]",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        },
        "MeSHAnatomy": {
          "Cholinergic Neurons": true,
          "Basal Forebrain": true
        }
      },
      "source": 61,
      "target": 140,
      "key": "9b692755f238b81e8c18fe4584f75e64dafad2c2ee4508e3a502589605ae3bf100852686b04f0744eaa2fcce8725302939b7fc195490a452dfc9616e4ba9212c"
    },
    {
      "line": 511,
      "relation": "association",
      "evidence": "These studies have demonstrated a significant downregulation of trkA, trkB and trkC gene expression during the development of AD [7]. An intermediate reduction was observed in MCI, with the greatest decrement in mild AD compared to aged controls. Moreover, two separate expressed sequence tag (EST) cDNAs for each trk gene (e.g., ESTs targeted to the extracellular domain [ECD] and tyrosine kinase [TK]) domains were downregulated. By contrast, there was a lack of regulation of p75NTR expression [7] in CBF neurons. A ‘step down’ dysregulation of trk expression may, in part, underlie CBF neuron demise associated with the clinical presentation of AD. Supporting this concept is the finding that trk downregulation is associated with measures of cognitive decline [7,14]",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        },
        "MeSHAnatomy": {
          "Cholinergic Neurons": true,
          "Basal Forebrain": true
        }
      },
      "source": 62,
      "target": 140,
      "key": "ecb0e156fd8417246c36c565995190dadcfa127493f954f2cfa8d5885bc6ab96cb83a9cfdc1dbabe00de6d07f12c3999afa559e66b032a1123819e7ed2ad85c7"
    },
    {
      "line": 512,
      "relation": "association",
      "evidence": "These studies have demonstrated a significant downregulation of trkA, trkB and trkC gene expression during the development of AD [7]. An intermediate reduction was observed in MCI, with the greatest decrement in mild AD compared to aged controls. Moreover, two separate expressed sequence tag (EST) cDNAs for each trk gene (e.g., ESTs targeted to the extracellular domain [ECD] and tyrosine kinase [TK]) domains were downregulated. By contrast, there was a lack of regulation of p75NTR expression [7] in CBF neurons. A ‘step down’ dysregulation of trk expression may, in part, underlie CBF neuron demise associated with the clinical presentation of AD. Supporting this concept is the finding that trk downregulation is associated with measures of cognitive decline [7,14]",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        },
        "MeSHAnatomy": {
          "Cholinergic Neurons": true,
          "Basal Forebrain": true
        }
      },
      "source": 63,
      "target": 140,
      "key": "d015000d0bd67dc448ee7cca2c84e0e2c4b3b212a263c611c0b5228fd47d3725850e185cb42b1c2c5b9536f98127c49a6b277498f5f235cffb5979be9469167b"
    },
    {
      "line": 525,
      "relation": "association",
      "evidence": " For example, NGF signal transduction activates the MAPK pathway, which participates in a wide array of biologic functions, including cell survival, differentiation and apoptosis [82–84]. MAPK is a serine/ threonine protein kinase which becomes activated upon phosphorylation and affects a wide variety of transcription factors [85].",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        }
      },
      "source": 20,
      "target": 22,
      "key": "e1374ddbc17d5ee35ab884a36225bbc7127e3e5437795ed895caeeac53330e38acb250ddfeeade8545f66ef9eea7ef3385eb8481302a935261aba13efb5ef07a"
    },
    {
      "line": 527,
      "relation": "association",
      "evidence": " For example, NGF signal transduction activates the MAPK pathway, which participates in a wide array of biologic functions, including cell survival, differentiation and apoptosis [82–84]. MAPK is a serine/ threonine protein kinase which becomes activated upon phosphorylation and affects a wide variety of transcription factors [85].",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        }
      },
      "source": 20,
      "target": 27,
      "key": "37d9f0ec9fb46afacfb7e4116c92d31b86b17f3130fff3c1b39eabf3bccbe6207874d7eaeadaf6bc1b3a7b4e39511382f639a0593f6c3bedd339247b58a3dc8a"
    },
    {
      "line": 542,
      "relation": "increases",
      "evidence": "The classic MAPK cascade involves activation of the small GTPase Ras, and the kinases Raf and MEK [86,87]. Downstream consequences of MAPK activation include activation of the ribosomal S6 kinases (Rsk) and the MAPK-activated protein kinase 2 (MAPKAP2), which phosphorylates several transcription factors including Elk-1 and cAMP-regulated response element binding protein (CREB) [85]. The physiological significance of this elaborate NGF-induced network remains unclear, but the sustained activation of MAPK is linked to neurotrophin-mediated neurite outgrowth [88,89]",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 20,
      "target": 67,
      "key": "3661862c82b037378124e9f0ea591da626c6a1e7e4b0adaa7c78a9ecb73e31ade0a52ff4cf3f936155bdf12107a22af1aa4c12d66c0ea67b8d343f5008571c85"
    },
    {
      "line": 543,
      "relation": "increases",
      "evidence": "The classic MAPK cascade involves activation of the small GTPase Ras, and the kinases Raf and MEK [86,87]. Downstream consequences of MAPK activation include activation of the ribosomal S6 kinases (Rsk) and the MAPK-activated protein kinase 2 (MAPKAP2), which phosphorylates several transcription factors including Elk-1 and cAMP-regulated response element binding protein (CREB) [85]. The physiological significance of this elaborate NGF-induced network remains unclear, but the sustained activation of MAPK is linked to neurotrophin-mediated neurite outgrowth [88,89]",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 20,
      "target": 66,
      "key": "61e0f29cdefe6bad89868342d964dda48ab679ea62c247825572909874ee4571cfbe7dac3cd3045604216f52b93e21c2b2b0a8f52d6c9bbb902b365cc4f2a2d0"
    },
    {
      "line": 544,
      "relation": "increases",
      "evidence": "The classic MAPK cascade involves activation of the small GTPase Ras, and the kinases Raf and MEK [86,87]. Downstream consequences of MAPK activation include activation of the ribosomal S6 kinases (Rsk) and the MAPK-activated protein kinase 2 (MAPKAP2), which phosphorylates several transcription factors including Elk-1 and cAMP-regulated response element binding protein (CREB) [85]. The physiological significance of this elaborate NGF-induced network remains unclear, but the sustained activation of MAPK is linked to neurotrophin-mediated neurite outgrowth [88,89]",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 20,
      "target": 64,
      "key": "a6c6e3bedc03f85ec5edcf4e5197ab5f2bfe21cb4187a958d9d3b793b83a79ae3528fa981e28aae5bbb175389cfc9b16ffd366014099a432d1e1237482b47858"
    },
    {
      "line": 545,
      "relation": "increases",
      "evidence": "The classic MAPK cascade involves activation of the small GTPase Ras, and the kinases Raf and MEK [86,87]. Downstream consequences of MAPK activation include activation of the ribosomal S6 kinases (Rsk) and the MAPK-activated protein kinase 2 (MAPKAP2), which phosphorylates several transcription factors including Elk-1 and cAMP-regulated response element binding protein (CREB) [85]. The physiological significance of this elaborate NGF-induced network remains unclear, but the sustained activation of MAPK is linked to neurotrophin-mediated neurite outgrowth [88,89]",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 20,
      "target": 65,
      "key": "14917e6270da9a7a34bf42cae9ba4fbe01e00760d2712aed9dc158ed8d385a4bf179ca47574dd2154050251feb17994fe398ad750e61f39856c8a38327622024"
    },
    {
      "line": 546,
      "relation": "increases",
      "evidence": "The classic MAPK cascade involves activation of the small GTPase Ras, and the kinases Raf and MEK [86,87]. Downstream consequences of MAPK activation include activation of the ribosomal S6 kinases (Rsk) and the MAPK-activated protein kinase 2 (MAPKAP2), which phosphorylates several transcription factors including Elk-1 and cAMP-regulated response element binding protein (CREB) [85]. The physiological significance of this elaborate NGF-induced network remains unclear, but the sustained activation of MAPK is linked to neurotrophin-mediated neurite outgrowth [88,89]",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 20,
      "target": 113,
      "key": "fc7fdfa7288764a14f61aafe4928119fb1815a69d12b42ba062027ec035f3122d886a87336f1f61ab81a8a98b3dabb274ba41f98385940e14d295a8d5d5a0417"
    },
    {
      "line": 527,
      "relation": "association",
      "evidence": " For example, NGF signal transduction activates the MAPK pathway, which participates in a wide array of biologic functions, including cell survival, differentiation and apoptosis [82–84]. MAPK is a serine/ threonine protein kinase which becomes activated upon phosphorylation and affects a wide variety of transcription factors [85].",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        }
      },
      "source": 27,
      "target": 20,
      "key": "90859e6ecb4ca6a2434404dc3a3c7f6ec517f7da38e57e548395faa78b1f9ca61878e3c021f1895f3fe5b785097853261087b697ceb816ecd79ae2d45aca915a"
    },
    {
      "line": 528,
      "relation": "increases",
      "evidence": " For example, NGF signal transduction activates the MAPK pathway, which participates in a wide array of biologic functions, including cell survival, differentiation and apoptosis [82–84]. MAPK is a serine/ threonine protein kinase which becomes activated upon phosphorylation and affects a wide variety of transcription factors [85].",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 71,
      "target": 70,
      "key": "d5edd827d3bce3d492f25f071b4dccd48c019609d51f847d29e80952507355c9dd7be3045fd920b838d7d6d28a1055d63f5e457af29b5ea1d61cbd005e822991"
    },
    {
      "relation": "hasVariant",
      "source": 70,
      "target": 71,
      "key": "24deceb207ce86482973fab68584e5345b63acebdd581606b86d26071a5e2de2bd1c408014340a49b9afb796458546fcc02b88290575b01a1388d1a624cf0520"
    },
    {
      "line": 549,
      "relation": "association",
      "evidence": "The classic MAPK cascade involves activation of the small GTPase Ras, and the kinases Raf and MEK [86,87]. Downstream consequences of MAPK activation include activation of the ribosomal S6 kinases (Rsk) and the MAPK-activated protein kinase 2 (MAPKAP2), which phosphorylates several transcription factors including Elk-1 and cAMP-regulated response element binding protein (CREB) [85]. The physiological significance of this elaborate NGF-induced network remains unclear, but the sustained activation of MAPK is linked to neurotrophin-mediated neurite outgrowth [88,89]",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 70,
      "target": 28,
      "key": "8198c4a1f7efc344c9410dcbc1ab957e8132a797dbd33f6a74ff5c7a4cfe5d7db6e76d9c64caba0a73dba205226a6c576c2b4c068571bd5d5f3a48988379b7f8"
    },
    {
      "line": 562,
      "relation": "association",
      "evidence": "A second downstream pathway is the PI3K/Akt pathway that regulates neurotrophin-mediated survival responses in PC12 cells [90,91]. Regulation of this pathway involves upstream elements including Ras/Gab1/IRS1 [92,93].",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        },
        "CellLine": {
          "PC12": true
        }
      },
      "source": 67,
      "target": 26,
      "key": "5b4119b0f72bcbdff0a190074181c03642828c110f3bcaa9294b6ccb6dc1a4a9a7b7d3edefcf4c111aa43bb905c0514f9fccc65bcbbc5fe08f05e94f3c10aca3"
    },
    {
      "line": 563,
      "relation": "association",
      "evidence": "A second downstream pathway is the PI3K/Akt pathway that regulates neurotrophin-mediated survival responses in PC12 cells [90,91]. Regulation of this pathway involves upstream elements including Ras/Gab1/IRS1 [92,93].",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        },
        "CellLine": {
          "PC12": true
        }
      },
      "source": 67,
      "target": 33,
      "key": "9b429e0fab93a908c0ae336c869bcf14ef97cbc761697600f020d33423eaad1942fd5d3438c309bde6a3ee89ab3fcc7a3db5e8b91264e36e1c33bfa363788760"
    },
    {
      "line": 547,
      "relation": "increases",
      "evidence": "The classic MAPK cascade involves activation of the small GTPase Ras, and the kinases Raf and MEK [86,87]. Downstream consequences of MAPK activation include activation of the ribosomal S6 kinases (Rsk) and the MAPK-activated protein kinase 2 (MAPKAP2), which phosphorylates several transcription factors including Elk-1 and cAMP-regulated response element binding protein (CREB) [85]. The physiological significance of this elaborate NGF-induced network remains unclear, but the sustained activation of MAPK is linked to neurotrophin-mediated neurite outgrowth [88,89]",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 113,
      "target": 109,
      "key": "cdec02e034a778effa6e6b735a762e428be28417e0fd93bed6dfaafdff81d3441e421343708699a254d69d430fa180720ccea97f2adbd76d9defdd1468ee04db"
    },
    {
      "line": 548,
      "relation": "increases",
      "evidence": "The classic MAPK cascade involves activation of the small GTPase Ras, and the kinases Raf and MEK [86,87]. Downstream consequences of MAPK activation include activation of the ribosomal S6 kinases (Rsk) and the MAPK-activated protein kinase 2 (MAPKAP2), which phosphorylates several transcription factors including Elk-1 and cAMP-regulated response element binding protein (CREB) [85]. The physiological significance of this elaborate NGF-induced network remains unclear, but the sustained activation of MAPK is linked to neurotrophin-mediated neurite outgrowth [88,89]",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 113,
      "target": 107,
      "key": "5d0fd5955ab0bb2437cb4ed9fd6ba936567ff6ec6b5e9b993b11760ff79b08e3fb3a73f759bddd3073cb8474d2e21845190b691f1316a6c4fa614536e8e0e82f"
    },
    {
      "relation": "hasVariant",
      "source": 108,
      "target": 109,
      "key": "4c209da8ccac60efcef4d370acf47fcda452c74bf40583573d1981b9fe6efa3333fd92884e39f128a0e75528f64fd91f2d2defccc5f3d31d3febf6a2dc549c72"
    },
    {
      "relation": "hasVariant",
      "source": 106,
      "target": 107,
      "key": "1f18c479763f2c52c382ee4c7f3d2adb55d6e5ae91e8eaa80a11ada9cea46a116d095b77fc14bd8b6624bdf8453b3ae4263192b6921ed1758a6073b3c942dcd7"
    },
    {
      "line": 560,
      "relation": "regulates",
      "evidence": "A second downstream pathway is the PI3K/Akt pathway that regulates neurotrophin-mediated survival responses in PC12 cells [90,91]. Regulation of this pathway involves upstream elements including Ras/Gab1/IRS1 [92,93].",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        },
        "CellLine": {
          "PC12": true
        }
      },
      "source": 26,
      "target": 47,
      "key": "ddc392f68586b98a65b884b32091f4736d0fad9e50e7785262d48822a4d0549ba673fc8de26d90300ada66c8ecfee0eb67f7991501fd41445e274f05c13b15e8"
    },
    {
      "line": 562,
      "relation": "association",
      "evidence": "A second downstream pathway is the PI3K/Akt pathway that regulates neurotrophin-mediated survival responses in PC12 cells [90,91]. Regulation of this pathway involves upstream elements including Ras/Gab1/IRS1 [92,93].",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        },
        "CellLine": {
          "PC12": true
        }
      },
      "source": 26,
      "target": 67,
      "key": "d3103c5262cfbe1d8e644f84c2f4a865c74e30a851a7a6ee37f148469f54d81052f794c6709b4db49e4803a7160597d84b62c87155e90c09c41168bdcd9c46a5"
    },
    {
      "line": 564,
      "relation": "association",
      "evidence": "A second downstream pathway is the PI3K/Akt pathway that regulates neurotrophin-mediated survival responses in PC12 cells [90,91]. Regulation of this pathway involves upstream elements including Ras/Gab1/IRS1 [92,93].",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        },
        "CellLine": {
          "PC12": true
        }
      },
      "source": 26,
      "target": 112,
      "key": "1f918051fe22955864413933210889d58b759a889a654a4f1a522ecaad12f080d2351a5bb928587b4f7fc45fc8b1473549f4c72cb4d1149e48e94730d736a234"
    },
    {
      "line": 566,
      "relation": "association",
      "evidence": "A second downstream pathway is the PI3K/Akt pathway that regulates neurotrophin-mediated survival responses in PC12 cells [90,91]. Regulation of this pathway involves upstream elements including Ras/Gab1/IRS1 [92,93].",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        },
        "CellLine": {
          "PC12": true
        }
      },
      "source": 26,
      "target": 110,
      "key": "5a83b912607cd9ea8b7d84ae7f5bac9ca5ff7279e1a800e7fbb49b6ff4ee0c9aa2a22c259477a677d33e28f901305ee63c0d73b851fbaf8dbb418d45568efbcf"
    },
    {
      "line": 561,
      "relation": "regulates",
      "evidence": "A second downstream pathway is the PI3K/Akt pathway that regulates neurotrophin-mediated survival responses in PC12 cells [90,91]. Regulation of this pathway involves upstream elements including Ras/Gab1/IRS1 [92,93].",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        },
        "CellLine": {
          "PC12": true
        }
      },
      "source": 33,
      "target": 47,
      "key": "f63661141343534de8e9ab6ff40a524dc11f922b6b4f4ba88de0091bbb3d3c6b73fde5a8469c35808b2291943b86f05918b0bc2bca89c63088ad4139bb270f19"
    },
    {
      "line": 563,
      "relation": "association",
      "evidence": "A second downstream pathway is the PI3K/Akt pathway that regulates neurotrophin-mediated survival responses in PC12 cells [90,91]. Regulation of this pathway involves upstream elements including Ras/Gab1/IRS1 [92,93].",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        },
        "CellLine": {
          "PC12": true
        }
      },
      "source": 33,
      "target": 67,
      "key": "3ed6492b5968316374ff959a92a913285abab9b68dd2eeeeaca27d27d434594d0e33a8b0dcba4728abd640353b9d7f78355ab0eb79d77b64c9c21578a071378d"
    },
    {
      "line": 565,
      "relation": "association",
      "evidence": "A second downstream pathway is the PI3K/Akt pathway that regulates neurotrophin-mediated survival responses in PC12 cells [90,91]. Regulation of this pathway involves upstream elements including Ras/Gab1/IRS1 [92,93].",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        },
        "CellLine": {
          "PC12": true
        }
      },
      "source": 33,
      "target": 112,
      "key": "8cfd4ead326d99474ec3a0f01f6c08d8517a2835e348fef8129352436cff1b70010882c0647ab21f5a77fe7d0add8cf8c4e0c78494a542609d385d4e34ba3f74"
    },
    {
      "line": 567,
      "relation": "association",
      "evidence": "A second downstream pathway is the PI3K/Akt pathway that regulates neurotrophin-mediated survival responses in PC12 cells [90,91]. Regulation of this pathway involves upstream elements including Ras/Gab1/IRS1 [92,93].",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        },
        "CellLine": {
          "PC12": true
        }
      },
      "source": 33,
      "target": 110,
      "key": "b46ae9221d1adad17176f72769af680fd3bf6ade800804fda2d79f795e79741dc015366d4309400c311355054148f80ed7b0acf03452c392715f28f34aaf8261"
    },
    {
      "line": 564,
      "relation": "association",
      "evidence": "A second downstream pathway is the PI3K/Akt pathway that regulates neurotrophin-mediated survival responses in PC12 cells [90,91]. Regulation of this pathway involves upstream elements including Ras/Gab1/IRS1 [92,93].",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        },
        "CellLine": {
          "PC12": true
        }
      },
      "source": 112,
      "target": 26,
      "key": "0efa8417349f8e918fb8cf229b99cae800b055df6298724b0391eb982794d82cca9cbceec33f5225c8f8f6d341f8bd95a6b10370fb90bf812af33b818a1ef9d4"
    },
    {
      "line": 565,
      "relation": "association",
      "evidence": "A second downstream pathway is the PI3K/Akt pathway that regulates neurotrophin-mediated survival responses in PC12 cells [90,91]. Regulation of this pathway involves upstream elements including Ras/Gab1/IRS1 [92,93].",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        },
        "CellLine": {
          "PC12": true
        }
      },
      "source": 112,
      "target": 33,
      "key": "98fe8f474f729cc3dbbffb5a64e6dc7ccd3248d07ca43fbd006fecb25583898b0cc43590fb9a82b033d5cc716cd9e18ed431aedfebda78bc153b569967939952"
    },
    {
      "line": 566,
      "relation": "association",
      "evidence": "A second downstream pathway is the PI3K/Akt pathway that regulates neurotrophin-mediated survival responses in PC12 cells [90,91]. Regulation of this pathway involves upstream elements including Ras/Gab1/IRS1 [92,93].",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        },
        "CellLine": {
          "PC12": true
        }
      },
      "source": 110,
      "target": 26,
      "key": "946b2981e30f613606c2629f79008b01e48e415d3f0854a0e769d42eae45b25c8597a79ae395509a41cd95b29a3acc6d26b162e8622c63366419857dcdefda4b"
    },
    {
      "line": 567,
      "relation": "association",
      "evidence": "A second downstream pathway is the PI3K/Akt pathway that regulates neurotrophin-mediated survival responses in PC12 cells [90,91]. Regulation of this pathway involves upstream elements including Ras/Gab1/IRS1 [92,93].",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        },
        "CellLine": {
          "PC12": true
        }
      },
      "source": 110,
      "target": 33,
      "key": "4fc5ca53c75d61e6a8127c9b0bc4398cbe1481667db470d2622da4d49060730f0eb9f5cddb12958c58cefab57520b8e1aa684d1cadb3758272e57abeada1c185"
    },
    {
      "line": 577,
      "relation": "association",
      "evidence": " A third downstream mediator is the PLCgamma pathway [94,95]. PLCgamma pathway dysfunction may play a role in Ca2+-mediated cellular degeneration in aging and disease by affecting oxidative stress systems [96].",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 121,
      "target": 49,
      "key": "a448c2ac526364d74dfe977c28aeacb69e731b93b3ced716b10f1f4775bef52a5a4117f851adfc7edaa15a04078e4b0a1d4b1c54fe2ac1bc6e36092903425168"
    },
    {
      "line": 577,
      "relation": "association",
      "evidence": " A third downstream mediator is the PLCgamma pathway [94,95]. PLCgamma pathway dysfunction may play a role in Ca2+-mediated cellular degeneration in aging and disease by affecting oxidative stress systems [96].",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 49,
      "target": 121,
      "key": "c2a936086929b775d6ed2ad1ec8e391068c7b245b187a0c6e8a6c14515cf8e54103734442a39b798d65f86df66d6cd4031e7446401bac8ba56ca997111467015"
    },
    {
      "line": 578,
      "relation": "association",
      "evidence": " A third downstream mediator is the PLCgamma pathway [94,95]. PLCgamma pathway dysfunction may play a role in Ca2+-mediated cellular degeneration in aging and disease by affecting oxidative stress systems [96].",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        }
      },
      "source": 49,
      "target": 132,
      "key": "a95bc1ecfb262018a35fde44497464cd1b54aaf6004ab25dc0a58c8d7b936e487410c4bcac542e382fbeff292cbc75c2f5c5ae6baf3afd953d6d2bb86fd1752a"
    },
    {
      "line": 580,
      "relation": "association",
      "evidence": " A third downstream mediator is the PLCgamma pathway [94,95]. PLCgamma pathway dysfunction may play a role in Ca2+-mediated cellular degeneration in aging and disease by affecting oxidative stress systems [96].",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        }
      },
      "source": 49,
      "target": 152,
      "key": "c7ac0a813478ad8c595df6d43b5d8e07b704d7691580eb9055749e4b7e40d8ffc899b0f789a9fd6b83b39620ce87eba266c44087efe9c30e8e9be50db608e533"
    },
    {
      "line": 578,
      "relation": "association",
      "evidence": " A third downstream mediator is the PLCgamma pathway [94,95]. PLCgamma pathway dysfunction may play a role in Ca2+-mediated cellular degeneration in aging and disease by affecting oxidative stress systems [96].",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        }
      },
      "source": 132,
      "target": 49,
      "key": "1fb2ede7aafd09f137b022da404b043e7ddb10c11fb9d8aaaa9456147d7d1ad6d746c6728fb461da8b0dbb44c0aae2168235f8b2d7e8db4a93b59b4af5b98afb"
    },
    {
      "line": 580,
      "relation": "association",
      "evidence": " A third downstream mediator is the PLCgamma pathway [94,95]. PLCgamma pathway dysfunction may play a role in Ca2+-mediated cellular degeneration in aging and disease by affecting oxidative stress systems [96].",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        }
      },
      "source": 152,
      "target": 49,
      "key": "49ef7d56213cc2b64fa1db6bdff1f1cacec84f87c19a1a6518909712ba008f0aaea1b02c6cfe68510646d70fbb24acef0b727b37ded798503c6d5619ce7b3e2a"
    },
    {
      "line": 591,
      "relation": "association",
      "evidence": "Recent evidence supports the notion that p75NTR has an intrinsic signaling capacity including: •   Sphingolipid metabolism [98–100] •      Activation of the JNK pathway [52,54,56,101–103] •      Activation of the NF-kappaB pathway [104–109] •         Activation of the Akt pathway [110] •   Activation of the MAPK pathway [97,111]",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 21,
      "target": 118,
      "key": "7ef39c146d70f259490da9f76b7ba0b69ba008f284078f6d6457588b82f9e7ae79fa39092751144042596b5b90f3ef542fae60778ea98e542eaadc98ca761a55"
    },
    {
      "relation": "hasComponent",
      "source": 51,
      "target": 17,
      "key": "fbbb892df9128b45685880dbaf28201ff2dae30d0c76412a1300bae03fc082161951f4cab8214423d7d1436fb61ffe59d3d11b2ed59c1275059410cec35842b9"
    },
    {
      "relation": "hasComponent",
      "source": 51,
      "target": 119,
      "key": "64996a78211de0749b9905c6bb7c2a2fed454dbe1b9f742f6a0592b6b31f74585c2e3370bea5f1d765619186d94a7f0fd2c210f4eb1fa2363bb024e9c532b500"
    },
    {
      "line": 608,
      "relation": "directlyIncreases",
      "evidence": "Gambogic amide binds selectively to TrkA (but not TrkB or TrkC), phosphorylates TrkA tyrosine residues, and activates the Akt and MAPK TrkA-mediated NGF signaling pathways. Gambogic amide has been demonstrated to ameliorate excitotoxic damage and promote neurite outgrowth in PC12 cells [116], making this a potential lead compound for chemical modification and clinical trial assessment.",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        }
      },
      "source": 51,
      "target": 120,
      "key": "95cc85c112cf8fe9caa72ed6ae3d98ffc49f61d22deb65dcd381ae0a3aa7cf6122c072df0d606c8654ab93b7ef5b9f8a698c1f87fe055089266439ff01619d36"
    },
    {
      "line": 614,
      "relation": "decreases",
      "evidence": "Gambogic amide binds selectively to TrkA (but not TrkB or TrkC), phosphorylates TrkA tyrosine residues, and activates the Akt and MAPK TrkA-mediated NGF signaling pathways. Gambogic amide has been demonstrated to ameliorate excitotoxic damage and promote neurite outgrowth in PC12 cells [116], making this a potential lead compound for chemical modification and clinical trial assessment.",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        },
        "CellLine": {
          "PC12": true
        }
      },
      "source": 17,
      "target": 42,
      "key": "720ad4ad377d9bd7411a04ac629f84a1fc9ed667b85a53965e115063e11cca6d5ef963ef52bc62d3425ecb78b4638bb8458ee004db5701d7879fb418d3a4d926"
    },
    {
      "line": 615,
      "relation": "increases",
      "evidence": "Gambogic amide binds selectively to TrkA (but not TrkB or TrkC), phosphorylates TrkA tyrosine residues, and activates the Akt and MAPK TrkA-mediated NGF signaling pathways. Gambogic amide has been demonstrated to ameliorate excitotoxic damage and promote neurite outgrowth in PC12 cells [116], making this a potential lead compound for chemical modification and clinical trial assessment.",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        },
        "CellLine": {
          "PC12": true
        }
      },
      "source": 17,
      "target": 28,
      "key": "bf7a18280fe48228a46799dda6fb993e009b3d8217b5f0c72f9e6bfba0966a116417f56c893752702d8feaac95f2dcbc1cbcd14e4a26f6cedd401948f314ddd6"
    },
    {
      "line": 609,
      "relation": "increases",
      "evidence": "Gambogic amide binds selectively to TrkA (but not TrkB or TrkC), phosphorylates TrkA tyrosine residues, and activates the Akt and MAPK TrkA-mediated NGF signaling pathways. Gambogic amide has been demonstrated to ameliorate excitotoxic damage and promote neurite outgrowth in PC12 cells [116], making this a potential lead compound for chemical modification and clinical trial assessment.",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        }
      },
      "source": 120,
      "target": 33,
      "key": "95585fed70c641f53399ffee4192c1474d081092bc541ca3feddc24b1a73b881a25aee50b56345e193182725bfdba046e81a57485ee0094b16784e7180a17299"
    },
    {
      "line": 610,
      "relation": "increases",
      "evidence": "Gambogic amide binds selectively to TrkA (but not TrkB or TrkC), phosphorylates TrkA tyrosine residues, and activates the Akt and MAPK TrkA-mediated NGF signaling pathways. Gambogic amide has been demonstrated to ameliorate excitotoxic damage and promote neurite outgrowth in PC12 cells [116], making this a potential lead compound for chemical modification and clinical trial assessment.",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        }
      },
      "source": 120,
      "target": 20,
      "key": "bc2596e02009ca7f67444c65bf1bb572428e931d1958c924af0a11d025df9cbc84c79b6385ac1f50302bfb756cd3c2924790bd318ffbe12789a9df0e69c1c1ef"
    },
    {
      "relation": "hasMember",
      "source": 69,
      "target": 91,
      "key": "21e9cf680293bd5d9a6c22feab2c8334ec99788fb8aaccf0766b65cd8f41aaed174ac2852f963410e3fe45e88c77a43d0a7f29c205172ea2b1605ca45ad66983"
    },
    {
      "relation": "hasMember",
      "source": 69,
      "target": 93,
      "key": "6722e526438b15f1592b6a404352e6059d10e48d4491da58ba43be0e89eca1a30cdecc45e0844afbebd34104cd06885034bd5c4e342b6602c56f15391be291bd"
    },
    {
      "relation": "hasMember",
      "source": 69,
      "target": 94,
      "key": "0af7cf3526d4fa6efcf2eeb04a0939c870e9601c414a7ed6deccd89c08473433b48e5317901c4e546ab1e3398fe037d9cf32fb0d399f44c1a3dfd13bdf4f70a7"
    },
    {
      "relation": "hasMember",
      "source": 69,
      "target": 95,
      "key": "5993a0c4625f73fea1b63b797bc6dcef379c097a2cb71c85dd80b24e6b97f39bfc6fdc25b02c7e8de8fd3d9faea0a17c1c72d7b0be07c9e6305d0bd891484ac4"
    },
    {
      "relation": "hasMember",
      "source": 69,
      "target": 96,
      "key": "190cd78d3ae7df453dcf41e0a8fb64fe6babe6e99c2f915320583b74806a92081cd3448ba421446c4f9e00b12ec30fc1b0240cadcaea33e5a69011bb735619d1"
    },
    {
      "relation": "hasMember",
      "source": 69,
      "target": 97,
      "key": "e798b3cc4c2251f522c346a8d30e1e7c524f59890d679fc289dc236ca3b1cf48e5b25d9e2c1d6a313268c559a5cd486167a42ee94717bd6d7913966ce47d41c5"
    },
    {
      "relation": "hasMember",
      "source": 69,
      "target": 98,
      "key": "c9926a71e1106285a2500a59dece8bc11c14b03a60771114dbc42a5d5a8459c4eca56dacdda96347416ba61d1b6f1821771997dbb3b6e120e08798f6e83760ea"
    },
    {
      "relation": "hasMember",
      "source": 69,
      "target": 99,
      "key": "482e9becb675420fb24f7fc8cb9dd5fcc8db318057cd24fc1b0b3b586e863195fb64285fbd1e3c4621090c2b4d3f1b6f1e8d2d2ce3e7bf2a3e77c948423e9978"
    },
    {
      "relation": "hasMember",
      "source": 69,
      "target": 92,
      "key": "69532181841d70c55caaddff0509b6b6ac88145a4ac4dc6c69f57c74252340c8561f7b9b9569e69530115ee5becb45e485fef300b461a977777728ae2bd4d0bf"
    },
    {
      "relation": "hasMember",
      "source": 69,
      "target": 100,
      "key": "5c0de4dfbe894fa631cb7217d43938371b68a4722bea44eae657b6d9ffb76e69927bd2ab86667460b3a62ee1c3efaa0d4e08da5f7426191c21b44eeacd768b72"
    },
    {
      "relation": "hasMember",
      "source": 69,
      "target": 101,
      "key": "2645aa68594fb605c4c4c06cac0ebf6955b534c60fde07458f1c50028a9abc3d43a94b89e78f2366964dc605f618f30198ae9c780039e3a5c0db76877633784a"
    },
    {
      "relation": "hasMember",
      "source": 69,
      "target": 102,
      "key": "f40a14df4f7addf198bec85ff682f2014ab50031f59c2c2d6816bb7a667e1bef117d83ae3366157f89d5509d3674f95f9a16a9d486cea8402aa0354e683afdd0"
    },
    {
      "relation": "hasMember",
      "source": 69,
      "target": 103,
      "key": "8943a335c8204c5510796b8e8f60fc55b13777267b7da7066d1d74349a0244c5e88e29e61794166e24273371e9a70016e40d8d63fffe74076a920731d224fa4b"
    },
    {
      "relation": "hasMember",
      "source": 69,
      "target": 104,
      "key": "d2508f5a944583ea8492b9cd73b3ace22d9a362343767ccab6910c7c35680962568235e2fb1c74b2a46109fdccbdafef2778b9056afb1be3e64aff4bc19acad6"
    },
    {
      "relation": "hasMember",
      "source": 69,
      "target": 105,
      "key": "633a675f2ec2668320fe862d16402a4f6233a26029b68b333683c895465e2843e3f3dc6da7acdd3636e3fd2bf26ee04763b54933f8d53421685c59687c691b37"
    },
    {
      "line": 697,
      "relation": "increases",
      "evidence": "Despite a putative beneficial role for increased CBF neuron alpha7 nAChR expression in AD (that may also be relevant to smoking behavior), evidence suggests that increased alpha7 nAChR expression contributes to cellular degeneration. Notably, alpha7 nAChR binds and/or interacts with APP and Ab peptides [123–125]. Increased NB neuronal alpha7 nAChR expression may arise as a compensatory response that is offset by aberrant Ab-alpha7 nAChR interactions, leading to cholinergic dysfunction.",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        },
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "source": 98,
      "target": 54,
      "key": "b5a987008b35b7bfcb6da307dd01857637f32efd2ead779ed8e886ade2ea285b99102273282d785614019f209dedff83e209d36b742214162cde42edd7f3831d"
    },
    {
      "line": 698,
      "relation": "increases",
      "evidence": "Despite a putative beneficial role for increased CBF neuron alpha7 nAChR expression in AD (that may also be relevant to smoking behavior), evidence suggests that increased alpha7 nAChR expression contributes to cellular degeneration. Notably, alpha7 nAChR binds and/or interacts with APP and Ab peptides [123–125]. Increased NB neuronal alpha7 nAChR expression may arise as a compensatory response that is offset by aberrant Ab-alpha7 nAChR interactions, leading to cholinergic dysfunction.",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        },
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "source": 98,
      "target": 50,
      "key": "8089939283599053d4cbe01b367cc6a8c1806c2b132fa88af8c7bf80299fce11c97b1bf17699a2fd50c16e95ff4ab2e11078b9d27f65ad996621f38c130fc01d"
    },
    {
      "relation": "hasMember",
      "source": 68,
      "target": 86,
      "key": "a8adb94967e00afb64303690cc0ee618e6e5c6e6330911078caf86551bc58568b790083b0b9db4ea5bcb9d78a30a59227bd5b5f288dc299cf915d35d90af6670"
    },
    {
      "relation": "hasMember",
      "source": 68,
      "target": 87,
      "key": "25072f152b1dd9be1db06da4c05f164e9a95e40c49f63d43888564bc9e8b863efaeaa415fca1fe08dc9a9079073465c9d66c65d8f21e4f280da819f261f4a423"
    },
    {
      "relation": "hasMember",
      "source": 68,
      "target": 88,
      "key": "1c76030b3fe55dc33060d9f4af0a937a334ba826bf4c1c10e59f20040cf15bba1b00a70485ce2d081887a2adbb1fce11c99f7ec42e318e6818caadedf94d3d72"
    },
    {
      "relation": "hasMember",
      "source": 68,
      "target": 89,
      "key": "4d5344f8d456d925ff7fa6ef64fc553ad8b81ef03db54323990c86e48bd6c97527baeb97c1b77f4eabd274e9096b16ea1cce3f99b890d2fdd31c78034c53c0cb"
    },
    {
      "relation": "hasMember",
      "source": 68,
      "target": 90,
      "key": "410b2d123ca605c1e0e4e81c8ec85fb49c82a26c165c3e4e19b89b5f3f81c6563e35694a9d03dcec97da5b3ec4e647dac7729f54725026bf0fe4a976f47ae067"
    },
    {
      "line": 713,
      "relation": "association",
      "evidence": "Conversely, M1 subunit gene expression in single CBF neurons is preserved during the progression of AD (Table 1) [119,126]. The M1 receptor is a most interesting drug target as it links several of the major hallmarks of this disorder, including cholinergic deficiency, cognitive dysfunctions, Ab and tau pathologies.",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        },
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "source": 86,
      "target": 160,
      "key": "4abbdc2abd87c6be63ab22f126bf2dfb72aca5f6b4ae35e7e898ef91dffcc7a894a3763c0a17c4ac7ab12decc69158f70be212e1eb1e3364663560248a68d9c7"
    },
    {
      "line": 715,
      "relation": "association",
      "evidence": "Conversely, M1 subunit gene expression in single CBF neurons is preserved during the progression of AD (Table 1) [119,126]. The M1 receptor is a most interesting drug target as it links several of the major hallmarks of this disorder, including cholinergic deficiency, cognitive dysfunctions, Ab and tau pathologies.",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        },
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "source": 86,
      "target": 157,
      "key": "137e3d0adff78a851081d7be00429a768c1d7a5fb6def6844b20243251d0614ed280188e8482df0c03355f2743caad7956c7452835c2228f1144b438d2bd4405"
    },
    {
      "line": 717,
      "relation": "association",
      "evidence": "Conversely, M1 subunit gene expression in single CBF neurons is preserved during the progression of AD (Table 1) [119,126]. The M1 receptor is a most interesting drug target as it links several of the major hallmarks of this disorder, including cholinergic deficiency, cognitive dysfunctions, Ab and tau pathologies.",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        },
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "source": 86,
      "target": 134,
      "key": "12c502adc44561310bb19a6f9e6a74114fe27ab128c21383106ce9ab2410ffe2b932d17cb29cf3f0db85f678827f156e8fc7db44687682dabd9f524e84963444"
    },
    {
      "line": 673,
      "relation": "negativeCorrelation",
      "evidence": "This increase in alpha7 nAChR expression levels within CBF neurons was inversely associated with cognitive performance. Increased alpha7 nAChR expression in CBF neurons may signal a compensatory response to maintain basocortical cholinergic activity during the onset of AD. Upregulation of the alpha7 nAChR within individual CBF neurons is also consistent with reports of increased alpha7 nAChR mRNA and protein expression levels in hippocampal neurons, astrocytes and peripheral blood leukocytes in AD [120–122]. The observed increase in alpha7 nAChR in early AD may regulate basocortical cholinergic tone through pre- and/or postsynaptic mechanisms within cholinergic NB neurons prior to their frank degeneration in the later stages of AD.",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        },
        "Disease": {
          "Alzheimer's disease": true
        },
        "MeSHAnatomy": {
          "Astrocytes": true,
          "Hippocampus": true,
          "Leukocytes": true
        }
      },
      "source": 166,
      "target": 140,
      "key": "a8dd472d1baf1d319c658a25d76740e871b313e749f42194d1240a94c7461b21d4021eb3579502f0d8cb0fcf0cfda69ed1b8432bc0b5baa3c5af2331e485a634"
    },
    {
      "line": 679,
      "relation": "regulates",
      "evidence": "This increase in alpha7 nAChR expression levels within CBF neurons was inversely associated with cognitive performance. Increased alpha7 nAChR expression in CBF neurons may signal a compensatory response to maintain basocortical cholinergic activity during the onset of AD. Upregulation of the alpha7 nAChR within individual CBF neurons is also consistent with reports of increased alpha7 nAChR mRNA and protein expression levels in hippocampal neurons, astrocytes and peripheral blood leukocytes in AD [120–122]. The observed increase in alpha7 nAChR in early AD may regulate basocortical cholinergic tone through pre- and/or postsynaptic mechanisms within cholinergic NB neurons prior to their frank degeneration in the later stages of AD.",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        },
        "Disease": {
          "Alzheimer's disease": true
        },
        "MeSHAnatomy": {
          "Cholinergic Neurons": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 166,
      "target": 14,
      "key": "b7b7abdd68ec13c7db109ce0017c8dec93af61768584c313e8b4f9c22012e8b2ef559fc22ef442c365139cd38aab4464f67b3a82104de40524ebdd03a63df44e"
    },
    {
      "line": 696,
      "relation": "increases",
      "evidence": "Despite a putative beneficial role for increased CBF neuron alpha7 nAChR expression in AD (that may also be relevant to smoking behavior), evidence suggests that increased alpha7 nAChR expression contributes to cellular degeneration. Notably, alpha7 nAChR binds and/or interacts with APP and Ab peptides [123–125]. Increased NB neuronal alpha7 nAChR expression may arise as a compensatory response that is offset by aberrant Ab-alpha7 nAChR interactions, leading to cholinergic dysfunction.",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        },
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "source": 166,
      "target": 152,
      "key": "07cb0ec3f69290dc2eaf5a89dc70772f954b99b4b241b076eb9d5456bae31a02db1f06afc9156629593faa21c0271b01ca7645047f7f16ca082ca3ebbd67f5c0"
    },
    {
      "relation": "hasComponent",
      "source": 54,
      "target": 81,
      "key": "64d05dcc42f324c9542568c1c53f68afb079745f5d082079acf06654aa3516f04d3f56613f65408fb5c1a905d8390d8035f3a71fd78e7c0def13b19b0dcf2c97"
    },
    {
      "relation": "hasComponent",
      "source": 54,
      "target": 98,
      "key": "f20f91163e198ad2ca1db0fd3443ce6ec2652b94c3941a6d397982862ff6c17708138186d545a54bccb54d1483dd3fa71e9eb974b3c59b7615d887959d632683"
    },
    {
      "relation": "hasComponent",
      "source": 50,
      "target": 1,
      "key": "6ca2c691749f9ea872915cbd8796c4af98480bb987070336174c5c8644a2edf1fb08d40e47072f7a38b842c6d431fbc5972984977be85089889ec31fa70a25f3"
    },
    {
      "relation": "hasComponent",
      "source": 50,
      "target": 98,
      "key": "a531cecbea520b5d662e13969127445e4f392b3137b52412b3f57f2753101e8ce37b8fe1d32c82552a076f4123bba2567447eadb2753a2072acc132ac0fe3164"
    },
    {
      "line": 699,
      "relation": "increases",
      "evidence": "Despite a putative beneficial role for increased CBF neuron alpha7 nAChR expression in AD (that may also be relevant to smoking behavior), evidence suggests that increased alpha7 nAChR expression contributes to cellular degeneration. Notably, alpha7 nAChR binds and/or interacts with APP and Ab peptides [123–125]. Increased NB neuronal alpha7 nAChR expression may arise as a compensatory response that is offset by aberrant Ab-alpha7 nAChR interactions, leading to cholinergic dysfunction.",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        },
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "source": 50,
      "target": 166,
      "key": "0f39361d3bfaa5aeafc900200f9943155668329532ed1ee855f0089bc91a663ec908382827a095a73cbad67c7323f742841432f6b25e73570f32d804a24aeb7d"
    },
    {
      "line": 700,
      "relation": "decreases",
      "evidence": "Despite a putative beneficial role for increased CBF neuron alpha7 nAChR expression in AD (that may also be relevant to smoking behavior), evidence suggests that increased alpha7 nAChR expression contributes to cellular degeneration. Notably, alpha7 nAChR binds and/or interacts with APP and Ab peptides [123–125]. Increased NB neuronal alpha7 nAChR expression may arise as a compensatory response that is offset by aberrant Ab-alpha7 nAChR interactions, leading to cholinergic dysfunction.",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        },
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "source": 50,
      "target": 25,
      "key": "97a12c3d984ed09e7ff78de0569037ae5d5953db9db905c2a903b383e9847d381f9ae620e4440d6545a9bc94e57f960d949b709858c9a565ff1d3e5fb04009bd"
    },
    {
      "line": 715,
      "relation": "association",
      "evidence": "Conversely, M1 subunit gene expression in single CBF neurons is preserved during the progression of AD (Table 1) [119,126]. The M1 receptor is a most interesting drug target as it links several of the major hallmarks of this disorder, including cholinergic deficiency, cognitive dysfunctions, Ab and tau pathologies.",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        },
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "source": 157,
      "target": 86,
      "key": "40ca21496f7a11516058984c934ded7c27815aec5f177e856ff06a666923e9418e96bd918a99a5648dc22512191e6938bf3bab81a478fa2e37602ad7843e7cce"
    },
    {
      "line": 717,
      "relation": "association",
      "evidence": "Conversely, M1 subunit gene expression in single CBF neurons is preserved during the progression of AD (Table 1) [119,126]. The M1 receptor is a most interesting drug target as it links several of the major hallmarks of this disorder, including cholinergic deficiency, cognitive dysfunctions, Ab and tau pathologies.",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        },
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "source": 134,
      "target": 86,
      "key": "67e2a04178ed92ac7873066827f78470c182341c9770a1a248d1b2cf88611cbf3a4e356b5fbafc50451e576818fdad7c394b935a712bd58f69609cf150ec226e"
    },
    {
      "line": 737,
      "relation": "decreases",
      "evidence": "Recently, a novel group of M1 partial agonists was developed (AF102B, AF150(S) and AF267B-i) [129]. In a series of studies using the 3x transgenic-AD mice, which recapitulate the major pathologies of AD [130], chronic AF267B treatment rescued cognitive impairment and decreased Abeta42 and tau pathologies in the cortex and hippocampus. These changes were associated with M1 mAChR-mediated activation of the TNFalpha-converting enzyme ADAM17/TACE, decreased BACE1 steady state levels and inhibition of GSK3beta [130].",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        },
        "MeSHAnatomy": {
          "Hippocampus": true,
          "Cerebral Cortex": true
        },
        "Disease": {
          "Alzheimer's disease": true
        },
        "Species": {
          "10090": true
        }
      },
      "source": 16,
      "target": 160,
      "key": "1e2667581413d8de379cfe1a9bc10ba12fcf1e0153d675e7f90a7a778d1c223d3ad304a8219243d861202ec5be86cf0f9996b37cdbc7c1b52b024abe6168f522"
    },
    {
      "line": 738,
      "relation": "decreases",
      "evidence": "Recently, a novel group of M1 partial agonists was developed (AF102B, AF150(S) and AF267B-i) [129]. In a series of studies using the 3x transgenic-AD mice, which recapitulate the major pathologies of AD [130], chronic AF267B treatment rescued cognitive impairment and decreased Abeta42 and tau pathologies in the cortex and hippocampus. These changes were associated with M1 mAChR-mediated activation of the TNFalpha-converting enzyme ADAM17/TACE, decreased BACE1 steady state levels and inhibition of GSK3beta [130].",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        },
        "MeSHAnatomy": {
          "Hippocampus": true,
          "Cerebral Cortex": true
        },
        "Disease": {
          "Alzheimer's disease": true
        },
        "Species": {
          "10090": true
        }
      },
      "source": 16,
      "target": 157,
      "key": "1045b729dc998ef20686508af4d986fc9a74014f3e6d8cdb6ba69a3ad89e8744f3159e3801919b1f1b961530338b61cd0cb414d3072baa513c3588a4294994bc"
    },
    {
      "line": 739,
      "relation": "decreases",
      "evidence": "Recently, a novel group of M1 partial agonists was developed (AF102B, AF150(S) and AF267B-i) [129]. In a series of studies using the 3x transgenic-AD mice, which recapitulate the major pathologies of AD [130], chronic AF267B treatment rescued cognitive impairment and decreased Abeta42 and tau pathologies in the cortex and hippocampus. These changes were associated with M1 mAChR-mediated activation of the TNFalpha-converting enzyme ADAM17/TACE, decreased BACE1 steady state levels and inhibition of GSK3beta [130].",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        },
        "MeSHAnatomy": {
          "Hippocampus": true,
          "Cerebral Cortex": true
        },
        "Disease": {
          "Alzheimer's disease": true
        },
        "Species": {
          "10090": true
        }
      },
      "source": 16,
      "target": 0,
      "key": "1650b1f5dc05e157433872b673eb5743a255b9537c43cacb337ec25244e9ac968e763deb56b0a515185195fdaf78ff4012be2bd2cedd1f860a0659d801ea2758"
    },
    {
      "line": 740,
      "relation": "increases",
      "evidence": "Recently, a novel group of M1 partial agonists was developed (AF102B, AF150(S) and AF267B-i) [129]. In a series of studies using the 3x transgenic-AD mice, which recapitulate the major pathologies of AD [130], chronic AF267B treatment rescued cognitive impairment and decreased Abeta42 and tau pathologies in the cortex and hippocampus. These changes were associated with M1 mAChR-mediated activation of the TNFalpha-converting enzyme ADAM17/TACE, decreased BACE1 steady state levels and inhibition of GSK3beta [130].",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        },
        "MeSHAnatomy": {
          "Hippocampus": true,
          "Cerebral Cortex": true
        },
        "Disease": {
          "Alzheimer's disease": true
        },
        "Species": {
          "10090": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 16,
      "target": 126,
      "key": "2a0a5f252d8d871d8baaee05dbfa78471e82aab916f865ab73c9ad74daec1a870038f1d9d2d13f8c8fe8e00ef494b213ac20215858da92530152995141dd9580"
    },
    {
      "line": 742,
      "relation": "decreases",
      "evidence": "Recently, a novel group of M1 partial agonists was developed (AF102B, AF150(S) and AF267B-i) [129]. In a series of studies using the 3x transgenic-AD mice, which recapitulate the major pathologies of AD [130], chronic AF267B treatment rescued cognitive impairment and decreased Abeta42 and tau pathologies in the cortex and hippocampus. These changes were associated with M1 mAChR-mediated activation of the TNFalpha-converting enzyme ADAM17/TACE, decreased BACE1 steady state levels and inhibition of GSK3beta [130].",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        },
        "MeSHAnatomy": {
          "Hippocampus": true,
          "Cerebral Cortex": true
        },
        "Disease": {
          "Alzheimer's disease": true
        },
        "Species": {
          "10090": true
        }
      },
      "source": 16,
      "target": 125,
      "key": "ff34c222cae3bc0f67b48d785e06e7e94cd47e22890f5807b4095aa6444fe49fcc2a292cbc15081c7bb3dbf9d9739502e47b003cb7152a0279e00b8a735c12b3"
    },
    {
      "line": 743,
      "relation": "decreases",
      "evidence": "Recently, a novel group of M1 partial agonists was developed (AF102B, AF150(S) and AF267B-i) [129]. In a series of studies using the 3x transgenic-AD mice, which recapitulate the major pathologies of AD [130], chronic AF267B treatment rescued cognitive impairment and decreased Abeta42 and tau pathologies in the cortex and hippocampus. These changes were associated with M1 mAChR-mediated activation of the TNFalpha-converting enzyme ADAM17/TACE, decreased BACE1 steady state levels and inhibition of GSK3beta [130].",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        },
        "MeSHAnatomy": {
          "Hippocampus": true,
          "Cerebral Cortex": true
        },
        "Disease": {
          "Alzheimer's disease": true
        },
        "Species": {
          "10090": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 16,
      "target": 127,
      "key": "f69149a954c510caee2d66f6a56823cf7432b38060d47e88980519baec77ec9118e60715829b6d8ef703d2e7efde7d37487ba01963b34684410a7ac3994e8aa2"
    },
    {
      "line": 741,
      "relation": "increases",
      "evidence": "Recently, a novel group of M1 partial agonists was developed (AF102B, AF150(S) and AF267B-i) [129]. In a series of studies using the 3x transgenic-AD mice, which recapitulate the major pathologies of AD [130], chronic AF267B treatment rescued cognitive impairment and decreased Abeta42 and tau pathologies in the cortex and hippocampus. These changes were associated with M1 mAChR-mediated activation of the TNFalpha-converting enzyme ADAM17/TACE, decreased BACE1 steady state levels and inhibition of GSK3beta [130].",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        },
        "MeSHAnatomy": {
          "Hippocampus": true,
          "Cerebral Cortex": true
        },
        "Disease": {
          "Alzheimer's disease": true
        },
        "Species": {
          "10090": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 126,
      "target": 124,
      "key": "3924d022a0d736377d2ec19628e5fe072cc5bb48f041ae55ec9329b22f36a9b76342ca241312a0d48ad5dd4fbd5687bb326d1b909ab3141ccb543c65a47d30ae"
    },
    {
      "line": 767,
      "relation": "association",
      "evidence": "Single cell gene array studies have shown that synaptic transcripts are selectively downregulated in CBF neurons in AD, with significant reductions in synaptophysin and synaptotagmin but not synaptobrevin or SNAP29 mRNA [134,135]. Intriguingly, synaptotagmin function is related to vesicle-presynaptic membrane fusion and neurotransmitter release, suggesting that perturbations in presynaptic vesicle trafficking comprise a common event in vulnerable neuronal populations in AD. In contrast to synaptic transcripts, mRNAs encoding APP and Notch were unchanged between control and AD subjects, whereas acid hydrolase cathepsin D mRNA was upregulated in AD [134–136].",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        }
      },
      "source": 73,
      "target": 29,
      "key": "c1acef31e83d16f9c3887269011bedae6242d022612f1f4d3e66066b13cfa3151bd3585614c6dffc976c94f78fc99a381b71293a8bda49e9820188fb28c0f372"
    },
    {
      "line": 769,
      "relation": "association",
      "evidence": "Single cell gene array studies have shown that synaptic transcripts are selectively downregulated in CBF neurons in AD, with significant reductions in synaptophysin and synaptotagmin but not synaptobrevin or SNAP29 mRNA [134,135]. Intriguingly, synaptotagmin function is related to vesicle-presynaptic membrane fusion and neurotransmitter release, suggesting that perturbations in presynaptic vesicle trafficking comprise a common event in vulnerable neuronal populations in AD. In contrast to synaptic transcripts, mRNAs encoding APP and Notch were unchanged between control and AD subjects, whereas acid hydrolase cathepsin D mRNA was upregulated in AD [134–136].",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        }
      },
      "source": 73,
      "target": 24,
      "key": "608364b47cfaa45a651255ab91b1edf416d1bd74afe106286dbfcafadac2c42486090928c4d390e6d6c151f7a13bc940b54320e735b940fd937d1ef3d1676b0c"
    },
    {
      "line": 767,
      "relation": "association",
      "evidence": "Single cell gene array studies have shown that synaptic transcripts are selectively downregulated in CBF neurons in AD, with significant reductions in synaptophysin and synaptotagmin but not synaptobrevin or SNAP29 mRNA [134,135]. Intriguingly, synaptotagmin function is related to vesicle-presynaptic membrane fusion and neurotransmitter release, suggesting that perturbations in presynaptic vesicle trafficking comprise a common event in vulnerable neuronal populations in AD. In contrast to synaptic transcripts, mRNAs encoding APP and Notch were unchanged between control and AD subjects, whereas acid hydrolase cathepsin D mRNA was upregulated in AD [134–136].",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        }
      },
      "source": 29,
      "target": 73,
      "key": "50c9144e7235433c27ac8c9f6832569037bf3e1cf7eada6348e30119fcf7d7944e378e5ab649e6166b2d1acb155b65a73aa0f2293b30ba1c5f6901a16b83dec9"
    },
    {
      "line": 769,
      "relation": "association",
      "evidence": "Single cell gene array studies have shown that synaptic transcripts are selectively downregulated in CBF neurons in AD, with significant reductions in synaptophysin and synaptotagmin but not synaptobrevin or SNAP29 mRNA [134,135]. Intriguingly, synaptotagmin function is related to vesicle-presynaptic membrane fusion and neurotransmitter release, suggesting that perturbations in presynaptic vesicle trafficking comprise a common event in vulnerable neuronal populations in AD. In contrast to synaptic transcripts, mRNAs encoding APP and Notch were unchanged between control and AD subjects, whereas acid hydrolase cathepsin D mRNA was upregulated in AD [134–136].",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        }
      },
      "source": 24,
      "target": 73,
      "key": "d95a2b4ce3f65ed71bf256ef84c388f97217e071ba8fd5a0ed55bb110942390c3910d8def73f4a65c0dec885d75f3a71494dadfb2f2e5e93fa7bb13b5107bb14"
    },
    {
      "line": 974,
      "relation": "association",
      "evidence": "In addition, indirect effects and unwanted side effects appeared with systemic administration including unregulated neurotransmitter release, hyperinnervation, sprouting of neurons, sympathetic stimulation, induction of antibodies, cachexia and hyperalgesia [178–181].",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        }
      },
      "source": 24,
      "target": 117,
      "key": "a9649757f198abb9d59ac92b309bad5705dedc077f6807be29f09772bd8f37c00b82002ef5d70b12cf9785c6674354ac4fbb947e874a4c416939661060562702"
    },
    {
      "line": 787,
      "relation": "increases",
      "evidence": "In addition, subunits of protein phosphatase PP1 (Unigene-NCBI annotation PPP1CA and PPP1CC) mRNAs were downregulated in CBF neurons in AD [135]. This observation is interesting in light of the observation that PP1 can phosphorylate tau on several serine/threonine residues and experimental downregulation of PP1 activity leads to increased tau hyperphosphorylation [137,138], which may affect NFT formation in CBF neurons.",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        },
        "MeSHAnatomy": {
          "Cholinergic Neurons": true
        },
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "source": 72,
      "target": 115,
      "key": "94b24e0eb1ab02f79da75d886730b5b1b896adf70a2bbbe44eedb08384e0c89fd272a827387f3f3bc3c1985093e854e570f70e6c0a7d64a79afc75df1390850a"
    },
    {
      "line": 788,
      "relation": "decreases",
      "evidence": "In addition, subunits of protein phosphatase PP1 (Unigene-NCBI annotation PPP1CA and PPP1CC) mRNAs were downregulated in CBF neurons in AD [135]. This observation is interesting in light of the observation that PP1 can phosphorylate tau on several serine/threonine residues and experimental downregulation of PP1 activity leads to increased tau hyperphosphorylation [137,138], which may affect NFT formation in CBF neurons.",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        },
        "MeSHAnatomy": {
          "Cholinergic Neurons": true
        },
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 72,
      "target": 44,
      "key": "8c6b7ecbeacc5d6e98ae60e0b15dd64990b89be91f999d7eeef70e27c840ac7676d21d1a9704ca06c5d755e9f0a67cc7487fb334d6779bf09538bb5259fc7a9a"
    },
    {
      "relation": "hasVariant",
      "source": 114,
      "target": 115,
      "key": "c4e71f1866eab20795e7e1d4b54fe09effb8b376e41712f8a130fe5192e07d83b0749cc2e2297b62cbea4bb7b1033909ea6d6423fa06166cb07543cee4249d48"
    },
    {
      "relation": "hasMember",
      "source": 114,
      "target": 74,
      "key": "65c2d33c90fa4f69056a5cb4b0a462cdd37b1963dd29443023cd3a7574f62cfe46e3f08ef7e3969e6fc0e2ab295ad23945f921574fbd0a9acab6f1a2b12b95c5"
    },
    {
      "relation": "hasMember",
      "source": 114,
      "target": 75,
      "key": "335c97103fc0f5bbdc28cfe7e0f9bd45172d4d20d394919f24962f6bb2054a7c0a7fe9c8c8eb89e36d17ed346c2350cde892ff87fd82fc83a8ba979370c9563d"
    },
    {
      "relation": "hasMember",
      "source": 114,
      "target": 76,
      "key": "56b58f30d193d0a3c1cb71275be1bba3f03ab40cc41c2f4753ce85104888284abfc97a3c9d5c8644a9a9061bfd5b1ad96702dfb162cbea59581f05747ecc80d7"
    },
    {
      "relation": "hasMember",
      "source": 114,
      "target": 77,
      "key": "5265f091ed50894df03a5d030d9fd448d63915d58b0d5ce1c65a5500b820226b5c112ab504c4a0384bee1cd76f7e16e367956a50293ef191d6b8f976da733d2e"
    },
    {
      "relation": "hasMember",
      "source": 114,
      "target": 78,
      "key": "ed3cb6ef293cc3cfe7e66676eec73b2bc3a85fae987cb72af2031135e94405dfb1a59d55b7ecac6cf2c22314c137fa419a08107e7c89fea99fd54a6df584aba2"
    },
    {
      "relation": "hasMember",
      "source": 114,
      "target": 79,
      "key": "dc8c1abd60d793ce4892c1ea1085103aabb9c3f9aea6e76cc2f4c50c9c07ed80a7f18583a607283d010b86f06e83c12a845a45ee86b0a87a24ae5318120838e9"
    },
    {
      "line": 789,
      "relation": "association",
      "evidence": "In addition, subunits of protein phosphatase PP1 (Unigene-NCBI annotation PPP1CA and PPP1CC) mRNAs were downregulated in CBF neurons in AD [135]. This observation is interesting in light of the observation that PP1 can phosphorylate tau on several serine/threonine residues and experimental downregulation of PP1 activity leads to increased tau hyperphosphorylation [137,138], which may affect NFT formation in CBF neurons.",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        },
        "MeSHAnatomy": {
          "Cholinergic Neurons": true
        },
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "source": 44,
      "target": 155,
      "key": "b3795d78445bedb3e5090a9d186f3e78da957f6958f745532fbe198fbba9b0d36c764bca0cc576d9809904ef8a4d5ba73c38552c98772c69737c31c2d81d43e0"
    },
    {
      "line": 789,
      "relation": "association",
      "evidence": "In addition, subunits of protein phosphatase PP1 (Unigene-NCBI annotation PPP1CA and PPP1CC) mRNAs were downregulated in CBF neurons in AD [135]. This observation is interesting in light of the observation that PP1 can phosphorylate tau on several serine/threonine residues and experimental downregulation of PP1 activity leads to increased tau hyperphosphorylation [137,138], which may affect NFT formation in CBF neurons.",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        },
        "MeSHAnatomy": {
          "Cholinergic Neurons": true
        },
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "source": 155,
      "target": 44,
      "key": "d6b5a241fa42688b393460cdba3ff22a6a91447cc6d9af636ec3f45a4b4541bac5b3504b7459dbf0612795ed48480b793f2d7b7e3176f80da0b1c0904ea26652"
    },
    {
      "line": 856,
      "relation": "association",
      "evidence": " For example, the neuropeptide GAL, which functions via the interaction with three G protein-coupled receptors termed GALR1, GALR2 and GALR3, has multiple biological actions, including effects on cognition and neuroplasticity [15,146,147]. In the late [148–150] but not early [151] stage of AD, fibers within the basal forebrain containing the neuropeptide GAL thicken and hyperinnervate surviving CBF neurons. Although animal and cell-culture studies have shown that GAL plays a crucial role in the regulation of CBF neuron activity [152] and rescues cholinergic cells from amyloid toxicity [153], the molecular consequences of this unique plasticity response upon CBF neurons in AD remain unclear. Gene expression studies of cholinergic transcripts have shown that GAL hyperinnervated, but not nonhyperinnervated, CBF neurons display an upregulation of ChAT expression in AD compared to controls [126]",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 111,
      "target": 140,
      "key": "5ef2862d208ee1c84e3a2b17630870ae875d3310243ab2852e8ab4cdc9eaf85a3f99b6d7575746246bb426bad55f95a521c2bb22634eb59d042976a4da52ba96"
    },
    {
      "line": 858,
      "relation": "association",
      "evidence": " For example, the neuropeptide GAL, which functions via the interaction with three G protein-coupled receptors termed GALR1, GALR2 and GALR3, has multiple biological actions, including effects on cognition and neuroplasticity [15,146,147]. In the late [148–150] but not early [151] stage of AD, fibers within the basal forebrain containing the neuropeptide GAL thicken and hyperinnervate surviving CBF neurons. Although animal and cell-culture studies have shown that GAL plays a crucial role in the regulation of CBF neuron activity [152] and rescues cholinergic cells from amyloid toxicity [153], the molecular consequences of this unique plasticity response upon CBF neurons in AD remain unclear. Gene expression studies of cholinergic transcripts have shown that GAL hyperinnervated, but not nonhyperinnervated, CBF neurons display an upregulation of ChAT expression in AD compared to controls [126]",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 111,
      "target": 48,
      "key": "f2ef065389581889c23e8559e293cebf68bcd375cc0eb289a968fadd4e3377edf04e0b3e63b1cfa450a6c057a28719eb2f41c494543ab20c37ecafc98b56c67f"
    },
    {
      "line": 863,
      "relation": "increases",
      "evidence": " For example, the neuropeptide GAL, which functions via the interaction with three G protein-coupled receptors termed GALR1, GALR2 and GALR3, has multiple biological actions, including effects on cognition and neuroplasticity [15,146,147]. In the late [148–150] but not early [151] stage of AD, fibers within the basal forebrain containing the neuropeptide GAL thicken and hyperinnervate surviving CBF neurons. Although animal and cell-culture studies have shown that GAL plays a crucial role in the regulation of CBF neuron activity [152] and rescues cholinergic cells from amyloid toxicity [153], the molecular consequences of this unique plasticity response upon CBF neurons in AD remain unclear. Gene expression studies of cholinergic transcripts have shown that GAL hyperinnervated, but not nonhyperinnervated, CBF neurons display an upregulation of ChAT expression in AD compared to controls [126]",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        },
        "Disease": {
          "Alzheimer's disease": true
        },
        "MeSHAnatomy": {
          "Cholinergic Neurons": true,
          "Basal Forebrain": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 111,
      "target": 37,
      "key": "c17f3dd1727048b92ab92df6ce5448a8e860f005199b69370fc6494e23b8276999860e62a574b50300a9ae262095e78ce2e6fc49e6d494afb45abca11e08e7de"
    },
    {
      "line": 864,
      "relation": "regulates",
      "evidence": " For example, the neuropeptide GAL, which functions via the interaction with three G protein-coupled receptors termed GALR1, GALR2 and GALR3, has multiple biological actions, including effects on cognition and neuroplasticity [15,146,147]. In the late [148–150] but not early [151] stage of AD, fibers within the basal forebrain containing the neuropeptide GAL thicken and hyperinnervate surviving CBF neurons. Although animal and cell-culture studies have shown that GAL plays a crucial role in the regulation of CBF neuron activity [152] and rescues cholinergic cells from amyloid toxicity [153], the molecular consequences of this unique plasticity response upon CBF neurons in AD remain unclear. Gene expression studies of cholinergic transcripts have shown that GAL hyperinnervated, but not nonhyperinnervated, CBF neurons display an upregulation of ChAT expression in AD compared to controls [126]",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        },
        "Disease": {
          "Alzheimer's disease": true
        },
        "MeSHAnatomy": {
          "Cholinergic Neurons": true,
          "Basal Forebrain": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 111,
      "target": 14,
      "key": "7cecc2a15222cae3476a49249fe5ddcf1888123e83719c75edbf3a97bc414dcd7da49474d2a7a393ddee74ee91b877ac0cbf4b28ac87bda8fb4c40ff89f89be8"
    },
    {
      "line": 865,
      "relation": "decreases",
      "evidence": " For example, the neuropeptide GAL, which functions via the interaction with three G protein-coupled receptors termed GALR1, GALR2 and GALR3, has multiple biological actions, including effects on cognition and neuroplasticity [15,146,147]. In the late [148–150] but not early [151] stage of AD, fibers within the basal forebrain containing the neuropeptide GAL thicken and hyperinnervate surviving CBF neurons. Although animal and cell-culture studies have shown that GAL plays a crucial role in the regulation of CBF neuron activity [152] and rescues cholinergic cells from amyloid toxicity [153], the molecular consequences of this unique plasticity response upon CBF neurons in AD remain unclear. Gene expression studies of cholinergic transcripts have shown that GAL hyperinnervated, but not nonhyperinnervated, CBF neurons display an upregulation of ChAT expression in AD compared to controls [126]",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        },
        "Disease": {
          "Alzheimer's disease": true
        },
        "MeSHAnatomy": {
          "Cholinergic Neurons": true,
          "Basal Forebrain": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 111,
      "target": 1,
      "key": "b5f1c19172022c7da9f32623c281e5e33acb80070f8bd2319879a3bfcbb210659c9df0755462d84020fdd9ab0b79bec9d539cc5f029091ff0c4a93b71cf759fd"
    },
    {
      "line": 866,
      "relation": "increases",
      "evidence": " For example, the neuropeptide GAL, which functions via the interaction with three G protein-coupled receptors termed GALR1, GALR2 and GALR3, has multiple biological actions, including effects on cognition and neuroplasticity [15,146,147]. In the late [148–150] but not early [151] stage of AD, fibers within the basal forebrain containing the neuropeptide GAL thicken and hyperinnervate surviving CBF neurons. Although animal and cell-culture studies have shown that GAL plays a crucial role in the regulation of CBF neuron activity [152] and rescues cholinergic cells from amyloid toxicity [153], the molecular consequences of this unique plasticity response upon CBF neurons in AD remain unclear. Gene expression studies of cholinergic transcripts have shown that GAL hyperinnervated, but not nonhyperinnervated, CBF neurons display an upregulation of ChAT expression in AD compared to controls [126]",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        },
        "Disease": {
          "Alzheimer's disease": true
        },
        "MeSHAnatomy": {
          "Cholinergic Neurons": true,
          "Basal Forebrain": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 111,
      "target": 164,
      "key": "fe6bcad0a56c827a9184b11186ab4f05c6de06ee3a0ad919d131626f57b3b7904a59ce6ef59b9927560e447e950ae1c96c8c06d11cf645a13b7e52f6e601d6c2"
    },
    {
      "line": 885,
      "relation": "causesNoChange",
      "evidence": "CBF neurons displaying the tau C3 epitope, a marker for early stage NFT formation, were often hyperinnervated by GAL-containing fibers, whereas CBF neurons displaying the tau epitope MN423, an end-stage NFT marker, were not associated with GAL. Single cell gene expression studies have demonstrated that the levels of mRNAs encoding select subclasses of PP1 subunits (e.g., PP1alpha and PP1gamma) are stable in GAL hyperinnervated but downregulated in non-hyperinnervated CBF neurons in AD [149]",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        },
        "Disease": {
          "Alzheimer's disease": true
        },
        "MeSHAnatomy": {
          "Cholinergic Neurons": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 111,
      "target": 7,
      "key": "5384fc6a58e1017b592b19dbfd5cfc068116478cb1413195a5576034a743941438baee02eaa941e5f67c7f97a1ca03b9432be4d593370724305c7809d366e75d"
    },
    {
      "line": 886,
      "relation": "increases",
      "evidence": "CBF neurons displaying the tau C3 epitope, a marker for early stage NFT formation, were often hyperinnervated by GAL-containing fibers, whereas CBF neurons displaying the tau epitope MN423, an end-stage NFT marker, were not associated with GAL. Single cell gene expression studies have demonstrated that the levels of mRNAs encoding select subclasses of PP1 subunits (e.g., PP1alpha and PP1gamma) are stable in GAL hyperinnervated but downregulated in non-hyperinnervated CBF neurons in AD [149]",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        },
        "Disease": {
          "Alzheimer's disease": true
        },
        "MeSHAnatomy": {
          "Cholinergic Neurons": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 111,
      "target": 170,
      "key": "4ead759d51fc37fd57527dac76787e01416b0e0e06d74abcd5f0fe0ecfa6d6a55fe98d8e63b21488b6d63c4e93c356f7afa740d8fbab5a2c6884619295cb5b85"
    },
    {
      "line": 887,
      "relation": "increases",
      "evidence": "CBF neurons displaying the tau C3 epitope, a marker for early stage NFT formation, were often hyperinnervated by GAL-containing fibers, whereas CBF neurons displaying the tau epitope MN423, an end-stage NFT marker, were not associated with GAL. Single cell gene expression studies have demonstrated that the levels of mRNAs encoding select subclasses of PP1 subunits (e.g., PP1alpha and PP1gamma) are stable in GAL hyperinnervated but downregulated in non-hyperinnervated CBF neurons in AD [149]",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        },
        "Disease": {
          "Alzheimer's disease": true
        },
        "MeSHAnatomy": {
          "Cholinergic Neurons": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 111,
      "target": 171,
      "key": "db2e8951210f8ff9a2738c6ab2987fd080499f5c2558d18acc51382e69f4d15ba320d4ac08f8905ee62f038fac9fab54fe273f42c9d122c565dd693a2b0e2e54"
    },
    {
      "line": 858,
      "relation": "association",
      "evidence": " For example, the neuropeptide GAL, which functions via the interaction with three G protein-coupled receptors termed GALR1, GALR2 and GALR3, has multiple biological actions, including effects on cognition and neuroplasticity [15,146,147]. In the late [148–150] but not early [151] stage of AD, fibers within the basal forebrain containing the neuropeptide GAL thicken and hyperinnervate surviving CBF neurons. Although animal and cell-culture studies have shown that GAL plays a crucial role in the regulation of CBF neuron activity [152] and rescues cholinergic cells from amyloid toxicity [153], the molecular consequences of this unique plasticity response upon CBF neurons in AD remain unclear. Gene expression studies of cholinergic transcripts have shown that GAL hyperinnervated, but not nonhyperinnervated, CBF neurons display an upregulation of ChAT expression in AD compared to controls [126]",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 48,
      "target": 111,
      "key": "832b3d28154232b3211f2dd12847fa8f372f4e960ff13d52809dab23346654c3123a877361315471fc68ddaffd00539d1435a1a5cc5dee5482df76f78b31921e"
    },
    {
      "line": 884,
      "relation": "biomarkerFor",
      "evidence": "CBF neurons displaying the tau C3 epitope, a marker for early stage NFT formation, were often hyperinnervated by GAL-containing fibers, whereas CBF neurons displaying the tau epitope MN423, an end-stage NFT marker, were not associated with GAL. Single cell gene expression studies have demonstrated that the levels of mRNAs encoding select subclasses of PP1 subunits (e.g., PP1alpha and PP1gamma) are stable in GAL hyperinnervated but downregulated in non-hyperinnervated CBF neurons in AD [149]",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        },
        "Disease": {
          "Alzheimer's disease": true
        },
        "MeSHAnatomy": {
          "Cholinergic Neurons": true
        }
      },
      "source": 6,
      "target": 159,
      "key": "f3cba7541635ddf69e368630a702e04bb198f6a79ad08dacc6f0b8594131d7f2abf7c7c2dfa2bee6f3c8c6a59776dde5011bb28de5a049a60c4f5059c007c15c"
    },
    {
      "line": 899,
      "relation": "increases",
      "evidence": " In this vein, intraventricular infusion of NGF increased hippocampal GAL mRNA expression in rats [158], suggesting that the use of NGF for the treatment of AD [113] may indirectly increase brain GAL providing a dual therapeutic benefit for the treatment of CBF dysfunction in AD.",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        }
      },
      "source": 129,
      "target": 175,
      "key": "d3b3b2bb1aa498314b55b2535d7645f34c3740ec26641d9749a0675fd4d02d71dbe71c92dfeb8cf7e1a2fc94fe685cc408a704c76c0bf1e6021317b8d48e1714"
    },
    {
      "line": 900,
      "relation": "decreases",
      "evidence": " In this vein, intraventricular infusion of NGF increased hippocampal GAL mRNA expression in rats [158], suggesting that the use of NGF for the treatment of AD [113] may indirectly increase brain GAL providing a dual therapeutic benefit for the treatment of CBF dysfunction in AD.",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        }
      },
      "source": 129,
      "target": 160,
      "key": "4da56a5a4ef9e71273870c76439bef2029a8f3407b89cccf36a04f4fcf2c198289a7c398f2b2eabd11e10cff9f06a3ba896abbd974d5e01f8dce41ff23aaa174"
    },
    {
      "line": 916,
      "relation": "association",
      "evidence": "Recent studies report that anticholinesterase drugs reduce circulating Ab deposition in several dementia types, including AD [159]. Evidence from clinical trials [160], noninvasive functional imaging [161] and basic science research suggest that cholinesterase inhibitors might alter APP processing and therefore provide some degree of neuroprotection [162,163]",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        },
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "source": 36,
      "target": 8,
      "key": "af2da41c7d8f3a2cce6c3d7d8f3e974c5865d7a2088a5c39d648af35f2deaf734f9af8ea65e5ce5fd494742f69956b41c1c37e3510a05e1db6f34f79cbc0a53e"
    },
    {
      "line": 943,
      "relation": "association",
      "evidence": "Since the cholinergic deficit is not an early defect in the progression of AD [18–20], the use of these drugs in the prodromal stages of AD should be continued. However, the limited effect of cholinesterase inhibitors for the treatment of cognitive decline in AD coupled with unwanted side effects such as diarrhea, nausea, insomnia, fatigue and loss of appetite indicates the need to move beyond this conventional drug treatment with somewhat circumscribed efficacy.",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        },
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "source": 147,
      "target": 8,
      "key": "94c1e544b93b0667b2ffcd9aa29aa8a8a2aa56c79d9e1f1d53fcfdde69db54637cb0f6bfb783124be3b26ee91081bdf7b17284e01870e88b670a2b1d22eba5f4"
    },
    {
      "line": 945,
      "relation": "association",
      "evidence": "Since the cholinergic deficit is not an early defect in the progression of AD [18–20], the use of these drugs in the prodromal stages of AD should be continued. However, the limited effect of cholinesterase inhibitors for the treatment of cognitive decline in AD coupled with unwanted side effects such as diarrhea, nausea, insomnia, fatigue and loss of appetite indicates the need to move beyond this conventional drug treatment with somewhat circumscribed efficacy.",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        },
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "source": 144,
      "target": 8,
      "key": "1029b0766beca9013c5c52cc3de7a190f37536ca18b6f5111701e7e19cf41d44929ea8c670f74d2e00b82f41088cc0b19891543e4caba232d2c4a9eb6351890d"
    },
    {
      "line": 947,
      "relation": "association",
      "evidence": "Since the cholinergic deficit is not an early defect in the progression of AD [18–20], the use of these drugs in the prodromal stages of AD should be continued. However, the limited effect of cholinesterase inhibitors for the treatment of cognitive decline in AD coupled with unwanted side effects such as diarrhea, nausea, insomnia, fatigue and loss of appetite indicates the need to move beyond this conventional drug treatment with somewhat circumscribed efficacy.",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        },
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "source": 151,
      "target": 8,
      "key": "affdcd995fafe9362d6405bd4be010aa9041ac6791a9c5387b296153e7b42a379c6c47e5d9c0e4108e32f39d56c4538e3c0a0bc42f583cca27707be1b216fc20"
    },
    {
      "line": 949,
      "relation": "association",
      "evidence": "Since the cholinergic deficit is not an early defect in the progression of AD [18–20], the use of these drugs in the prodromal stages of AD should be continued. However, the limited effect of cholinesterase inhibitors for the treatment of cognitive decline in AD coupled with unwanted side effects such as diarrhea, nausea, insomnia, fatigue and loss of appetite indicates the need to move beyond this conventional drug treatment with somewhat circumscribed efficacy.",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        },
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "source": 145,
      "target": 8,
      "key": "9be3d92ff7f9f8d6e859ca6305aa5896c744b7f2bce7fba8a0bd5426003a5db6a06594a10f2a88a3f73d9bb1771a6c2c5fc7f937a601513455543f4a7ab82051"
    },
    {
      "line": 951,
      "relation": "association",
      "evidence": "Since the cholinergic deficit is not an early defect in the progression of AD [18–20], the use of these drugs in the prodromal stages of AD should be continued. However, the limited effect of cholinesterase inhibitors for the treatment of cognitive decline in AD coupled with unwanted side effects such as diarrhea, nausea, insomnia, fatigue and loss of appetite indicates the need to move beyond this conventional drug treatment with somewhat circumscribed efficacy.",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        },
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "source": 135,
      "target": 8,
      "key": "8b923bf7c01708075d587c3e688e3b1e6a34668173281c9e03808ad09bc97bf05a3296e1338ae2b86c4c087de4139731e66cea845e27cf0214e315fba7025a72"
    },
    {
      "line": 976,
      "relation": "association",
      "evidence": "In addition, indirect effects and unwanted side effects appeared with systemic administration including unregulated neurotransmitter release, hyperinnervation, sprouting of neurons, sympathetic stimulation, induction of antibodies, cachexia and hyperalgesia [178–181].",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        }
      },
      "source": 35,
      "target": 117,
      "key": "ea185642d43567dcb2ec497e308e487e6279a16c3eef013108713f625faa657315d7aad0b94f29dfe83b1f93cb6fa1ad4ffe7c6b39553d3295f4cc15b1cd608b"
    },
    {
      "line": 978,
      "relation": "association",
      "evidence": "In addition, indirect effects and unwanted side effects appeared with systemic administration including unregulated neurotransmitter release, hyperinnervation, sprouting of neurons, sympathetic stimulation, induction of antibodies, cachexia and hyperalgesia [178–181].",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        }
      },
      "source": 139,
      "target": 117,
      "key": "4a88c49f55501ececd71e50b748d48c99b8ee0c20708dd344d57e4f9bfa142ed04d4a198b36a9aa00ec86763947d822428edcb33ed689dbc91f9bf7a3f1fb921"
    },
    {
      "line": 980,
      "relation": "association",
      "evidence": "In addition, indirect effects and unwanted side effects appeared with systemic administration including unregulated neurotransmitter release, hyperinnervation, sprouting of neurons, sympathetic stimulation, induction of antibodies, cachexia and hyperalgesia [178–181].",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        }
      },
      "source": 146,
      "target": 117,
      "key": "899f8fe2b262e5fd2e00aee2d6da5ccd47101b7c01e9284aad896a0a0c562cc326910a3c9ae6297c49d11ddc1c794f321c205702cf5546776e58d0a23307e65d"
    },
    {
      "line": 998,
      "relation": "directlyIncreases",
      "evidence": "The ex vivo Phase I trial attempted to move beyond currently available treatments for AD [113]. The goal of this NGF trial was to protect CBF neurons from degeneration, as well as augment the function of remaining cholinergic neurons by delivery of human NGF. After obtaining informed consent, skin biopsies were attained to generate primary cultures of autologous fibroblasts that were transfected to produce human NGF [184]. If fibroblasts were found to be acceptable based on NGF production rates, then grafts were stereotaxically placed into multiple locations within the region of the CBF neurons. Following a period of 22 months, no long-term post-surgical adverse effects were found and the rate of cognitive decline appeared to be reduced [113]. ",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        },
        "MeSHAnatomy": {
          "Fibroblasts": true
        }
      },
      "source": 59,
      "target": 117,
      "key": "11ee9dd19dc6984f370b616201e2a6a122160ef7ebf3900e5233b257b4b31a9a6f39bcf1ddf2919fdbceee1d4a21618c33de65b4d09c4c665885a4db8467e537"
    },
    {
      "line": 1012,
      "relation": "decreases",
      "evidence": "Recently, the novel non-selective antihistamine dimebon (2,3,4,5-tetrahydro2,8-dimethyl-5–2[-6methyl 3-pyridnyl)ethyl]-1H-pyrido[4,3-b] indole) was shown to inhibit BChE and AChE, block the NMDA receptor signaling pathway, inhibit mitochondrial permeability and provide neuroprotective effects in models of AD [194].",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        },
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 19,
      "target": 83,
      "key": "6be1aa21c7d198b85c2daed05036ffcedce5887342b8ff1b3a2535b7f97dab10ee6bcc426d876b254b8cab9deb70e4b8a83c755710f45f2641bf0e1226304e92"
    },
    {
      "line": 1013,
      "relation": "decreases",
      "evidence": "Recently, the novel non-selective antihistamine dimebon (2,3,4,5-tetrahydro2,8-dimethyl-5–2[-6methyl 3-pyridnyl)ethyl]-1H-pyrido[4,3-b] indole) was shown to inhibit BChE and AChE, block the NMDA receptor signaling pathway, inhibit mitochondrial permeability and provide neuroprotective effects in models of AD [194].",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        },
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 19,
      "target": 80,
      "key": "0f21f0cc4556113692ae7ae6219ce77449f70ba358d56cc72cd6d6aac0e5f08f27e420d4e59b99b7de4e80dffbd64e7254fdfdb463c7a40156508d555366a8f2"
    },
    {
      "line": 1015,
      "relation": "decreases",
      "evidence": "Recently, the novel non-selective antihistamine dimebon (2,3,4,5-tetrahydro2,8-dimethyl-5–2[-6methyl 3-pyridnyl)ethyl]-1H-pyrido[4,3-b] indole) was shown to inhibit BChE and AChE, block the NMDA receptor signaling pathway, inhibit mitochondrial permeability and provide neuroprotective effects in models of AD [194].",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        },
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "source": 19,
      "target": 38,
      "key": "8b61339e9aae7696f6faceeb53fd5e67d170d0dc7056ec73fe7f9cd74c86ff751f06914f715ef92e7f5a293c2f736a68aa94d6f23a55277eb2b3fe7ff4097251"
    },
    {
      "line": 1017,
      "relation": "decreases",
      "evidence": "Recently, the novel non-selective antihistamine dimebon (2,3,4,5-tetrahydro2,8-dimethyl-5–2[-6methyl 3-pyridnyl)ethyl]-1H-pyrido[4,3-b] indole) was shown to inhibit BChE and AChE, block the NMDA receptor signaling pathway, inhibit mitochondrial permeability and provide neuroprotective effects in models of AD [194].",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        },
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "source": 19,
      "target": 34,
      "key": "aa9e0d3ce9fa4e5eba1dd38475c052bf1d89741a2a0ec6ffeeddf55981a5eb9de0a424b495247a2cff241a7b093104dff48fbc462c59e40437bf2f976443b6f3"
    },
    {
      "line": 1018,
      "relation": "increases",
      "evidence": "Recently, the novel non-selective antihistamine dimebon (2,3,4,5-tetrahydro2,8-dimethyl-5–2[-6methyl 3-pyridnyl)ethyl]-1H-pyrido[4,3-b] indole) was shown to inhibit BChE and AChE, block the NMDA receptor signaling pathway, inhibit mitochondrial permeability and provide neuroprotective effects in models of AD [194].",
      "citation": {
        "type": "PubMed",
        "reference": "18986241",
        "name": "Expert review of neurotherapeutics",
        "title": "Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.",
        "volume": "8",
        "pages": "1703-18",
        "date": "2008-11-01",
        "first": "Mufson EJ",
        "last": "Ginsberg SD",
        "authors": [
          "Counts SE",
          "Ginsberg SD",
          "Mufson EJ",
          "Perez SE"
        ]
      },
      "annotations": {
        "MeSHDisease": {
          "Cognitive Dysfunction": true
        },
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "source": 19,
      "target": 45,
      "key": "b7a56997a4db73c41396ac7e46fc30a5e09e832b3806bbadd2fc4f5f679233fd5639c8f7d2f46b4f674438dcd8c8f07313cccf3326d48d49edfa11d98338b045"
    }
  ]
}